<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28817687</article-id><article-id pub-id-type="pmc">5560737</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0183572</article-id><article-id pub-id-type="publisher-id">PONE-D-17-11447</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Blood Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>Macrophages</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>Macrophages</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>Macrophages</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>Macrophages</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Transmembrane Receptors</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Signal Transduction</subject><subj-group><subject>Transmembrane Receptors</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Immune Receptors</subject><subj-group><subject>Cytokine Receptors</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Immune Receptors</subject><subj-group><subject>Cytokine Receptors</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Immune Receptors</subject><subj-group><subject>Cytokine Receptors</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Signal Transduction</subject><subj-group><subject>Immune Receptors</subject><subj-group><subject>Cytokine Receptors</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cell Motility</subject><subj-group><subject>Chemotaxis</subject><subj-group><subject>Chemokines</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Lipoproteins</subject><subj-group><subject>Lipoprotein Receptors</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Signal Transduction</subject><subj-group><subject>Lipoprotein Receptors</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Animals</subject><subj-group><subject>Vertebrates</subject><subj-group><subject>Amniotes</subject><subj-group><subject>Mammals</subject><subj-group><subject>Dogs</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Immune Receptors</subject><subj-group><subject>Complement Receptors</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Immune Receptors</subject><subj-group><subject>Complement Receptors</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Immune System Proteins</subject><subj-group><subject>Immune Receptors</subject><subj-group><subject>Complement Receptors</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Signal Transduction</subject><subj-group><subject>Immune Receptors</subject><subj-group><subject>Complement Receptors</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Response</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Response</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Morphologic, phenotypic, and transcriptomic characterization of classically and alternatively activated canine blood-derived macrophages <italic>in vitro</italic></article-title><alt-title alt-title-type="running-head">Characterization of polarized canine macrophages</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Heinrich</surname><given-names>Franziska</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lehmbecker</surname><given-names>Annika</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Raddatz</surname><given-names>Barbara B.</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kegler</surname><given-names>Kristel</given-names></name><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tipold</surname><given-names>Andrea</given-names></name><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Stein</surname><given-names>Veronika M.</given-names></name><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kalkuhl</surname><given-names>Arno</given-names></name><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Software</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Deschl</surname><given-names>Ulrich</given-names></name><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Software</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Baumg&#x000e4;rtner</surname><given-names>Wolfgang</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Ulrich</surname><given-names>Reiner</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-9935-3700</contrib-id><name><surname>Spitzbarth</surname><given-names>Ingo</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Pathology, University of Veterinary Medicine Hannover Foundation, B&#x000fc;nteweg 17, Hannover, Germany</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Center for Systems Neuroscience, B&#x000fc;nteweg 2, Hannover, Germany</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Department of Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover Foundation, B&#x000fc;nteweg 2, Hannover, Germany</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Department of Clinical Veterinary Sciences, Vetsuisse Faculty, University of Bern, Laenggassstrasse 128, Bern, Switzerland</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>Boehringer Ingelheim Pharma GmbH &#x00026; Co.KG, Department of Non-clinical Drug Safety, Birkendorfer Str. 65, Biberach, Germany</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>Friedrich-Loeffler-Institute, Department of Experimental Animal Facilities and Biorisk Management, S&#x000fc;dufer 10, Greifswald, Germany</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Olszewski</surname><given-names>Michal A.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>University of Michigan Health System, UNITED STATES</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>Arno Kalkuhl and Ulrich Deschl are employed by Boehringer Ingelheim Pharma GmbH&#x00026;Co KG. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.</p></fn><corresp id="cor001">* E-mail: <email>Wolfgang.Baumgaertner@tiho-hannover.de</email></corresp></author-notes><pub-date pub-type="epub"><day>17</day><month>8</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>12</volume><issue>8</issue><elocation-id>e0183572</elocation-id><history><date date-type="received"><day>23</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>7</day><month>8</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 Heinrich et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Heinrich et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0183572.pdf"/><abstract><p>Macrophages are a heterogeneous cell population playing a pivotal role in tissue homeostasis and inflammation, and their phenotype strongly depends on the micromilieu. Despite its increasing importance as a translational animal model for human diseases, there is a considerable gap of knowledge with respect to macrophage polarization in dogs. The present study comprehensively investigated the morphologic, phenotypic, and transcriptomic characteristics of unstimulated (M0), M1- (GM-CSF, LPS, IFN&#x003b3;-stimulated) and M2- (M-CSF, IL-4-stimulated)-polarized canine blood-derived macrophages <italic>in vitro</italic>. Scanning electron microscopy revealed distinct morphologies of polarized macrophages with formation of multinucleated cells in M2-macrophages, while immunofluorescence employing literature-based prototype-antibodies against CD16, CD32, iNOS, MHC class II (M1-markers), CD163, CD206, and arginase-1 (M2-markers) demonstrated that only CD206 was able to discriminate M2-macrophages from both other phenotypes, highlighting this molecule as a promising marker for canine M2-macrophages. Global microarray analysis revealed profound changes in the transcriptome of polarized canine macrophages. Functional analysis pointed out that M1-polarization was associated with biological processes such as &#x0201c;respiratory burst&#x0201d;, whereas M2-polarization was associated with processes such as &#x0201c;mitosis&#x0201d;. Literature-based marker gene selection revealed only minor overlaps in the gene sets of the dog compared to prototype markers of murine and human macrophages. Biomarker selection using supervised clustering suggested <italic>latexin (LXN)</italic> and <italic>membrane-spanning 4-domains</italic>, <italic>subfamily A</italic>, <italic>member 2 (MS4A2)</italic> to be the most powerful predicting biomarkers for canine M1- and M2-macrophages, respectively. Immunofluorescence for both markers demonstrated expression of both proteins by macrophages <italic>in vitro</italic> but failed to reveal differences between canine M1 and M2-macrophages. The present study provides a solid basis for future studies upon the role of macrophage polarization in spontaneous diseases of the dog, a species that has emerging importance for translational research.</p></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>BA 815/10-2</award-id><principal-award-recipient><name><surname>Baumg&#x000e4;rtner</surname><given-names>Wolfgang</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>UL 421/1-2</award-id><principal-award-recipient><name><surname>Ulrich</surname><given-names>Reiner</given-names></name></principal-award-recipient></award-group><award-group id="award003"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100004350</institution-id><institution>Studienstiftung des Deutschen Volkes</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Heinrich</surname><given-names>Franziska</given-names></name></principal-award-recipient></award-group><award-group id="award004"><funding-source><institution>Niedersachsen-Research Network on Neuroinfectiology (N-RENNT) of the Ministry of Science and Culture of Lower Saxony</institution></funding-source></award-group><funding-statement>This study was in part supported by the German Research Foundation (FOR 1103; BA 815/10-2 and UL 421/1-2) and in part by the Niedersachsen-Research Network on Neuroinfectiology (N-RENNT) of the Ministry of Science and Culture of Lower Saxony. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Franziska Heinrich was supported by the German National Academic Foundation, Bonn, Germany. AK and UD are employed by the commercial company Boehringer Ingelheim Pharma GmbH &#x00026; Co. KG. The funder provided support in the form of salaries for authors [AK, UD], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="6"/><table-count count="7"/><page-count count="33"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files. Raw and processed microarray data sets of the present study are deposited and publicly available in the ArrayExpress database (accession number: E-MTAB-5458; <ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/arrayexpress">http://www.ebi.ac.uk/arrayexpress</ext-link>).</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files. Raw and processed microarray data sets of the present study are deposited and publicly available in the ArrayExpress database (accession number: E-MTAB-5458; <ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/arrayexpress">http://www.ebi.ac.uk/arrayexpress</ext-link>).</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Circulating peripheral blood mononuclear cells (PBMCs) play an important role during both the steady state and inflammation. Monocytes, which originate from hematopoietic stem cells, are capable of migrating from the blood into distinct tissues and differentiate into macrophages in order to replenish specific tissue-specific macrophage populations [<xref rid="pone.0183572.ref001" ref-type="bibr">1</xref>]. Functional diversity and plasticity are hallmarks of macrophages [<xref rid="pone.0183572.ref002" ref-type="bibr">2</xref>, <xref rid="pone.0183572.ref003" ref-type="bibr">3</xref>]. Together they represent a heterogeneous cell population of the mononuclear phagocyte system playing a pivotal role in tissue homeostasis, inflammation, host defense, and tissue repair [<xref rid="pone.0183572.ref004" ref-type="bibr">4</xref>, <xref rid="pone.0183572.ref005" ref-type="bibr">5</xref>]. Depending on the micromilieu, two extremes of macrophage phenotypes have been described following external or endogenous stimulation: &#x0201c;classically&#x0201d; activated M1-macrophages and &#x0201c;alternatively&#x0201d; activated M2-macrophages [<xref rid="pone.0183572.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0183572.ref007" ref-type="bibr">7</xref>]. Classically activated M1-macrophages develop after exposure to pro-inflammatory stimuli such as interferon &#x00263; (IFN&#x00263;), lipopolysaccharide (LPS), or tumor necrosis factor (TNF). Subsequent to such stimulation, M1-macrophages release pro-inflammatory cytokines, reactive oxygen species (ROS), and nitric oxide (NO) [<xref rid="pone.0183572.ref008" ref-type="bibr">8</xref>]. Hence, on the functional level, M1-macrophages are characterized by an increased microbicidal, tumoricidal, and antigen presenting capacity [<xref rid="pone.0183572.ref002" ref-type="bibr">2</xref>, <xref rid="pone.0183572.ref004" ref-type="bibr">4</xref>, <xref rid="pone.0183572.ref009" ref-type="bibr">9</xref>]. In contrast, M2-macrophages become activated in the presence of interleukin (IL)-4, IL-10, IL-13, glucocorticoids, and transforming growth factor &#x003b2; (TGF&#x003b2;) leading to enhanced secretion of anti-inflammatory cytokines. Accordingly, M2-macrophages are functionally associated with hypersensitivity, parasite clearance, inflammatory dampening, tissue remodeling, angiogenesis, immunoregulation, and tumor promotion [<xref rid="pone.0183572.ref002" ref-type="bibr">2</xref>, <xref rid="pone.0183572.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0183572.ref010" ref-type="bibr">10</xref>]. However, it should be taken into consideration that the M1-/M2&#x02013;paradigm is a simplified classification, representing only two extremes of phenotypes which do not fully mirror the complexity of the dynamic biological processes behind cell polarization [<xref rid="pone.0183572.ref007" ref-type="bibr">7</xref>]. Hence, gene expression profiling has been applied as a sophisticated technique to detect the underlying molecular mechanisms following macrophage activation in murine and human cells [<xref rid="pone.0183572.ref011" ref-type="bibr">11</xref>&#x02013;<xref rid="pone.0183572.ref014" ref-type="bibr">14</xref>]. In fact, macrophage activation by any agonist involves a massive change in gene expression during the transition from one steady state to another [<xref rid="pone.0183572.ref005" ref-type="bibr">5</xref>]. Notably, current comparative studies strongly support the observation of marked interspecies differences and variability between mice and humans indicating that about 50% of polarization specific markers are selectively expressed in only one of both species [<xref rid="pone.0183572.ref013" ref-type="bibr">13</xref>, <xref rid="pone.0183572.ref014" ref-type="bibr">14</xref>].</p><p>Currently, spontaneous diseases in dogs play an established and increasing role as suitable animal models for human disorders including for instance demyelinating central nervous system (CNS) diseases, measles, cancer, and spinal cord injury (SCI) [<xref rid="pone.0183572.ref015" ref-type="bibr">15</xref>&#x02013;<xref rid="pone.0183572.ref021" ref-type="bibr">21</xref>]. Conclusively, dogs represent a promising so called large animal model in the development of novel therapeutic approaches for naturally occurring diseases. However, despite the essential role of dogs as a translational animal model, there is a considerable lack of knowledge of the role of macrophage polarization in this species, and morphologic, phenotypic, and transcriptomic properties of polarized canine macrophages are enigmatic so far. However, a detailed knowledge of these basic principles doubtlessly represents a prerequisite for envisaged pharmacotherapeutic and cell transplantation studies.</p><p>Therefore, this <italic>in vitro</italic> study aimed to (i) characterize morphological differences of polarized canine macrophages, (ii) to test the capability of established murine and human prototypical markers to differentiate canine M1- and M2-macrophages using immunofluorescence, and (iii) to unravel differences in the transcriptome of canine polarized macrophages using microarray technique in order to establish unique gene signatures, which differentiate these polarization states.</p><p>The presented results provide a highly needed basis for future research upon canine spontaneous diseases such as SCI and distemper leukoencephalitis with a special emphasis upon the so far enigmatic role of macrophage polarization in these diseases.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and methods</title><sec id="sec003"><title>Blood cell isolation</title><p>Blood samples were collected from a total number of 12 healthy Beagle dogs, which were kept in regulatory approved animal housing facilities of the Departments of Small Animal Medicine and Surgery and the Institute for Parasitology, University of Veterinary Medicine, Hannover, Germany. Blood collection was done by professional veterinarians from non-anesthetized dogs following the regulations of the German Animal Welfare Law and with permission provided by the Nieders&#x000e4;chsisches Landesamt f&#x000fc;r Verbraucherschutz und Lebensmittelsicherheit, Oldenburg, Germany (permission number: AZ33.9-42502-05-13A303). Following a clinical examination of each animal, which included auscultation of the lung and heart, and rectal measurement of the body temperature, the puncture spot was disinfected. A volume of 20 ml blood was collected from the cephalic vein of each dog. Following blood collection, local manual pressure was used to avoid bleeding. No animals were euthanized for the present study.</p><p>Peripheral blood mononuclear cells (PBMCs) were isolated via density gradient centrifugation using a routine protocol as described previously [<xref rid="pone.0183572.ref022" ref-type="bibr">22</xref>]. Briefly, blood samples were diluted 1:3 in phosphate buffered saline (PBS) containing 1% penicillin/streptomycin (Biochrom GmbH, Berlin, Germany) and added onto a gradient with equal volumes of histopaque 1.077 g/ml and 1.119 g/ml (Sigma Aldrich, Taufkirchen, Germany). After 30 minutes of centrifugation, cells were harvested using a Pasteur pipette, washed with PBS and 1% penicillin/streptomycin followed by depletion of erythrocyte contamination by hypotone lysis with distilled water. Subsequently, cells were resuspended in Roswell Park Memorial Institute (RPMI)-medium 1640 (Biochrom GmbH, Berlin, Germany) containing 10% fetal calf serum (PAA, C&#x000f6;lbe, Germany) and 1% penicillin/streptomycin and seeded onto 96&#x000bd;-well plates (ThermoScientific, Waltham, MA, USA) at a density of 0.3 x 10^6 cells/well. After 24 hours of cultivation under standard conditions (5% CO<sub>2</sub>, 37&#x000b0;C), medium was completely removed and cells were washed twice with PBS and 1% penicillin/streptomycin. Cells attached to the base of wells with strong plastic adherence were referred to as monocytes [<xref rid="pone.0183572.ref023" ref-type="bibr">23</xref>&#x02013;<xref rid="pone.0183572.ref026" ref-type="bibr">26</xref>].</p></sec><sec id="sec004"><title>Cell culture and polarization</title><p>To culture canine macrophages <italic>in vitro</italic> from blood-derived monocytes, a protocol according to Durafourt et al. (2012) [<xref rid="pone.0183572.ref027" ref-type="bibr">27</xref>] was used with slight modifications. Briefly, canine monocytes were cultured over 7 days towards M1-/M2-macrophages by stimulation with hematopoietic growth factors over 5 days followed by activation over 2 days with distinct cytokines, purchased from companies that guarantee an endotoxin level below 0.1 EU/&#x003bc;g of protein. In particular, to obtain M1-macrophages, monocytes were treated with 5 ng/ml canine recombinant granulocyte macrophage colony-stimulating factor (GM-CSF; R&#x00026;D Systems, Minneapolis, MN, USA), 100 ng/ml LPS (Sigma Aldrich, Taufkirchen, Germany), and 20 ng/ml recombinant canine IFN&#x00263; (Kingfisher Biotech Inc., Saint Paul, Minnesota, USA). M2-macrophages were developed by treatment with 25 ng/ml human macrophage colony-stimulating factor (M-CSF, PeproTech Inc., Rocky Hill, NJ, USA) and 20 ng/ml canine recombinant IL-4 (R&#x00026;D Systems, Minneapolis, MN, USA). Serving as a control, unstimulated monocytes were cultured under the same conditions with medium change every second day (M0-macrophages). After 7 days of cultivation, morphology, phenotype, and transcriptomic changes of M0-, M1-, and M2-macrophages were assessed. Pictures were taken with an inverted fluorescence microscope (Olympus IX-70, Olympus, Optical Co GmbH, Hamburg, Germany).</p><p>The overall number of cells for each polarization was counted on at least 4 microscopic pictures (200x magnification) of three individual dogs on day 7 in culture and the mean numbers of cells per 200x field were compared using one-factorial ANOVA and post-hoc t tests applying SPSS version 21 for windows (IBM Inc., Chicago, USA).</p><p>For quantification of cellular morphology, microphotographs were taken at 200x magnification and the number of cells with a distinct morphologic appearance out of at least 100 randomly selected cells was counted for each polarization (M0, M1, M2). Here, 4 distinct morphologic types were defined. In particular, cells with a cellular diameter &#x02264; 10 &#x003bc;m and absent cytoplasmic projections on the cellular surface were defined as small/roundish cells (morphology 1); cells with a cellular diameter &#x02265; 10 &#x003bc;m and numerous cytoplasmic processes were defined as amoeboid (morphology 2); cells obtaining an elongated bipolar morphology were classified as spindeloid (morphology 3); and cells possessing a large, round, and flattened morphology with a cellular diameter &#x02265; 30 &#x003bc;m and &#x0003e; 1 nuclei were classified as multinucleated giant cells (MNGs; morphology 4).</p><p>The percentage of each of the four different morphologies was calculated in M0-, M1-, and M2-macrophages from 3 animals. A mixed ANOVA with post-hoc alpha adjustment (Tukey-Kramer) and significance level at p&#x02264;0.05 was performed using the statistical software programme SPSS version 21 for windows (IBM Inc., Chicago, USA) in order to compare the percentages of each of the morphologies between M0-, M1-, and M2-macrophages. Graphical compilation was done with GraphPad Prism 5.0 (GraphPad Software Inc., La Jolla, USA).</p></sec><sec id="sec005"><title>Scanning electron microscopy</title><p>M0-, M1-, and M2-macrophages were prepared for representative ultrastructural characterization using scanning electron microscopy as described previously [<xref rid="pone.0183572.ref028" ref-type="bibr">28</xref>]. Briefly, cells were fixed in 2.5% glutaraldehyde/cacodylate buffer, post-fixed in 1% osmium tetroxide, and dehydrated in a graded series of alcohol. Subsequently, cells were dried under a Critical Point Dryer (E3000, Polaron, London, UK), and sputter-coated with gold, and examined under a digital scanning electron microscope (DSM 940, Zeiss, Oberkochen, Germany). At least 50 cells were photographed for each morphology and evaluated with regard to ultrastructural morphology.</p></sec><sec id="sec006"><title>Immunocytochemistry</title><p>Immunolabelling of canine M0-, M1-, and M2-macrophages from 5 individuals was performed using a routine protocol described previously [<xref rid="pone.0183572.ref029" ref-type="bibr">29</xref>, <xref rid="pone.0183572.ref030" ref-type="bibr">30</xref>]. A panel of different literature-based prototype marker antibodies, reported to distinguish between M1- and M2-macrophages was applied (<xref ref-type="table" rid="pone.0183572.t001">Table 1</xref>; [<xref rid="pone.0183572.ref004" ref-type="bibr">4</xref>, <xref rid="pone.0183572.ref031" ref-type="bibr">31</xref>]). Briefly, cells were fixed with paraformaldehyde (PFA, 4%) for 20 minutes at room temperature (RT) and permeabilized with Triton X (0.25%) diluted in PBS (PBST). Non-specific binding was blocked by treatment of cells with bovine serum albumin (BSA, 3%; Sigma Aldrich, Taufkirchen, Germany) and normal goat serum (5%) diluted in PBST for 15 minutes at RT, except for cells intended to be stained with antibodies directed against Fc-receptors, <italic>i</italic>.<italic>e</italic>. CD16 and CD32. Subsequently, primary antibodies (<xref ref-type="table" rid="pone.0183572.t001">Table 1</xref>) were added and incubated for 2 hours at RT. All unconjugated primary antibodies were labeled with secondary goat-anti-mouse antibodies coupled to cyanine 3 (Cy3), goat-anti-rat antibodies coupled to Cy2, and goat-anti-rabbit antibodies coupled to Cy3 (all received from Jackson ImmunoResearch Laboratories, Dianova, Hamburg, Germany; dilution 1:200 in PBS), respectively, and incubated for 2 hours at RT. Following appropriate washing steps with PBS and distilled water, nuclei were counterstained with bisbenzimide (H33258, 0.01% in distilled water) for 5 minutes at RT. Species-specific immunoglobulins from mouse, rat, goat, and rabbit diluted according to the immunoglobulin concentration of the primary antibodies served as appropriate negative controls. M0-, M1-, and M2-macrophages were investigated using an inverted fluorescence microscope (Olympus IX-70, Olympus, Optical Co GmbH, Hamburg, Germany). For quantification of immunopositivity, microphotographs were taken at 200x magnification and at least 100 randomly selected cells were counted for each treatment (M0, M1, M2) with respect to the number of immunopositive cells and the total number of cells. Statistical comparison of the percentage of immunopositive cells between M0-, M1-, and M2-macrophages was done using a Kruskal-Wallis-Test and pairwise Mann-Whitney-U-Tests with significance level at p&#x02264;0.05 employing the statistical software programme SPSS version 21 for windows, and box plots were depicted using GraphPad Prism 5.0 (GraphPad Software Inc., La Jolla, USA).</p><table-wrap id="pone.0183572.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183572.t001</object-id><label>Table 1</label><caption><title>List of antibodies used for immunofluorescence.</title></caption><alternatives><graphic id="pone.0183572.t001g" xlink:href="pone.0183572.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" rowspan="1" colspan="1">Polarity</th><th align="justify" rowspan="1" colspan="1">Antigen</th><th align="justify" rowspan="1" colspan="1">Clone</th><th align="justify" rowspan="1" colspan="1">Clonality</th><th align="justify" rowspan="1" colspan="1">Source</th><th align="justify" rowspan="1" colspan="1">Dilution</th></tr></thead><tbody><tr><td align="left" rowspan="5" colspan="1">M1</td><td align="left" rowspan="1" colspan="1">CD16</td><td align="left" rowspan="1" colspan="1">LNK16</td><td align="left" rowspan="1" colspan="1">Monoclonal mouse</td><td align="left" rowspan="1" colspan="1">Abcam<xref ref-type="table-fn" rid="t001fn002">&#x02021;</xref></td><td align="left" rowspan="1" colspan="1">1:20</td></tr><tr><td align="left" rowspan="1" colspan="1">CD32</td><td align="left" rowspan="1" colspan="1">AT10</td><td align="left" rowspan="1" colspan="1">Monoclonal mouse</td><td align="left" rowspan="1" colspan="1">Abcam<xref ref-type="table-fn" rid="t001fn002">&#x02021;</xref></td><td align="left" rowspan="1" colspan="1">1:10</td></tr><tr><td align="left" rowspan="1" colspan="1">MHC class II</td><td align="left" rowspan="1" colspan="1">Dog 26</td><td align="left" rowspan="1" colspan="1">Monoclonal rat</td><td align="left" rowspan="1" colspan="1">Helmholtz Zentrum<xref ref-type="table-fn" rid="t001fn003">&#x02020;</xref></td><td align="left" rowspan="1" colspan="1">1:10</td></tr><tr><td align="left" rowspan="1" colspan="1">iNOS</td><td align="left" rowspan="1" colspan="1">n.a.</td><td align="left" rowspan="1" colspan="1">Polyclonal rabbit</td><td align="left" rowspan="1" colspan="1">Merck Milipore<xref ref-type="table-fn" rid="t001fn004">&#x016ed;</xref></td><td align="left" rowspan="1" colspan="1">1:50</td></tr><tr><td align="left" rowspan="1" colspan="1">LXN</td><td align="left" rowspan="1" colspan="1">n.a.</td><td align="left" rowspan="1" colspan="1">Polyclonal goat</td><td align="left" rowspan="1" colspan="1">Biologo <xref ref-type="table-fn" rid="t001fn008">*</xref></td><td align="left" rowspan="1" colspan="1">1:10</td></tr><tr><td align="left" rowspan="4" colspan="1">M2</td><td align="left" rowspan="1" colspan="1">MS4A2</td><td align="left" rowspan="1" colspan="1">n.a.</td><td align="left" rowspan="1" colspan="1">Polyclonal rabbit</td><td align="left" rowspan="1" colspan="1">Biologo <xref ref-type="table-fn" rid="t001fn008">*</xref></td><td align="left" rowspan="1" colspan="1">1:10</td></tr><tr><td align="left" rowspan="1" colspan="1">CD163</td><td align="left" rowspan="1" colspan="1">AM-3K</td><td align="left" rowspan="1" colspan="1">Monoclonal mouse</td><td align="left" rowspan="1" colspan="1">TransGenic Inc. <xref ref-type="table-fn" rid="t001fn005">&#x02016;</xref></td><td align="left" rowspan="1" colspan="1">1:20</td></tr><tr><td align="left" rowspan="1" colspan="1">CD206</td><td align="left" rowspan="1" colspan="1">3.29B1.10</td><td align="left" rowspan="1" colspan="1">Monoclonal mouse</td><td align="left" rowspan="1" colspan="1">BeckmanCoulter Inc.<xref ref-type="table-fn" rid="t001fn006">&#x000b6;</xref></td><td align="left" rowspan="1" colspan="1">1:20</td></tr><tr><td align="left" rowspan="1" colspan="1">Arginase-1</td><td align="left" rowspan="1" colspan="1">n.a.</td><td align="left" rowspan="1" colspan="1">Polyclonal rabbit</td><td align="left" rowspan="1" colspan="1">Sigma Aldrich<xref ref-type="table-fn" rid="t001fn007">&#x000a7;</xref></td><td align="left" rowspan="1" colspan="1">1:125</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>CD, cluster of differentiation; MHC, major histocompatibility complex; iNOS, inducible nitric oxide synthase, LXN, latexin; n.a. = not applicable</p></fn><fn id="t001fn002"><p>&#x02021;Cambridge, UK</p></fn><fn id="t001fn003"><p>&#x02020;kindly provided by Dr. E Kremmer, Institute of Molecular Immunology, Helmholtz Zentrum, M&#x000fc;nchen, German Research Center for Environmental Health (GmbH), Munich, Germany</p></fn><fn id="t001fn004"><p>&#x016ed;Darmstadt, Germany</p></fn><fn id="t001fn005"><p>&#x02016;Kobe, Japan</p></fn><fn id="t001fn006"><p>&#x000b6;Krefeld, Germany</p></fn><fn id="t001fn007"><p>&#x000a7; Taufkirchen, Germany</p></fn><fn id="t001fn008"><p>* Kronshagen, Germany</p></fn></table-wrap-foot></table-wrap><p>Based on the results of the transcriptome investigations (see below), two additional antibodies targeting LXN and MS4A2 (<xref ref-type="table" rid="pone.0183572.t001">Table 1</xref>) were applied on isolated and polarized cells of 3 dogs. Immunofluorescence was performed analogously to the above mentioned methods. For these antibodies, blocking was done with normal horse serum. Donkey-anti-goat and donkey-anti-rabbit antibodies were used as secondary antibodies. Due to the lower n (3 dogs), statistical comparison of the percentage of immunopositive cells between M0-, M1-, and M2-macrophages was done using parametrical tests (one-factorial ANOVA and pairwise t tests) for these both antibodies.</p></sec><sec id="sec007"><title>RNA isolation, microarray hybridization, and low level analysis</title><p>For RNA-isolation a separate and analogous <italic>in vitro</italic> experiment was performed using blood-derived cells from 6 healthy Beagles. Total RNA was isolated from 6 biological replicates of M0-, M1- and M2- macrophages using the RNeasy Mini Kit according to the manufacturer&#x02019;s instructions (Qiagen, Hilden, Germany). Quality and integrity of isolated RNA were controlled using the Agilent 6000 RNA Nano Kit and an Agilent Bioanalyzer 2100 (Agilent, B&#x000f6;blingen, Germany). 200 ng RNA of each sample was amplified and biotin-labeled employing the Ovation RNA Amplification Kit V2 and the Encore Biotin Module (NuGen, San Carlos, USA), and hybridized to GeneChip Canine Genome 2.0 arrays (Affymetrix, Santa Clara, USA) in a rotating oven (45&#x000b0;C, 16 hours). Subsequently, arrays were washed and stained with R-phycoerythrin-streptavidin employing Affymetrix GeneChip Fluidics Station 450 (Affymetrix, Santa Clara, USA). For scanning, an Affymetrix GeneChip Scanner 3000 (Affymetrix, Santa Clara, USA) was employed for signal detection. Background adjustment, quantile normalization, and probe-set summarization were performed using the Gene Chip Robust Multichip Average (GC-RMA) algorithm (Bioconductor <italic>gcrma</italic> for R package, Version 2.3) as previously described [<xref rid="pone.0183572.ref032" ref-type="bibr">32</xref>]. Raw and processed data sets of the present study are deposited and publically available in the ArrayExpress database (accession number: E-MTAB-5458; <ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/arrayexpress">http://www.ebi.ac.uk/arrayexpress</ext-link>).</p></sec><sec id="sec008"><title>Differentially expressed probe sets</title><p>Differentially expressed probe sets (DEPs) were detected using the Linear Models for Microarray Data (LIMMA) algorithm, implemented in Babelomics 4.3 (<ext-link ext-link-type="uri" xlink:href="http://babelomics.bioinfo.cipf.es/">http://babelomics.bioinfo.cipf.es</ext-link>; [<xref rid="pone.0183572.ref033" ref-type="bibr">33</xref>]), with a maximal false discovery rate (FDR) of 5% (q&#x02264;0.05) according to Benjamini and Hochberg, followed by <italic>post-hoc</italic> pairwise comparison of the expression levels of M0-, M1-, and M2-macrophages [<xref rid="pone.0183572.ref032" ref-type="bibr">32</xref>, <xref rid="pone.0183572.ref034" ref-type="bibr">34</xref>]. The fold change (FC) was calculated as the ratio of the inverse-transformed arithmetic means of the log<sub>2</sub>-transformed expression values. Down-regulations are shown as negative reciprocal values [<xref rid="pone.0183572.ref034" ref-type="bibr">34</xref>, <xref rid="pone.0183572.ref035" ref-type="bibr">35</xref>]. Probe sets were annotated with canine gene symbols and gene names according to the Affymetrix annotation file (release 35; 06. October 2014). A statistical significance filter (LIMMA q&#x02264;0.05) and a fold change filter (FC&#x02265;2.0 or &#x02264;2.0) were employed to identify differentially expressed probe sets (DEPs) [<xref rid="pone.0183572.ref032" ref-type="bibr">32</xref>]. Differentially expressed genes (DEGs) were defined as probe sets with a unique canine gene symbol annotation [<xref rid="pone.0183572.ref036" ref-type="bibr">36</xref>].</p></sec><sec id="sec009"><title>Functional annotation and hierarchical clustering analysis</title><p>Functional enrichment analysis of the DEPs for overexpressed Gene Ontology (GO) terms of the biological process category and the Kyoto encyclopedia of genes and genomes (KEGG) was performed using Web-based Gene Set Analysis Toolkit (WebGestalt; <ext-link ext-link-type="uri" xlink:href="http://bioinfo.vanderbilt.edu/webgestalt/">http://bioinfo.vanderbilt.edu/webgestalt/</ext-link>; [<xref rid="pone.0183572.ref037" ref-type="bibr">37</xref>&#x02013;<xref rid="pone.0183572.ref039" ref-type="bibr">39</xref>]). In order to detect the genes in the pairwise comparison of M0-, M1-, and M2-macrophages, whose expression was most severely affected, genes with a FC&#x02265;50.0 or &#x02264;-50.0 were selected and grouped into biological categories [<xref rid="pone.0183572.ref036" ref-type="bibr">36</xref>].</p><p>Moreover, unsupervised hierarchical clustering analysis of the DEPs was performed on log<sub>2</sub>-transformed data using TM4 MultiExperimentViewer (MeV) with default settings (Euclidean distance and complete linkage) [<xref rid="pone.0183572.ref040" ref-type="bibr">40</xref>]. The list of DEPs for each of the resulting clusters was functionally analyzed for significant enrichment applying WebGestalt as described above.</p></sec><sec id="sec010"><title>Correlation-based marker gene selection</title><p>Based on the transcriptional profile, a subset of probe sets for polarization prediction was selected using Prophet [<xref rid="pone.0183572.ref041" ref-type="bibr">41</xref>], provided by Babelomics 4.3 [<xref rid="pone.0183572.ref033" ref-type="bibr">33</xref>, <xref rid="pone.0183572.ref042" ref-type="bibr">42</xref>]. Correlation-based feature selection was used to pre-select the informative subset of probe sets and K-nearest-neighbors (KNN) algorithm was used for class prediction with leave-one out error validation [<xref rid="pone.0183572.ref042" ref-type="bibr">42</xref>]. The informative subset of 369 probe sets derived from Prophet was further analyzed for the polarization prediction strength of each individual probe set in three independent &#x0201c;M0 <italic>versus</italic> M1 and M2&#x0201d;, &#x0201c;M1 <italic>versus</italic> M0 and M2&#x0201d;, and &#x0201c;M2 <italic>versus</italic> M0 and M1&#x0201d; tests using Signature evaluation tool (SET; [<xref rid="pone.0183572.ref042" ref-type="bibr">42</xref>, <xref rid="pone.0183572.ref043" ref-type="bibr">43</xref>]). The log<sub>2</sub>-transformed expression values of three biomarkers, suggested by Prophet, were additionally statistically compared between M0-, M1-, and M2-macrophages, employing Kruskal-Wallis-Test and subsequent pairwise Mann-Whitney-U-Tests with significance value p&#x02264;0.05.</p></sec><sec id="sec011"><title>Comparative evaluation of canine M1-/M2-genes with established literature-based human and murine orthologous genes</title><p>All unique gene symbols, which were up-regulated (FC&#x02265;2; q&#x02264;0.05) in the comparison of M1 <italic>vs</italic>. M0 and simultaneously up-regulated in the comparison of M1 <italic>vs</italic>. M2 were defined as M1-exclusive-genes (n = 404). Likewise, all unique gene symbols, which were up-regulated (FC&#x02265; 2; q&#x02264;0.05) in the comparison of M2 <italic>vs</italic>. M0 and simultaneously up-regulated in the comparison of M2 <italic>vs</italic>. M1 were defined as M2-exclusive-genes (n = 700). The gene sets of these exclusive M1- or M2-associated canine genes were compared with a list of established human and murine genes specifically associated with M1- or M2-macrophages. This list was generated based on peer-reviewed publications [<xref rid="pone.0183572.ref004" ref-type="bibr">4</xref>, <xref rid="pone.0183572.ref027" ref-type="bibr">27</xref>, <xref rid="pone.0183572.ref031" ref-type="bibr">31</xref>, <xref rid="pone.0183572.ref044" ref-type="bibr">44</xref>] as previously described [<xref rid="pone.0183572.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0183572.ref045" ref-type="bibr">45</xref>]. This list was translated into canine orthologous gene symbols by employing MADgene (<ext-link ext-link-type="uri" xlink:href="http://cardioserve.nantes.inserm.fr/madtools/madgene/">http://cardioserve.nantes.inserm.fr/madtools/madgene/</ext-link>; [<xref rid="pone.0183572.ref046" ref-type="bibr">46</xref>]) and missing orthologous canine official gene symbols were manually added with the help of the web-based &#x0201c;information hyperlinked over proteins&#x0201d; (ihop; <ext-link ext-link-type="uri" xlink:href="http://www.ihop-net.org/UniPub/iHOP/">http://www.ihop-net.org/UniPub/iHOP/</ext-link>; [<xref rid="pone.0183572.ref047" ref-type="bibr">47</xref>]) as described previously [<xref rid="pone.0183572.ref036" ref-type="bibr">36</xref>]. Summarized, the literature-based gene list included a total number of 65 orthologous canine genes for M1-macrophages and 58 orthologous canine genes for M2-macrophages [<xref rid="pone.0183572.ref036" ref-type="bibr">36</xref>]. Venn diagrams (<ext-link ext-link-type="uri" xlink:href="http://bioinfogp.cnb.csic.es/tools/venny/index.html">http://bioinfogp.cnb.csic.es/tools/venny/index.html</ext-link>) were used to reveal the intersections between established literature-based genes and the gene sets identified by the present analysis.</p></sec></sec><sec sec-type="results" id="sec012"><title>Results</title><sec id="sec013"><title>Morphological characterization of polarized canine macrophages</title><p>On day 7 in culture, the overall number of cells differed between the three polarities (p = 0.02; <xref ref-type="supplementary-material" rid="pone.0183572.s001">S1 Fig</xref>). The number of cells was highest in M2-polarized cells (mean = 135 cells per field), while M0-macrophages were lowest in number (mean = 30 cells per field). M1-macrophages had a mean number of 52 cells per field. T tests revealed that the number of M2-macrophages was significantly higher than M0-macrophages (p = 0.02), while comparisons between M0- and M1-macrophages and M1-and M2-macrophages failed to reach the level of significance (p = 0.30 and p = 0.06, respectively).</p><p>Morphologically, striking differences between M0-, M1-, and M2-polarized cells were observed at day 7 in culture by scanning electron microscopy and phase contrast microscopy (<xref ref-type="fig" rid="pone.0183572.g001">Fig 1</xref>). Canine M0-macrophages predominantly appeared as small and roundish cells with an average size of 8 &#x003bc;m in diameter and no or little cytoplasmic extensions that measured up to 1 &#x003bc;m in length (<xref ref-type="fig" rid="pone.0183572.g001">Fig 1</xref>). However, a noteworthy proportion of M0-macrophages (about 25%) also obtained an amoeboid morphology, which however was predominantly observed in M1 macrophages (<xref ref-type="fig" rid="pone.0183572.g001">Fig 1</xref>). The majority of M1-macrophages was amoeboid and had a mean size of 15 &#x003bc;m and numerous fibrillary cytoplasmic processes on the cellular surface that had a length of up to 5 &#x003bc;m (<xref ref-type="fig" rid="pone.0183572.g001">Fig 1</xref>). M2-macrophages appeared as a heterogeneous cell population with a mixture of 4 different morphologies. Besides roundish and amoeboid macrophages, large bipolar spindeloid macrophages were present measuring up to 35 &#x003bc;m that were characterized by an elongated cell body with cytoplasmic extensions with an average length of 7 &#x003bc;m at both poles (<xref ref-type="fig" rid="pone.0183572.g001">Fig 1</xref>). Moreover, large MNGs appeared that had a mean size of 40 &#x003bc;m with an extensive cytoplasm and numerous evenly distributed processes that measured up to 7 &#x003bc;m (<xref ref-type="fig" rid="pone.0183572.g001">Fig 1</xref>). Allover, the mean percentage of small/roundish macrophages (morphology 1) was significantly higher in untreated cultures (M0) compared to polarity 2 at days 5 and 7 (p&#x02264;0.05; <xref ref-type="fig" rid="pone.0183572.g001">Fig 1E</xref>). For amoeboid macrophages (morphology 2), there was a trend towards a higher mean percentage in polarity 1 compared to polarity 0 at day 5 (p = 0.07) and day 7 (p = 0.06; <xref ref-type="fig" rid="pone.0183572.g001">Fig 1F</xref>). The mean percentage of spindeloid macrophages (morphology 3) was significantly higher in polarity 2 at day 5 compared to polarity 1 at day 5 (p&#x02264;0.05; <xref ref-type="fig" rid="pone.0183572.g001">Fig 1G</xref>). MNGs (morphology 4) were exclusively present in polarity 2, as compared to the polarities 0 and 1 at day 7 (p&#x02264;0.05; <xref ref-type="fig" rid="pone.0183572.g001">Fig 1H</xref>).</p><fig id="pone.0183572.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183572.g001</object-id><label>Fig 1</label><caption><title>Polarization-dependent morphological differences in canine M0-, M1-, and M2-macrophage cultures.</title><p><bold>A)</bold> In scanning electron microscopy, unstimulated macrophages (M0; day 7) obtain a small and roundish morphology, lacking cytoplasmic extensions. <bold>B)</bold> M1-treated macrophages (day 7) are characterized by an enlarged amoeboid cell shape with roundish cell bodies and numerous delicate cytoplasmic extensions on the cellular surface. <bold>C; D)</bold> M2-treated macrophage cultures (day 7) demonstrate a marked heterogeneity with two dominating cell types. Large &#x0201c;spindeloid&#x0201d; macrophages with an elongated cell body and cytoplasmic extensions on the apical ends of the cell bodies <bold>(C)</bold>. Second, in M2-cultures, numerous multinucleated giant cells (MNGs) with abundant cytoplasmic projections on the cellular surface are present <bold>(D)</bold>. <bold>E-H)</bold> Dot plot diagrams depicting the morphological changes of macrophage cultures (n = 3) following stimulation (M0, M1, M2) over the time course as calculated with a mixed ANOVA with post-hoc alpha adjustment (Tukey-Kramer) and significance level at p&#x02264;0.05 (asterisks). <bold>E)</bold> Small/roundish macrophages dominate in untreated M0 cell cultures and their relative percentage is significantly higher in M0 when compared to M2 at days 5 and 7. <bold>F)</bold> Amoeboid macrophages display a statistical trend of predominance in M1 compared to M0 at day 5 and 7. <bold>G)</bold> The relative percentage of spindeloid macrophages is significantly increased in M2 at day 5 compared to M1. <bold>H)</bold> MNGs are almost exclusively observed in M2-macrophages at the end of the culturing period and their percentage is significantly higher at day 7 in M2 compared to both M0 and M1.</p></caption><graphic xlink:href="pone.0183572.g001"/></fig></sec><sec id="sec014"><title>Phenotypical characterization of polarized canine macrophages</title><p>For the phenotypical characterization of canine macrophages, the percentage of immunopositive cells for selected literature-based M1-/M2-antigens was evaluated in 5 animals and related to the polarization of cells (polarity 0, 1, 2). Interestingly, except for MHC class II and CD206, none of the remaining tested antigens (CD16, CD32, iNOS, CD163, and arginase-1) were differently expressed between canine M0-, M1-, and M2-macrophages (p-values ranging from 0.101 to 0.691; Kruskal-Wallis-Test; <xref ref-type="fig" rid="pone.0183572.g002">Fig 2</xref>).</p><fig id="pone.0183572.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183572.g002</object-id><label>Fig 2</label><caption><title>Immunofluorescence staining of <italic>in vitro</italic> cultured canine M0-, M1-, and M2-macrophages labeled with prototypic literature-based antibodies for the M1- (CD16, CD32, MHC class II, and iNOS) and M2-phenotype (CD163, CD206, and arginase 1), respectively.</title><p><bold>A-C)</bold> Low to moderate membranous staining of M0-, M1-, and M2-macrophages for CD16. <bold>D-F)</bold> Likewise, CD32 shows a low to moderate staining in all three treatment conditions. <bold>G-I)</bold> M0-, M1-, and M2-macrophages demonstrate a moderate to high membranous staining with CD163. <bold>J-L)</bold> Intense membranous staining of M0-, M1-, and M2-macrophages with an anti-MHC class II antibody. <bold>M-O)</bold> Strong intracytoplasmic labeling of macrophages in all treatments (polarity 0, 1, 2) for inducible nitric oxide synthase (iNOS). <bold>P-R)</bold> High intracytoplasmic expression of arginase 1 in small/roundish, amoeboid, and spindeloid macrophages as well as in multinucleated giant cells (MNGs). <bold>a-f)</bold> Statistical evaluation of the mean expression percentages of prototypic M1-/M2-markers evaluated in 5 dogs and related to the polarization state of the macrophages (polarity 0, 1, 2). Note that, except for MHC class II, none of the remaining tested antigens (CD16, CD32, iNOS, CD163, and arginase-1) were differently expressed between canine M0-, M1-, and M2-macrophages (* = p&#x02264;0.05; Kruskal-Wallis-Test with pairwise Mann-Whitney-U-Tests). Scale bars = 100 &#x003bc;m. Nuclear counterstaining with bisbenzimide.</p></caption><graphic xlink:href="pone.0183572.g002"/></fig><p>The mean percentage of immunopositive cells expressing MHC class II was significantly higher in M2-macrophages (mean positive cells: 93.64%) when compared to untreated M0-cells (mean positive cells: 72.22%; p = 0.008). However, there was no statistical difference in the percentage of positive cells for MHC class II, when M1-macophages (mean positive cells: 89.92%) were compared to M2-macrophages and M0-macrophages, respectively (<xref ref-type="fig" rid="pone.0183572.g002">Fig 2</xref>).</p><p>For CD206, the mean percentage of immunopositive cells was highest in M2-macrophages (mean: 66.54%) as compared to both M0-macrophages (mean: 33.33%; p = 0.008) and M1-macrophages (mean: 28.67%; p = 0.032, <xref ref-type="fig" rid="pone.0183572.g003">Fig 3</xref>). No statistical difference was observed between M1- and M0-macrophages (<xref ref-type="fig" rid="pone.0183572.g003">Fig 3</xref>). The results were validated in the microarray data set, which similarly revealed significantly higher expression levels of CD206 in canine M2-macrophages as compared to both M1- (p = 0.002) and M0-macrophages (p = 0.004; <xref ref-type="fig" rid="pone.0183572.g003">Fig 3</xref>).</p><fig id="pone.0183572.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183572.g003</object-id><label>Fig 3</label><caption><title>Phenotypical characterization of canine M0-, M1-, and M2-macrophages.</title><p><bold>A)</bold> Low membranous expression of CD206 antigen by small/roundish M0-macrophages. <bold>B)</bold> Moderate membranous staining of amoeboid M1-macrophages for CD206. <bold>C)</bold> Intense membranous expression of CD206 antigen by M2-macrophages. Scale bars = 100 &#x003bc;m. Nuclear counterstaining with bisbenzimide. <bold>D)</bold> The mean percentage of CD206-immunopositive cells is significantly higher in M2-macrophages as compared to both M1- and M0-macrophages (* = p&#x02264;0.05; Kruskal-Wallis-Test with pair-wise Mann-Whitney-U-Tests). <bold>E)</bold> The log<sub>2</sub>-transformed expression values of the probe set encoding for the gene CD206 is similarly significantly higher in M2-macrophages compared to both M1- and M0-macrophages (* = p&#x02264;0.05; Kruskal-Wallis-Test with pair-wise Mann-Whitney-U-Tests), thus confirming the results of the immunofluorescence investigation.</p></caption><graphic xlink:href="pone.0183572.g003"/></fig></sec><sec id="sec015"><title>Differentially expressed genes between M0-, M1-, and M2-polarized macrophage cultures</title><p>One-factorial multigroup analysis of microarray data and fold change criteria identified 6358 probe sets that were differentially expressed in at least one of the three post-hoc pairwise comparisons. The total number of DEPs was 3555 in M1 <italic>vs</italic>. M0, 4831 in M2 <italic>vs</italic>. M0, and 3141 in M2 <italic>vs</italic>. M1, respectively (<xref ref-type="table" rid="pone.0183572.t002">Table 2</xref>). In all pairwise comparisons, the number of up- and down-regulated probe sets was nearly equally distributed (M1 <italic>vs</italic>. M0: 1699 up, 1856 down; M2 <italic>vs</italic>. M0: 2467 up, 2364 down; M2 <italic>vs</italic>. M1: 1572 up, 1569 down). Functional annotation of enriched biological processes in DEPs, up&#x02013;regulated in the comparison M1 <italic>vs</italic>. M0, revealed terms for &#x0201c;organonitrogen compound metabolic process&#x0201d;, &#x0201c;carbohydrate metabolic process&#x0201d;, &#x0201c;carboxylic acid metabolic process&#x0201d;, and &#x0201c;tricarboxylic acid cycle&#x0201d; (<xref ref-type="table" rid="pone.0183572.t002">Table 2</xref>). In contrast, biological terms in down-regulated DEPs in this comparison reflected terms for &#x0201c;positive regulation of immune response&#x0201d;, &#x0201c;immune response-regulating signaling pathway&#x0201d;, and &#x0201c;regulation of innate immune response&#x0201d;. In both comparisons M2 <italic>vs</italic>. M0 and M2 <italic>vs</italic>. M1, up-regulated DEPs displayed significantly enriched gene ontology terms for &#x0201c;M phase of mitotic cell cycle&#x0201d; and &#x0201c;mitotic spindle organization&#x0201d;. Additionally, in M2 <italic>vs</italic>. M0 comparison, up-regulated DEPs were associated with &#x0201c;oxidation-reduction process&#x0201d;, &#x0201c;carboxylic acid metabolic process&#x0201d;, and &#x0201c;organonitrogen compound metabolic process&#x0201d;, whereas down-regulated DEPs were related to the biological term &#x0201c;immune response-activating signal transduction&#x0201d;. In the comparisons M2 <italic>vs</italic>. M1, down-regulated DEPs were functionally associated to biological terms such as &#x0201c;response to other organism&#x0201d;, &#x0201c;defense response&#x0201d;, &#x0201c;regulation of lymphocyte activation&#x0201d;, and &#x0201c;regulation of immune response&#x0201d; (<xref ref-type="table" rid="pone.0183572.t002">Table 2</xref>).</p><table-wrap id="pone.0183572.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183572.t002</object-id><label>Table 2</label><caption><title>Summarized results of the functional annotation of the pairwise comparisons of differentially expressed probe sets (DEPs) in canine M0-, M1-, and M2-macrophages.</title></caption><alternatives><graphic id="pone.0183572.t002g" xlink:href="pone.0183572.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Pairwise comparison</th><th align="center" rowspan="1" colspan="1">Differentially expressed probe sets</th><th align="center" rowspan="1" colspan="1">Up-/down-regulated probe sets</th><th align="center" rowspan="1" colspan="1">Enriched biological process categories<xref ref-type="table-fn" rid="t002fn001">*</xref></th><th align="center" rowspan="1" colspan="1">Enriched KEGG pathways<xref ref-type="table-fn" rid="t002fn001">*</xref></th></tr></thead><tbody><tr><td align="center" rowspan="2" colspan="1">M1 <italic>vs</italic>. M0</td><td align="center" rowspan="2" colspan="1">3555</td><td align="center" rowspan="1" colspan="1">Up: 1699</td><td align="left" rowspan="1" colspan="1">&#x02022; Organonitrogen compound metabolic process<break/>&#x02022; Carbohydrate metabolic process<break/>&#x02022; Tricarboxylic acid cycle</td><td align="left" rowspan="1" colspan="1">&#x02022; Metabolic pathways<break/>&#x02022; Glutathione metabolism<break/>&#x02022; Steroid biosynthesis<break/>&#x02022; Glycolysis/Gluconeogenesis</td></tr><tr><td align="center" rowspan="1" colspan="1">Down: 1856</td><td align="left" rowspan="1" colspan="1">&#x02022; Positive regulation of immune response<break/>&#x02022; Immune response-regulating signaling pathway<break/>&#x02022; Regulation of innate immune response</td><td align="left" rowspan="1" colspan="1">&#x02022; Hematopoietic cell lineage<break/>&#x02022; RIG-I-like receptor signaling pathway<break/>&#x02022; T cell receptor signaling pathway<break/>&#x02022; Cell adhesion molecules</td></tr><tr><td align="center" rowspan="2" colspan="1">M2 <italic>vs</italic>. M0</td><td align="center" rowspan="2" colspan="1">4831</td><td align="center" rowspan="1" colspan="1">Up: 2467</td><td align="left" rowspan="1" colspan="1">&#x02022; Oxidation-reduction process<break/>&#x02022; Carboxylic acid metabolic process<break/>&#x02022; Organonitrogen compound metabolic process<break/>&#x02022; M-phase of mitotic cell cycle</td><td align="left" rowspan="1" colspan="1">&#x02022; Metabolic pathways<break/>&#x02022; Glycolysis/Gluconeogenesis<break/>&#x02022; Propanoate and pyruvate metabolism<break/>&#x02022; Steroid biosynthesis<break/>&#x02022; Cell cycle</td></tr><tr><td align="center" rowspan="1" colspan="1">Down: 2364</td><td align="left" rowspan="1" colspan="1">&#x02022; Immune response-activating signal transduction</td><td align="left" rowspan="1" colspan="1">&#x02022; T cell receptor signaling pathway<break/>&#x02022; Natural killer cell mediated cytotoxicity<break/>&#x02022; Hematopoietic cell lineage</td></tr><tr><td align="center" rowspan="2" colspan="1">M2 <italic>vs</italic>. M1</td><td align="center" rowspan="2" colspan="1">3141</td><td align="center" rowspan="1" colspan="1">Up: 1572</td><td align="left" rowspan="1" colspan="1">&#x02022; Mitotic spindle organization</td><td align="left" rowspan="1" colspan="1">&#x02022; Cell cycle<break/>&#x02022; Metabolic pathways<break/>&#x02022; Ribosome biogenesis in eukaryotes<break/>&#x02022; PPAR signaling pathway</td></tr><tr><td align="center" rowspan="1" colspan="1">Down: 1569</td><td align="left" rowspan="1" colspan="1">&#x02022; Response to other organism<break/>&#x02022; Defense response<break/>&#x02022; Regulation of lymphocyte activation<break/>&#x02022; Regulation of immune response</td><td align="left" rowspan="1" colspan="1">&#x02022; NOD-like receptor signaling pathway<break/>&#x02022; Osteoclast differentiation<break/>&#x02022; Toll-like receptor signaling pathway<break/>&#x02022; B and T cell receptor signaling pathway</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>* employing Web-based Gene Set Analysis Toolkit (WebGestalt; <ext-link ext-link-type="uri" xlink:href="http://bioinfo.vanderbilt.edu/webgestalt/">http://bioinfo.vanderbilt.edu/webgestalt/</ext-link>) with default settings</p></fn><fn id="t002fn002"><p>adjusted p-value &#x02264;0.05</p></fn></table-wrap-foot></table-wrap><p>Enriched KEGG-pathways, significantly associated with up-regulated canine DEPs in M1 <italic>vs</italic>. M0 (1699 DEPs), were functionally related to &#x0201c;metabolic pathways&#x0201d;, &#x0201c;glutathione metabolism&#x0201d;, &#x0201c;steroid biosynthesis&#x0201d;, and &#x0201c;glycolysis/gluconeogenesis&#x0201d;. The comparison M2 <italic>vs</italic>. M0 (2467 up-regulated DEPs) contained enriched KEGG-pathways for &#x0201c;metabolic pathways&#x0201d;, &#x0201c;glycolysis/gluconeogenesis&#x0201d;, &#x0201c;propanoate and pyruvate metabolism&#x0201d;, &#x0201c;steroid biosynthesis&#x0201d;, and &#x0201c;cell cycle&#x0201d;. In the comparison M2 <italic>vs</italic>. M1 (1572 up-regulated DEPs), enriched KEGG-pathways included terms for &#x0201c;cell cycle&#x0201d;, &#x0201c;metabolic pathways&#x0201d;, &#x0201c;ribosome biogenesis in eukaryotes&#x0201d;, and &#x0201c;PPAR signaling pathway&#x0201d;. In contrast, down-regulated DEPs in the three comparisons were associated with &#x0201c;hematopoietic cell lineage&#x0201d;, &#x0201c;RIG-I-like receptor signaling pathway&#x0201d;, &#x0201c;T cell receptor signaling pathway&#x0201d;, and &#x0201c;cell adhesion molecules&#x0201d; (M1 <italic>vs</italic>. M0), &#x0201c;T cell receptor signaling pathway&#x0201d;, &#x0201c;natural killer cell mediated cytotoxicity&#x0201d;, and &#x0201c;hematopoietic cell lineage&#x0201d; (M2 <italic>vs</italic>. M0), and &#x0201c;NOD-like receptor signaling pathway&#x0201d;, &#x0201c;osteoclast differentiation&#x0201d;, &#x0201c;Toll-like receptor signaling pathway&#x0201d;, and &#x0201c;B and T cell receptor signaling pathway&#x0201d; (M2 <italic>vs</italic>. M1; <xref ref-type="table" rid="pone.0183572.t002">Table 2</xref>).</p><p>Genes whose expression was most severely affected (FC &#x02265;50.0 or &#x02264;-50.0) in the pairwise comparison are depicted in Tables <xref ref-type="table" rid="pone.0183572.t003">3</xref>, <xref ref-type="table" rid="pone.0183572.t004">4</xref> and <xref ref-type="table" rid="pone.0183572.t005">5</xref>. Fortynine genes fulfilled these filtering criteria in the M1 <italic>vs</italic>. M0 contrast (25 up, 24 down), whereas 99 genes were retrieved in the comparison of M2 <italic>vs</italic>. M0 (41 up; 58 down). Comparing M2 with M1, 66 genes fulfilled the criteria (32 up; 34 down). Focusing on potentially promising cell surface markers, the pairwise comparison of three genes encoding for such surface molecules were up-regulated in M1 <italic>vs</italic>. M0, namely <italic>SUCNR1</italic>, <italic>SDC4</italic>, and <italic>CHRNA9</italic>, whereas <italic>CD209</italic>, <italic>CD180</italic>, <italic>KLRG1</italic>, <italic>COLEC12</italic>, and <italic>C3AR1</italic> were down-regulated (<xref ref-type="table" rid="pone.0183572.t003">Table 3</xref>). Comparing M2 <italic>vs</italic>. M0, nine cell surface makers were up-regulated, <italic>i</italic>.<italic>e</italic>. <italic>LYVE1</italic>, <italic>SUCNR1</italic>, <italic>CD1e</italic>, <italic>MRC1</italic>, <italic>TSPAN7</italic>, <italic>JAM3</italic>, <italic>ANTXR1</italic>, <italic>MS4A2</italic>, and <italic>CLEC4G</italic> (<xref ref-type="table" rid="pone.0183572.t004">Table 4</xref>). In contrast, a total amount of 18 cell surface marker genes was down-regulated, namely <italic>ITGB8</italic>, <italic>LY6E</italic>, <italic>TRDC</italic>, <italic>NCR3</italic>, <italic>SELL</italic>, <italic>SIGLEC1</italic>, <italic>KLRD1</italic>, <italic>KLRB1</italic>, <italic>MPP6</italic>, <italic>P2RY14</italic>, <italic>TRBC2</italic>, <italic>TARP</italic>, <italic>FCRLA</italic>, <italic>KCNK5</italic>, <italic>P2RX5</italic>, <italic>NKG7</italic>, <italic>CD69</italic>, and <italic>CD7</italic> (<xref ref-type="table" rid="pone.0183572.t004">Table 4</xref>). In the comparison M2 <italic>vs</italic>. M1, the up-regulated cell surface marker genes contained 10 terms for <italic>FCER1A</italic>, <italic>CD209</italic>, <italic>LYVE1</italic>, <italic>CLEC4G</italic>, <italic>COLEC12</italic>, <italic>JAM3</italic>, <italic>MS4A2</italic>, <italic>STAB1</italic>, <italic>MRC1</italic>, and <italic>SLC15A1</italic> (<xref ref-type="table" rid="pone.0183572.t005">Table 5</xref>). Down-regulated cell surface marker genes were <italic>P2RY14</italic>, <italic>SLC39A14</italic>, <italic>ITGB8</italic>, <italic>TMEM150C</italic>, <italic>TMEM176A</italic>, and <italic>SLC22A15</italic> (<xref ref-type="table" rid="pone.0183572.t005">Table 5</xref>).</p><table-wrap id="pone.0183572.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183572.t003</object-id><label>Table 3</label><caption><title>List and subgrouping of the top hits of highly differentially expressed genes (fold change &#x02265; 50 or &#x02264; -50) in canine M1- <italic>vs</italic>. M0-macrophages.</title></caption><alternatives><graphic id="pone.0183572.t003g" xlink:href="pone.0183572.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Gene name</th><th align="left" rowspan="1" colspan="1">Gene symbol</th><th align="left" rowspan="1" colspan="1">Fold change</th></tr></thead><tbody><tr><td align="center" colspan="3" rowspan="1"><bold><italic>Up-regulated genes</italic></bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Cell surface markers</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Succinate receptor 1</td><td align="left" rowspan="1" colspan="1">SUCNR1</td><td align="right" rowspan="1" colspan="1">212.94</td></tr><tr><td align="left" rowspan="1" colspan="1">Syndecan 4</td><td align="left" rowspan="1" colspan="1">SDC4</td><td align="right" rowspan="1" colspan="1">58.61</td></tr><tr><td align="left" rowspan="1" colspan="1">Cholinergic receptor, nicotinic, alpha 9 (neuronal)</td><td align="left" rowspan="1" colspan="1">CHRNA9</td><td align="right" rowspan="1" colspan="1">53.74</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Enzymes</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ADP-ribosylhydrolase like 2</td><td align="left" rowspan="1" colspan="1">ADPRHL2</td><td align="right" rowspan="1" colspan="1">535.59</td></tr><tr><td align="left" rowspan="1" colspan="1">Ceruloplasmin (ferroxidase)</td><td align="left" rowspan="1" colspan="1">CP</td><td align="right" rowspan="1" colspan="1">161.88</td></tr><tr><td align="left" rowspan="1" colspan="1">Epoxide hydrolase 2, cytoplasmic</td><td align="left" rowspan="1" colspan="1">EPHX2</td><td align="right" rowspan="1" colspan="1">119.72</td></tr><tr><td align="left" rowspan="1" colspan="1">Ectonucleotide pyrophosphatase/phosphodiesterase 2</td><td align="left" rowspan="1" colspan="1">ENPP2</td><td align="right" rowspan="1" colspan="1">117.43</td></tr><tr><td align="left" rowspan="1" colspan="1">Interstitial collagenase-like</td><td align="left" rowspan="1" colspan="1">LOC489428</td><td align="right" rowspan="1" colspan="1">87.83</td></tr><tr><td align="left" rowspan="1" colspan="1">E3 ubiquitin-protein ligase NEURL3-like</td><td align="left" rowspan="1" colspan="1">LOC102152163</td><td align="right" rowspan="1" colspan="1">86.20</td></tr><tr><td align="left" rowspan="1" colspan="1">NOP2/Sun domain family, member 7</td><td align="left" rowspan="1" colspan="1">NSUN7</td><td align="right" rowspan="1" colspan="1">66.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Nucleoredoxin</td><td align="left" rowspan="1" colspan="1">NXN</td><td align="right" rowspan="1" colspan="1">64.78</td></tr><tr><td align="left" rowspan="1" colspan="1">WNK lysine deficient protein kinase 2</td><td align="left" rowspan="1" colspan="1">WNK2</td><td align="right" rowspan="1" colspan="1">52.35</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Cytokines</italic>, <italic>chemokines</italic>, <italic>and their Receptors</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Interleukin 6 (interferon, beta 2)</td><td align="left" rowspan="1" colspan="1">IL6</td><td align="right" rowspan="1" colspan="1">252.32</td></tr><tr><td align="left" rowspan="1" colspan="1">Chemokine (C-C motif) ligand 22</td><td align="left" rowspan="1" colspan="1">CCL22</td><td align="right" rowspan="1" colspan="1">187.96</td></tr><tr><td align="left" rowspan="1" colspan="1">Chemokine (C-X-C motif) receptor 7</td><td align="left" rowspan="1" colspan="1">ACKR3</td><td align="right" rowspan="1" colspan="1">178.18</td></tr><tr><td align="left" rowspan="1" colspan="1">Interleukin 22 receptor, alpha 2</td><td align="left" rowspan="1" colspan="1">IL22RA2</td><td align="right" rowspan="1" colspan="1">116.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Chemokine (C-X-C motif) ligand 14</td><td align="left" rowspan="1" colspan="1">CXCL14</td><td align="right" rowspan="1" colspan="1">108.55</td></tr><tr><td align="left" rowspan="1" colspan="1">Chemokine (C-C motif) ligand 17</td><td align="left" rowspan="1" colspan="1">CCL17</td><td align="right" rowspan="1" colspan="1">95.26</td></tr><tr><td align="left" rowspan="1" colspan="1">Chemokine (C-C motif) ligand 20</td><td align="left" rowspan="1" colspan="1">CCL20</td><td align="right" rowspan="1" colspan="1">67.90</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Soluble factors</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Chitinase 3-like 1 (cartilage glycoprotein-39)</td><td align="left" rowspan="1" colspan="1">CHI3L1</td><td align="right" rowspan="1" colspan="1">83.25</td></tr><tr><td align="left" rowspan="1" colspan="1">Clusterin</td><td align="left" rowspan="1" colspan="1">CLU</td><td align="right" rowspan="1" colspan="1">66.23</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Miscellaneous</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Ras homolog family member U</td><td align="left" rowspan="1" colspan="1">RHOU</td><td align="right" rowspan="1" colspan="1">446.23</td></tr><tr><td align="left" rowspan="1" colspan="1">Interferon, alpha-inducible protein 6</td><td align="left" rowspan="1" colspan="1">IFI6</td><td align="right" rowspan="1" colspan="1">269.13</td></tr><tr><td align="left" rowspan="1" colspan="1">CXADR-like membrane protein</td><td align="left" rowspan="1" colspan="1">CLMP</td><td align="right" rowspan="1" colspan="1">213.81</td></tr><tr><td align="left" rowspan="1" colspan="1">Retinoic acid induced 14</td><td align="left" rowspan="1" colspan="1">RAI14</td><td align="right" rowspan="1" colspan="1">118.86</td></tr><tr><td align="center" colspan="3" rowspan="1"><bold><italic>Down-regulated genes</italic></bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Cell surface markers</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CD209 molecule</td><td align="left" rowspan="1" colspan="1">CD209</td><td align="right" rowspan="1" colspan="1">-345.12</td></tr><tr><td align="left" rowspan="1" colspan="1">CD180 molecule</td><td align="left" rowspan="1" colspan="1">CD180</td><td align="right" rowspan="1" colspan="1">-75.00</td></tr><tr><td align="left" rowspan="1" colspan="1">Killer cell lectin-like receptor subfamily G, member 1</td><td align="left" rowspan="1" colspan="1">KLRG1</td><td align="right" rowspan="1" colspan="1">-66.25</td></tr><tr><td align="left" rowspan="1" colspan="1">Collectin sub-family member 12</td><td align="left" rowspan="1" colspan="1">COLEC12</td><td align="right" rowspan="1" colspan="1">-61.81</td></tr><tr><td align="left" rowspan="1" colspan="1">Complement component 3a receptor 1</td><td align="left" rowspan="1" colspan="1">C3AR1</td><td align="right" rowspan="1" colspan="1">-55.16</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Enzymes</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Carboxypeptidase M</td><td align="left" rowspan="1" colspan="1">CPM</td><td align="right" rowspan="1" colspan="1">-134.50</td></tr><tr><td align="left" rowspan="1" colspan="1">N-acetylneuraminate pyruvate lyase (dihydrodipicolinate synthase)</td><td align="left" rowspan="1" colspan="1">NPL</td><td align="right" rowspan="1" colspan="1">-78.98</td></tr><tr><td align="left" rowspan="1" colspan="1">Cathepsin E</td><td align="left" rowspan="1" colspan="1">CTSE</td><td align="right" rowspan="1" colspan="1">-76.30</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Cytokines</italic>, <italic>chemokines</italic>, <italic>and their receptors</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Chemokine (C-X-C motif) ligand 12</td><td align="left" rowspan="1" colspan="1">CXCL12</td><td align="right" rowspan="1" colspan="1">-401.92</td></tr><tr><td align="left" rowspan="1" colspan="1">Pro-platelet basic protein (chemokine (C-X-C motif) ligand 7)</td><td align="left" rowspan="1" colspan="1">PPBP</td><td align="right" rowspan="1" colspan="1">-100.42</td></tr><tr><td align="left" rowspan="1" colspan="1">Interleukin 2</td><td align="left" rowspan="1" colspan="1">IL2</td><td align="right" rowspan="1" colspan="1">-95.84</td></tr><tr><td align="left" rowspan="1" colspan="1">Interleukin 1 receptor, type II</td><td align="left" rowspan="1" colspan="1">IL1R2</td><td align="right" rowspan="1" colspan="1">-79.71</td></tr><tr><td align="left" rowspan="1" colspan="1">Chemokine (C-C motif) receptor 3</td><td align="left" rowspan="1" colspan="1">CCR3</td><td align="right" rowspan="1" colspan="1">-51.05</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Soluble factors</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Lipocalin 2</td><td align="left" rowspan="1" colspan="1">LCN2</td><td align="right" rowspan="1" colspan="1">-180.73</td></tr><tr><td align="left" rowspan="1" colspan="1">CD5 molecule-like</td><td align="left" rowspan="1" colspan="1">CD5L</td><td align="right" rowspan="1" colspan="1">-153.48</td></tr><tr><td align="left" rowspan="1" colspan="1">Secreted phosphoprotein 2, 24kDa</td><td align="left" rowspan="1" colspan="1">SPP2</td><td align="right" rowspan="1" colspan="1">-51.92</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Miscellaneous</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Coagulation factor XIII, A1 polypeptide</td><td align="left" rowspan="1" colspan="1">F13A1</td><td align="right" rowspan="1" colspan="1">-3305.03</td></tr><tr><td align="left" rowspan="1" colspan="1">Fatty acid binding protein 4, adipocyte</td><td align="left" rowspan="1" colspan="1">FABP4</td><td align="right" rowspan="1" colspan="1">-370.34</td></tr><tr><td align="left" rowspan="1" colspan="1">G protein-coupled receptor 116</td><td align="left" rowspan="1" colspan="1">GPR116</td><td align="right" rowspan="1" colspan="1">-130.89</td></tr><tr><td align="left" rowspan="1" colspan="1">Interferon-induced transmembrane protein 3-like</td><td align="left" rowspan="1" colspan="1">LOC606890</td><td align="right" rowspan="1" colspan="1">-114.16</td></tr><tr><td align="left" rowspan="1" colspan="1">Plexin domain containing 2</td><td align="left" rowspan="1" colspan="1">PLXDC2</td><td align="right" rowspan="1" colspan="1">-67.07</td></tr><tr><td align="left" rowspan="1" colspan="1">ADP-ribosylation factor-like 4C</td><td align="left" rowspan="1" colspan="1">ARL4C</td><td align="right" rowspan="1" colspan="1">-56.52</td></tr><tr><td align="left" rowspan="1" colspan="1">Cyclin J-like</td><td align="left" rowspan="1" colspan="1">CCNJL</td><td align="right" rowspan="1" colspan="1">-54.76</td></tr><tr><td align="left" rowspan="1" colspan="1">Thrombospondin 1</td><td align="left" rowspan="1" colspan="1">THBS1</td><td align="right" rowspan="1" colspan="1">-53.38</td></tr></tbody></table></alternatives></table-wrap><table-wrap id="pone.0183572.t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183572.t004</object-id><label>Table 4</label><caption><title>List and subgrouping of the top hits of highly differentially expressed genes (fold change &#x02265; 50 or &#x02264; -50) in canine M2- <italic>vs</italic>. M0-macrophages.</title></caption><alternatives><graphic id="pone.0183572.t004g" xlink:href="pone.0183572.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Gene name</th><th align="left" rowspan="1" colspan="1">Gene symbol</th><th align="left" rowspan="1" colspan="1">Fold change</th></tr></thead><tbody><tr><td align="center" colspan="3" rowspan="1"><bold><italic>Up-regulated genes</italic></bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Cell surface markers</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Lymphatic vessel endothelial hyaluronan receptor 1</td><td align="left" rowspan="1" colspan="1">LYVE1</td><td align="right" rowspan="1" colspan="1">322.32</td></tr><tr><td align="left" rowspan="1" colspan="1">Succinate receptor 1</td><td align="left" rowspan="1" colspan="1">SUCNR1</td><td align="right" rowspan="1" colspan="1">151.91</td></tr><tr><td align="left" rowspan="1" colspan="1">CD1e molecule</td><td align="left" rowspan="1" colspan="1">CD1E</td><td align="right" rowspan="1" colspan="1">147.40</td></tr><tr><td align="left" rowspan="1" colspan="1">Mannose receptor, C type 1</td><td align="left" rowspan="1" colspan="1">MRC1</td><td align="right" rowspan="1" colspan="1">104.41</td></tr><tr><td align="left" rowspan="1" colspan="1">Tetraspanin 7</td><td align="left" rowspan="1" colspan="1">TSPAN7</td><td align="right" rowspan="1" colspan="1">83.25</td></tr><tr><td align="left" rowspan="1" colspan="1">Junctional adhesion molecule 3</td><td align="left" rowspan="1" colspan="1">JAM3</td><td align="right" rowspan="1" colspan="1">78.46</td></tr><tr><td align="left" rowspan="1" colspan="1">Anthrax toxin receptor 1</td><td align="left" rowspan="1" colspan="1">ANTXR1</td><td align="right" rowspan="1" colspan="1">72.95</td></tr><tr><td align="left" rowspan="1" colspan="1">Membrane-spanning 4-domains, subfamily A, member 2</td><td align="left" rowspan="1" colspan="1">MS4A2</td><td align="right" rowspan="1" colspan="1">54.98</td></tr><tr><td align="left" rowspan="1" colspan="1">C-type lectin domain family 4, member G</td><td align="left" rowspan="1" colspan="1">CLEC4G</td><td align="right" rowspan="1" colspan="1">54.14</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Enzymes</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">ADP-ribosylhydrolase like 2</td><td align="left" rowspan="1" colspan="1">ADPRHL2</td><td align="right" rowspan="1" colspan="1">614.52</td></tr><tr><td align="left" rowspan="1" colspan="1">Guanine deaminase</td><td align="left" rowspan="1" colspan="1">GDA</td><td align="right" rowspan="1" colspan="1">174.44</td></tr><tr><td align="left" rowspan="1" colspan="1">Ubiquitin-conjugating enzyme E2 C-like</td><td align="left" rowspan="1" colspan="1">LOC481325</td><td align="right" rowspan="1" colspan="1">151.23</td></tr><tr><td align="left" rowspan="1" colspan="1">Ribonucleotide reductase M2</td><td align="left" rowspan="1" colspan="1">RRM2</td><td align="right" rowspan="1" colspan="1">131.03</td></tr><tr><td align="left" rowspan="1" colspan="1">Fructose-1,6-bisphosphatase 1</td><td align="left" rowspan="1" colspan="1">FBP1</td><td align="right" rowspan="1" colspan="1">57.95</td></tr><tr><td align="left" rowspan="1" colspan="1">Matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)</td><td align="left" rowspan="1" colspan="1">MMP9</td><td align="right" rowspan="1" colspan="1">56.03</td></tr><tr><td align="left" rowspan="1" colspan="1">Lipoprotein lipase</td><td align="left" rowspan="1" colspan="1">LPL</td><td align="right" rowspan="1" colspan="1">52.03</td></tr><tr><td align="left" rowspan="1" colspan="1">Trimethyllysine hydroxylase, epsilon</td><td align="left" rowspan="1" colspan="1">TMLHE</td><td align="right" rowspan="1" colspan="1">51.05</td></tr><tr><td align="left" rowspan="1" colspan="1">3-hydroxybutyrate dehydrogenase, type 2</td><td align="left" rowspan="1" colspan="1">BDH2</td><td align="right" rowspan="1" colspan="1">50.68</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Cytokines</italic>, <italic>chemokines</italic>, <italic>and their receptors</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Chemokine (C-C motif) ligand 24</td><td align="left" rowspan="1" colspan="1">CCL24</td><td align="right" rowspan="1" colspan="1">1060.82</td></tr><tr><td align="left" rowspan="1" colspan="1">Chemokine (C-X-C motif) receptor 7</td><td align="left" rowspan="1" colspan="1">ACKR3</td><td align="right" rowspan="1" colspan="1">390.67</td></tr><tr><td align="left" rowspan="1" colspan="1">Chemokine (C-C motif) ligand 17</td><td align="left" rowspan="1" colspan="1">CCL17</td><td align="right" rowspan="1" colspan="1">209.36</td></tr><tr><td align="left" rowspan="1" colspan="1">Chemokine (C-C motif) ligand 13</td><td align="left" rowspan="1" colspan="1">CCL13</td><td align="right" rowspan="1" colspan="1">172.58</td></tr><tr><td align="left" rowspan="1" colspan="1">Interleukin 13 receptor, alpha 2</td><td align="left" rowspan="1" colspan="1">IL13RA2</td><td align="right" rowspan="1" colspan="1">170.59</td></tr><tr><td align="left" rowspan="1" colspan="1">Transforming growth factor, beta 2</td><td align="left" rowspan="1" colspan="1">TGFB2</td><td align="right" rowspan="1" colspan="1">61.84</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Soluble factors</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Nephronectin</td><td align="left" rowspan="1" colspan="1">NPNT</td><td align="right" rowspan="1" colspan="1">444.07</td></tr><tr><td align="left" rowspan="1" colspan="1">Norrie disease (pseudoglioma)</td><td align="left" rowspan="1" colspan="1">NDP</td><td align="right" rowspan="1" colspan="1">213.72</td></tr><tr><td align="left" rowspan="1" colspan="1">Endothelin 1</td><td align="left" rowspan="1" colspan="1">EDN1</td><td align="right" rowspan="1" colspan="1">115.81</td></tr><tr><td align="left" rowspan="1" colspan="1">Cystatin 9 (testatin)</td><td align="left" rowspan="1" colspan="1">CST9</td><td align="right" rowspan="1" colspan="1">58.21</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Miscellaneous</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Sodium channel, voltage-gated, type II, beta subunit</td><td align="left" rowspan="1" colspan="1">SCN2B</td><td align="right" rowspan="1" colspan="1">1061.28</td></tr><tr><td align="left" rowspan="1" colspan="1">Caldesmon 1</td><td align="left" rowspan="1" colspan="1">CALD1</td><td align="right" rowspan="1" colspan="1">224.66</td></tr><tr><td align="left" rowspan="1" colspan="1">CXADR-like membrane protein</td><td align="left" rowspan="1" colspan="1">CLMP</td><td align="right" rowspan="1" colspan="1">169.27</td></tr><tr><td align="left" rowspan="1" colspan="1">SHC SH2-domain binding protein 1</td><td align="left" rowspan="1" colspan="1">SHCBP1</td><td align="right" rowspan="1" colspan="1">117.77</td></tr><tr><td align="left" rowspan="1" colspan="1">Dynamin 1</td><td align="left" rowspan="1" colspan="1">DNM1</td><td align="right" rowspan="1" colspan="1">112.78</td></tr><tr><td align="left" rowspan="1" colspan="1">NACC family member 2, BEN and BTB (POZ) domain containing</td><td align="left" rowspan="1" colspan="1">NACC2</td><td align="right" rowspan="1" colspan="1">110.49</td></tr><tr><td align="left" rowspan="1" colspan="1">Retinoic acid induced 14</td><td align="left" rowspan="1" colspan="1">RAI14</td><td align="right" rowspan="1" colspan="1">84.35</td></tr><tr><td align="left" rowspan="1" colspan="1">Scinderin</td><td align="left" rowspan="1" colspan="1">SCIN</td><td align="right" rowspan="1" colspan="1">71.66</td></tr><tr><td align="left" rowspan="1" colspan="1">Kinesin family member 23</td><td align="left" rowspan="1" colspan="1">KIF23</td><td align="right" rowspan="1" colspan="1">66.78</td></tr><tr><td align="left" rowspan="1" colspan="1">Kinesin family member 11</td><td align="left" rowspan="1" colspan="1">KIF11</td><td align="right" rowspan="1" colspan="1">64.20</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa-mir-125b-2</td><td align="left" rowspan="1" colspan="1">cfa-mir-125b-2</td><td align="right" rowspan="1" colspan="1">58.78</td></tr><tr><td align="left" rowspan="1" colspan="1">AHNAK nucleoprotein</td><td align="left" rowspan="1" colspan="1">AHNAK</td><td align="right" rowspan="1" colspan="1">57.19</td></tr><tr><td align="left" rowspan="1" colspan="1">NUF2, NDC80 kinetochore complex component</td><td align="left" rowspan="1" colspan="1">NUF2</td><td align="right" rowspan="1" colspan="1">54.62</td></tr><tr><td align="center" colspan="3" rowspan="1"><bold><italic>Down-regulated genes</italic></bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Cell surface markers</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Integrin, beta 8</td><td align="left" rowspan="1" colspan="1">ITGB8</td><td align="right" rowspan="1" colspan="1">-199.37</td></tr><tr><td align="left" rowspan="1" colspan="1">Lymphocyte antigen 6 complex, locus E</td><td align="left" rowspan="1" colspan="1">LY6E</td><td align="right" rowspan="1" colspan="1">-116.70</td></tr><tr><td align="left" rowspan="1" colspan="1">T cell receptor delta constant</td><td align="left" rowspan="1" colspan="1">TRDC</td><td align="right" rowspan="1" colspan="1">-112.73</td></tr><tr><td align="left" rowspan="1" colspan="1">Natural cytotoxicity triggering receptor 3</td><td align="left" rowspan="1" colspan="1">NCR3</td><td align="right" rowspan="1" colspan="1">-105.99</td></tr><tr><td align="left" rowspan="1" colspan="1">Selectin L</td><td align="left" rowspan="1" colspan="1">SELL</td><td align="right" rowspan="1" colspan="1">-95.45</td></tr><tr><td align="left" rowspan="1" colspan="1">Sialic acid binding Ig-like lectin 1, sialoadhesin</td><td align="left" rowspan="1" colspan="1">SIGLEC1</td><td align="right" rowspan="1" colspan="1">-91.39</td></tr><tr><td align="left" rowspan="1" colspan="1">Killer cell lectin-like receptor subfamily D, member 1</td><td align="left" rowspan="1" colspan="1">KLRD1</td><td align="right" rowspan="1" colspan="1">-87.12</td></tr><tr><td align="left" rowspan="1" colspan="1">Killer cell lectin-like receptor subfamily B, member 1</td><td align="left" rowspan="1" colspan="1">KLRB1</td><td align="right" rowspan="1" colspan="1">-74.56</td></tr><tr><td align="left" rowspan="1" colspan="1">Membrane protein, palmitoylated 6 (MAGUK p55 subfamily member 6)</td><td align="left" rowspan="1" colspan="1">MPP6</td><td align="right" rowspan="1" colspan="1">-72.60</td></tr><tr><td align="left" rowspan="1" colspan="1">Purinergic receptor P2Y, G-protein coupled, 14</td><td align="left" rowspan="1" colspan="1">P2RY14</td><td align="right" rowspan="1" colspan="1">-71.69</td></tr><tr><td align="left" rowspan="1" colspan="1">T cell receptor beta constant 2</td><td align="left" rowspan="1" colspan="1">TRBC2</td><td align="right" rowspan="1" colspan="1">-64.26</td></tr><tr><td align="left" rowspan="1" colspan="1">TCR gamma alternate reading frame protein</td><td align="left" rowspan="1" colspan="1">TARP</td><td align="right" rowspan="1" colspan="1">-62.39</td></tr><tr><td align="left" rowspan="1" colspan="1">Fc receptor-like A</td><td align="left" rowspan="1" colspan="1">FCRLA</td><td align="right" rowspan="1" colspan="1">-60.06</td></tr><tr><td align="left" rowspan="1" colspan="1">Potassium channel, subfamily K, member 5</td><td align="left" rowspan="1" colspan="1">KCNK5</td><td align="right" rowspan="1" colspan="1">-58.16</td></tr><tr><td align="left" rowspan="1" colspan="1">Purinergic receptor P2X, ligand-gated ion channel, 5</td><td align="left" rowspan="1" colspan="1">P2RX5</td><td align="right" rowspan="1" colspan="1">-58.16</td></tr><tr><td align="left" rowspan="1" colspan="1">Natural killer cell group 7 sequence</td><td align="left" rowspan="1" colspan="1">NKG7</td><td align="right" rowspan="1" colspan="1">-57.26</td></tr><tr><td align="left" rowspan="1" colspan="1">CD69 molecule</td><td align="left" rowspan="1" colspan="1">CD69</td><td align="right" rowspan="1" colspan="1">-54.53</td></tr><tr><td align="left" rowspan="1" colspan="1">CD7 molecule</td><td align="left" rowspan="1" colspan="1">CD7</td><td align="right" rowspan="1" colspan="1">-52.57</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Enzymes</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Interferon stimulated exonuclease gene 20kDa</td><td align="left" rowspan="1" colspan="1">ISG20</td><td align="right" rowspan="1" colspan="1">-514.04</td></tr><tr><td align="left" rowspan="1" colspan="1">Prostaglandin E synthase</td><td align="left" rowspan="1" colspan="1">PTGES</td><td align="right" rowspan="1" colspan="1">-382.20</td></tr><tr><td align="left" rowspan="1" colspan="1">Cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial</td><td align="left" rowspan="1" colspan="1">CMPK2</td><td align="right" rowspan="1" colspan="1">-266.50</td></tr><tr><td align="left" rowspan="1" colspan="1">Granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3)</td><td align="left" rowspan="1" colspan="1">GZMA</td><td align="right" rowspan="1" colspan="1">-131.27</td></tr><tr><td align="left" rowspan="1" colspan="1">Granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1)</td><td align="left" rowspan="1" colspan="1">GZMB</td><td align="right" rowspan="1" colspan="1">-130.63</td></tr><tr><td align="left" rowspan="1" colspan="1">Hexokinase 3 (white cell)</td><td align="left" rowspan="1" colspan="1">HK3</td><td align="right" rowspan="1" colspan="1">-127.10</td></tr><tr><td align="left" rowspan="1" colspan="1">Ubiquitin specific peptidase 18</td><td align="left" rowspan="1" colspan="1">USP18</td><td align="right" rowspan="1" colspan="1">-81.72</td></tr><tr><td align="left" rowspan="1" colspan="1">Phospholipase A1 member A</td><td align="left" rowspan="1" colspan="1">PLA1A</td><td align="right" rowspan="1" colspan="1">-72.65</td></tr><tr><td align="left" rowspan="1" colspan="1">Cathepsin E</td><td align="left" rowspan="1" colspan="1">CTSE</td><td align="right" rowspan="1" colspan="1">-72.13</td></tr><tr><td align="left" rowspan="1" colspan="1">GTP cyclohydrolase 1</td><td align="left" rowspan="1" colspan="1">GCH1</td><td align="right" rowspan="1" colspan="1">-66.29</td></tr><tr><td align="left" rowspan="1" colspan="1">Chymase 1, mast cell</td><td align="left" rowspan="1" colspan="1">CMA1</td><td align="right" rowspan="1" colspan="1">-61.45</td></tr><tr><td align="left" rowspan="1" colspan="1">Phospholipid scramblase 1-like</td><td align="left" rowspan="1" colspan="1">LOC611500</td><td align="right" rowspan="1" colspan="1">-61.09</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Cytokines</italic>, <italic>chemokines</italic>, <italic>and their receptors</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Chemokine (C-X-C motif) ligand 12</td><td align="left" rowspan="1" colspan="1">CXCL12</td><td align="right" rowspan="1" colspan="1">-417.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Interleukin 2</td><td align="left" rowspan="1" colspan="1">IL2</td><td align="right" rowspan="1" colspan="1">-195.40</td></tr><tr><td align="left" rowspan="1" colspan="1">Interleukin 7 receptor</td><td align="left" rowspan="1" colspan="1">IL7R</td><td align="right" rowspan="1" colspan="1">-66.71</td></tr><tr><td align="left" rowspan="1" colspan="1">Transforming growth factor, beta receptor III</td><td align="left" rowspan="1" colspan="1">TGFBR3</td><td align="right" rowspan="1" colspan="1">-50.94</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Soluble factors</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Lipocalin 2</td><td align="left" rowspan="1" colspan="1">LCN2</td><td align="right" rowspan="1" colspan="1">-217.74</td></tr><tr><td align="left" rowspan="1" colspan="1">Adrenomedullin</td><td align="left" rowspan="1" colspan="1">ADM</td><td align="right" rowspan="1" colspan="1">-100.37</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Miscellaneous</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Radical S-adenosyl methionine domain containing 2</td><td align="left" rowspan="1" colspan="1">RSAD2</td><td align="right" rowspan="1" colspan="1">-559.34</td></tr><tr><td align="left" rowspan="1" colspan="1">Interferon-induced transmembrane protein 3-like</td><td align="left" rowspan="1" colspan="1">LOC606890</td><td align="right" rowspan="1" colspan="1">-435.57</td></tr><tr><td align="left" rowspan="1" colspan="1">ISG15 ubiquitin-like modifier</td><td align="left" rowspan="1" colspan="1">ISG15</td><td align="right" rowspan="1" colspan="1">-254.32</td></tr><tr><td align="left" rowspan="1" colspan="1">Apolipoprotein L, 5</td><td align="left" rowspan="1" colspan="1">APOL5</td><td align="right" rowspan="1" colspan="1">-200.23</td></tr><tr><td align="left" rowspan="1" colspan="1">Fatty acid binding protein 4, adipocyte</td><td align="left" rowspan="1" colspan="1">FABP4</td><td align="right" rowspan="1" colspan="1">-182.17</td></tr><tr><td align="left" rowspan="1" colspan="1">Interferon-induced protein with tetratricopeptide repeats 1</td><td align="left" rowspan="1" colspan="1">IFIT1</td><td align="right" rowspan="1" colspan="1">-142.72</td></tr><tr><td align="left" rowspan="1" colspan="1">Interferon regulatory factor 4-like</td><td align="left" rowspan="1" colspan="1">LOC609817</td><td align="right" rowspan="1" colspan="1">-118.68</td></tr><tr><td align="left" rowspan="1" colspan="1">Carcinoembryonic antigen-related cell adhesion molecule 25</td><td align="left" rowspan="1" colspan="1">CAECAM1</td><td align="right" rowspan="1" colspan="1">-113.27</td></tr><tr><td align="left" rowspan="1" colspan="1">Interferon regulatory factor 7</td><td align="left" rowspan="1" colspan="1">IRF7</td><td align="right" rowspan="1" colspan="1">-102.93</td></tr><tr><td align="left" rowspan="1" colspan="1">OCIA domain containing 2</td><td align="left" rowspan="1" colspan="1">OCIAD2</td><td align="right" rowspan="1" colspan="1">-100.84</td></tr><tr><td align="left" rowspan="1" colspan="1">Piwi-like RNA-mediated gene silencing 4</td><td align="left" rowspan="1" colspan="1">PIWIL4</td><td align="right" rowspan="1" colspan="1">-97.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Synaptotagmin-like 3</td><td align="left" rowspan="1" colspan="1">SYTL3</td><td align="right" rowspan="1" colspan="1">-94.94</td></tr><tr><td align="left" rowspan="1" colspan="1">Testis expressed 14</td><td align="left" rowspan="1" colspan="1">TEX14</td><td align="right" rowspan="1" colspan="1">-92.58</td></tr><tr><td align="left" rowspan="1" colspan="1">Myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 (mouse)</td><td align="left" rowspan="1" colspan="1">MX1</td><td align="right" rowspan="1" colspan="1">-91.32</td></tr><tr><td align="left" rowspan="1" colspan="1">Structural maintenance of chromosomes flexible hinge domain containing 1</td><td align="left" rowspan="1" colspan="1">SMCHD1</td><td align="right" rowspan="1" colspan="1">-84.97</td></tr><tr><td align="left" rowspan="1" colspan="1">Interferon-induced transmembrane protein 1-like</td><td align="left" rowspan="1" colspan="1">LOC475935</td><td align="right" rowspan="1" colspan="1">-83.91</td></tr><tr><td align="left" rowspan="1" colspan="1">eukaryotic peptide chain release factor GTP-binding subunit ERF3B-like</td><td align="left" rowspan="1" colspan="1">LOC480921</td><td align="right" rowspan="1" colspan="1">-74.06</td></tr><tr><td align="left" rowspan="1" colspan="1">Lactotransferrin</td><td align="left" rowspan="1" colspan="1">LTF</td><td align="right" rowspan="1" colspan="1">-72.08</td></tr><tr><td align="left" rowspan="1" colspan="1">DEAD (Asp-Glu-Ala-Asp) box polypeptide 58</td><td align="left" rowspan="1" colspan="1">DDX58</td><td align="right" rowspan="1" colspan="1">-69.54</td></tr><tr><td align="left" rowspan="1" colspan="1">TNFAIP3 interacting protein 3</td><td align="left" rowspan="1" colspan="1">TNIP3</td><td align="right" rowspan="1" colspan="1">-58.03</td></tr><tr><td align="left" rowspan="1" colspan="1">Syntrophin, beta 1 (dystrophin-associated protein A1, 59kDa, basic component 1)</td><td align="left" rowspan="1" colspan="1">SNTB1</td><td align="right" rowspan="1" colspan="1">-55.46</td></tr><tr><td align="left" rowspan="1" colspan="1">Src kinase associated phosphoprotein 1</td><td align="left" rowspan="1" colspan="1">SKAP1</td><td align="right" rowspan="1" colspan="1">-50.58</td></tr></tbody></table></alternatives></table-wrap><table-wrap id="pone.0183572.t005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183572.t005</object-id><label>Table 5</label><caption><title>List and subgrouping of the top hits of highly differentially expressed genes (fold change &#x02265; 50 or &#x02264; -50) in M2- <italic>vs</italic>. M1-macrophages.</title></caption><alternatives><graphic id="pone.0183572.t005g" xlink:href="pone.0183572.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Gene name</th><th align="left" rowspan="1" colspan="1">Gene symbol</th><th align="left" rowspan="1" colspan="1">Fold change</th></tr></thead><tbody><tr><td align="center" colspan="3" rowspan="1"><bold><italic>Up-regulated genes</italic></bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Cell surface markers</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide</td><td align="left" rowspan="1" colspan="1">FCER1A</td><td align="right" rowspan="1" colspan="1">376.89</td></tr><tr><td align="left" rowspan="1" colspan="1">CD209 molecule</td><td align="left" rowspan="1" colspan="1">CD209</td><td align="right" rowspan="1" colspan="1">335.12</td></tr><tr><td align="left" rowspan="1" colspan="1">Lymphatic vessel endothelial hyaluronan receptor 1</td><td align="left" rowspan="1" colspan="1">LYVE1</td><td align="right" rowspan="1" colspan="1">321.11</td></tr><tr><td align="left" rowspan="1" colspan="1">C-type lectin domain family 4, member G</td><td align="left" rowspan="1" colspan="1">CLEC4G</td><td align="right" rowspan="1" colspan="1">183.13</td></tr><tr><td align="left" rowspan="1" colspan="1">Collectin sub-family member 12</td><td align="left" rowspan="1" colspan="1">COLEC12</td><td align="right" rowspan="1" colspan="1">181.04</td></tr><tr><td align="left" rowspan="1" colspan="1">Junctional adhesion molecule 3</td><td align="left" rowspan="1" colspan="1">JAM3</td><td align="right" rowspan="1" colspan="1">145.24</td></tr><tr><td align="left" rowspan="1" colspan="1">Membrane-spanning 4-domains, subfamily A, member 2</td><td align="left" rowspan="1" colspan="1">MS4A2</td><td align="right" rowspan="1" colspan="1">137.95</td></tr><tr><td align="left" rowspan="1" colspan="1">Stabilin 1</td><td align="left" rowspan="1" colspan="1">STAB1</td><td align="right" rowspan="1" colspan="1">127.60</td></tr><tr><td align="left" rowspan="1" colspan="1">Mannose receptor, C type 1</td><td align="left" rowspan="1" colspan="1">MRC1</td><td align="right" rowspan="1" colspan="1">52.68</td></tr><tr><td align="left" rowspan="1" colspan="1">Solute carrier family 15 (oligopeptide transporter), member 1</td><td align="left" rowspan="1" colspan="1">SLC15A1</td><td align="right" rowspan="1" colspan="1">52.03</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Enzymes</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Fructose-1,6-bisphosphatase 1</td><td align="left" rowspan="1" colspan="1">FBP1</td><td align="right" rowspan="1" colspan="1">149.73</td></tr><tr><td align="left" rowspan="1" colspan="1">Uronyl-2-sulfotransferase</td><td align="left" rowspan="1" colspan="1">UST</td><td align="right" rowspan="1" colspan="1">85.20</td></tr><tr><td align="left" rowspan="1" colspan="1">Alanyl (membrane) aminopeptidase</td><td align="left" rowspan="1" colspan="1">ANPEP</td><td align="right" rowspan="1" colspan="1">82.13</td></tr><tr><td align="left" rowspan="1" colspan="1">Lipoprotein lipase</td><td align="left" rowspan="1" colspan="1">LPL</td><td align="right" rowspan="1" colspan="1">57.39</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Cytokines</italic>, <italic>chemokines</italic>, <italic>and their receptors</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Chemokine (C-C motif) ligand 24</td><td align="left" rowspan="1" colspan="1">CCL24</td><td align="right" rowspan="1" colspan="1">1050.11</td></tr><tr><td align="left" rowspan="1" colspan="1">Transforming growth factor, beta 2</td><td align="left" rowspan="1" colspan="1">TGFB2</td><td align="right" rowspan="1" colspan="1">66.97</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Soluble factors</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CD5 molecule-like</td><td align="left" rowspan="1" colspan="1">CD5L</td><td align="right" rowspan="1" colspan="1">209.01</td></tr><tr><td align="left" rowspan="1" colspan="1">Secreted phosphoprotein 2, 24kDa</td><td align="left" rowspan="1" colspan="1">SPP2</td><td align="right" rowspan="1" colspan="1">121.14</td></tr><tr><td align="left" rowspan="1" colspan="1">Nephronectin</td><td align="left" rowspan="1" colspan="1">NPNT</td><td align="right" rowspan="1" colspan="1">105.07</td></tr><tr><td align="left" rowspan="1" colspan="1">Secretogranin V (7B2 protein)</td><td align="left" rowspan="1" colspan="1">SCG5</td><td align="right" rowspan="1" colspan="1">82.69</td></tr><tr><td align="left" rowspan="1" colspan="1">Complement component 3</td><td align="left" rowspan="1" colspan="1">C3</td><td align="right" rowspan="1" colspan="1">67.78</td></tr><tr><td align="left" rowspan="1" colspan="1">Cystatin 9 (testatin)</td><td align="left" rowspan="1" colspan="1">CST9</td><td align="right" rowspan="1" colspan="1">58.53</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Miscellaneous</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Coagulation factor XIII, A1 polypeptide</td><td align="left" rowspan="1" colspan="1">F13A1</td><td align="right" rowspan="1" colspan="1">1309.86</td></tr><tr><td align="left" rowspan="1" colspan="1">Sodium channel, voltage-gated, type II, beta subunit</td><td align="left" rowspan="1" colspan="1">SCN2B</td><td align="right" rowspan="1" colspan="1">1120.45</td></tr><tr><td align="left" rowspan="1" colspan="1">Dynamin 1</td><td align="left" rowspan="1" colspan="1">DNM1</td><td align="right" rowspan="1" colspan="1">247.10</td></tr><tr><td align="left" rowspan="1" colspan="1">Caldesmon 1</td><td align="left" rowspan="1" colspan="1">CALD1</td><td align="right" rowspan="1" colspan="1">239.74</td></tr><tr><td align="left" rowspan="1" colspan="1">Rho GTPase activating protein 6</td><td align="left" rowspan="1" colspan="1">ARHGAP6</td><td align="right" rowspan="1" colspan="1">147.58</td></tr><tr><td align="left" rowspan="1" colspan="1">Fibronectin 1</td><td align="left" rowspan="1" colspan="1">FN1</td><td align="right" rowspan="1" colspan="1">141.81</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa-mir-125b-2</td><td align="left" rowspan="1" colspan="1">cfa-mir-125b-2</td><td align="right" rowspan="1" colspan="1">103.61</td></tr><tr><td align="left" rowspan="1" colspan="1">Plexin domain containing 2</td><td align="left" rowspan="1" colspan="1">PLXDC2</td><td align="right" rowspan="1" colspan="1">71.70</td></tr><tr><td align="left" rowspan="1" colspan="1">Transforming growth factor, beta-induced, 68kDa</td><td align="left" rowspan="1" colspan="1">TGFBI</td><td align="right" rowspan="1" colspan="1">59.20</td></tr><tr><td align="left" rowspan="1" colspan="1">G protein-coupled receptor 116</td><td align="left" rowspan="1" colspan="1">GPR116</td><td align="right" rowspan="1" colspan="1">51.83</td></tr><tr><td align="center" colspan="3" rowspan="1"><bold><italic>Down-regulated genes</italic></bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Cell surface markers</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Purinergic receptor P2Y, G-protein coupled, 14</td><td align="left" rowspan="1" colspan="1">P2RY14</td><td align="right" rowspan="1" colspan="1">-344.22</td></tr><tr><td align="left" rowspan="1" colspan="1">Solute carrier family 39 (zinc transporter), member 14</td><td align="left" rowspan="1" colspan="1">SLC39A14</td><td align="right" rowspan="1" colspan="1">-200.01</td></tr><tr><td align="left" rowspan="1" colspan="1">Integrin, beta 8</td><td align="left" rowspan="1" colspan="1">ITGB8</td><td align="right" rowspan="1" colspan="1">-134.58</td></tr><tr><td align="left" rowspan="1" colspan="1">Transmembrane protein 150C</td><td align="left" rowspan="1" colspan="1">TMEM150C</td><td align="right" rowspan="1" colspan="1">-103.02</td></tr><tr><td align="left" rowspan="1" colspan="1">Transmembrane protein 176A</td><td align="left" rowspan="1" colspan="1">TMEM176A</td><td align="right" rowspan="1" colspan="1">-78.17</td></tr><tr><td align="left" rowspan="1" colspan="1">Solute carrier family 22, member 15</td><td align="left" rowspan="1" colspan="1">SLC22A15</td><td align="right" rowspan="1" colspan="1">-58.69</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Enzymes</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Prostaglandin E synthase</td><td align="left" rowspan="1" colspan="1">PTGES</td><td align="right" rowspan="1" colspan="1">-1274.66</td></tr><tr><td align="left" rowspan="1" colspan="1">Epoxide hydrolase 2, cytoplasmic</td><td align="left" rowspan="1" colspan="1">EPHX2</td><td align="right" rowspan="1" colspan="1">-222.01</td></tr><tr><td align="left" rowspan="1" colspan="1">Interferon stimulated exonuclease gene 20kDa</td><td align="left" rowspan="1" colspan="1">ISG20</td><td align="right" rowspan="1" colspan="1">-187.95</td></tr><tr><td align="left" rowspan="1" colspan="1">Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)</td><td align="left" rowspan="1" colspan="1">PTGS2</td><td align="right" rowspan="1" colspan="1">-183.48</td></tr><tr><td align="left" rowspan="1" colspan="1">E3 ubiquitin-protein ligase NEURL3-like</td><td align="left" rowspan="1" colspan="1">LOC102152163</td><td align="right" rowspan="1" colspan="1">-156.11</td></tr><tr><td align="left" rowspan="1" colspan="1">Indoleamine 2,3-dioxygenase 2</td><td align="left" rowspan="1" colspan="1">IDO2</td><td align="right" rowspan="1" colspan="1">-127.88</td></tr><tr><td align="left" rowspan="1" colspan="1">STEAP family member 4</td><td align="left" rowspan="1" colspan="1">STEAP4</td><td align="right" rowspan="1" colspan="1">-92.42</td></tr><tr><td align="left" rowspan="1" colspan="1">Ceruloplasmin (ferroxidase)</td><td align="left" rowspan="1" colspan="1">CP</td><td align="right" rowspan="1" colspan="1">-90.30</td></tr><tr><td align="left" rowspan="1" colspan="1">Granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1)</td><td align="left" rowspan="1" colspan="1">GZMB</td><td align="right" rowspan="1" colspan="1">-69.42</td></tr><tr><td align="left" rowspan="1" colspan="1">Phospholipase A2, group XVI-like</td><td align="left" rowspan="1" colspan="1">LOC476045</td><td align="right" rowspan="1" colspan="1">-57.39</td></tr><tr><td align="left" rowspan="1" colspan="1">cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial</td><td align="left" rowspan="1" colspan="1">CMPK2</td><td align="right" rowspan="1" colspan="1">-57.00</td></tr><tr><td align="left" rowspan="1" colspan="1">WNK lysine deficient protein kinase 2</td><td align="left" rowspan="1" colspan="1">WNK2</td><td align="right" rowspan="1" colspan="1">-52.30</td></tr><tr><td align="left" rowspan="1" colspan="1">Interleukin-1 receptor-associated kinase 3</td><td align="left" rowspan="1" colspan="1">IRAK3</td><td align="right" rowspan="1" colspan="1">-50.40</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Cytokines</italic>, <italic>chemokines</italic>, <italic>and their receptors</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Chemokine (C-X-C motif) receptor 3</td><td align="left" rowspan="1" colspan="1">CXCR3</td><td align="right" rowspan="1" colspan="1">-140.97</td></tr><tr><td align="left" rowspan="1" colspan="1">Chemokine (C-C motif) ligand 20</td><td align="left" rowspan="1" colspan="1">CCL20</td><td align="right" rowspan="1" colspan="1">-119.64</td></tr><tr><td align="left" rowspan="1" colspan="1">Interleukin 6 (interferon, beta 2)</td><td align="left" rowspan="1" colspan="1">IL6</td><td align="right" rowspan="1" colspan="1">-69.50</td></tr><tr><td align="left" rowspan="1" colspan="1">Tumor necrosis factor</td><td align="left" rowspan="1" colspan="1">TNF</td><td align="right" rowspan="1" colspan="1">-55.63</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Soluble factors</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Complement component 2</td><td align="left" rowspan="1" colspan="1">C2</td><td align="right" rowspan="1" colspan="1">-78.67</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold><italic>Miscellaneous</italic></bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Peptidase inhibitor 3, skin-derived</td><td align="left" rowspan="1" colspan="1">PI3</td><td align="right" rowspan="1" colspan="1">-235.52</td></tr><tr><td align="left" rowspan="1" colspan="1">TNFAIP3 interacting protein 3</td><td align="left" rowspan="1" colspan="1">TNIP3</td><td align="right" rowspan="1" colspan="1">-178.37</td></tr><tr><td align="left" rowspan="1" colspan="1">Ras homolog family member U</td><td align="left" rowspan="1" colspan="1">RHOU</td><td align="right" rowspan="1" colspan="1">-168.17</td></tr><tr><td align="left" rowspan="1" colspan="1">Radical S-adenosyl methionine domain containing 2</td><td align="left" rowspan="1" colspan="1">RSAD2</td><td align="right" rowspan="1" colspan="1">-82.43</td></tr><tr><td align="left" rowspan="1" colspan="1">Cochlin</td><td align="left" rowspan="1" colspan="1">COCH</td><td align="right" rowspan="1" colspan="1">-70.23</td></tr><tr><td align="left" rowspan="1" colspan="1">Interferon, alpha-inducible protein 6</td><td align="left" rowspan="1" colspan="1">IFI6</td><td align="right" rowspan="1" colspan="1">-68.46</td></tr><tr><td align="left" rowspan="1" colspan="1">multiple C2 domains, transmembrane 2</td><td align="left" rowspan="1" colspan="1">MCTP2</td><td align="right" rowspan="1" colspan="1">-66.09</td></tr><tr><td align="left" rowspan="1" colspan="1">Fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus)</td><td align="left" rowspan="1" colspan="1">FSCN1</td><td align="right" rowspan="1" colspan="1">-58.64</td></tr><tr><td align="left" rowspan="1" colspan="1">Interferon regulatory factor 4-like</td><td align="left" rowspan="1" colspan="1">LOC609817</td><td align="right" rowspan="1" colspan="1">-50.92</td></tr><tr><td align="left" rowspan="1" colspan="1">ISG15 ubiquitin-like modifier</td><td align="left" rowspan="1" colspan="1">ISG15</td><td align="right" rowspan="1" colspan="1">-50.28</td></tr></tbody></table></alternatives></table-wrap><p>Interestingly, gene expression of <italic>CD209</italic> markedly decreased in the pairwise comparison of M1 <italic>vs</italic>. M0 (FC = -345.12) whereas it was highly up-regulated in the comparison M2 <italic>vs</italic>. M1 (FC = 335.12). In both comparisons, M2 <italic>vs</italic>. M0 and M2 <italic>vs</italic>. M1, genes for <italic>LYVE1</italic>, <italic>MRC1</italic>, <italic>MS4A2</italic>, <italic>JAM3</italic>, and <italic>CLEC4G</italic> were up-regulated, whereas genes for <italic>ITGB8</italic> and <italic>P2RY14</italic> were down-regulated. <italic>SUCNR1</italic> was up-regulated in both M1 <italic>vs</italic>. M0 and M2 <italic>vs</italic>. M0.</p></sec><sec id="sec016"><title>Hierarchical cluster analysis</title><p>Unsupervised hierarchical clustering analysis formed 9 different clusters based on similarities and differences in the expression profile of DEPs (<xref ref-type="fig" rid="pone.0183572.g004">Fig 4</xref>). Two out of these 9 clusters had an expression profile that was visually clearly associated with either the M1- or M2-phenotype (<xref ref-type="fig" rid="pone.0183572.g004">Fig 4</xref>). Functional annotation of these clusters identified that the M1-polarization cluster (cluster 8) was significantly associated with the biological process &#x0201c;respiratory burst involved in defense response&#x0201d; (<xref ref-type="fig" rid="pone.0183572.g004">Fig 4</xref>). The M2-cluster (cluster 6) was significantly associated with multiple biological processes of mitosis such as &#x0201c;M phase of mitotic cell cycle&#x0201d; and &#x0201c;mitotic spindle organization&#x0201d; (<xref ref-type="fig" rid="pone.0183572.g004">Fig 4</xref>). The genes associated with these M1- and M2-specific clusters are listed with their particular fold changes in <xref ref-type="supplementary-material" rid="pone.0183572.s002">S1</xref> and <xref ref-type="supplementary-material" rid="pone.0183572.s003">S2</xref> Tables. The remaining 7 clusters were neither specific for M1- nor for M2-macrophages and were associated with biological terms like &#x0201c;peptidyl-lysine mono- and dimethylation&#x0201d; (cluster 1), &#x0201c;immune response-activating signal transduction&#x0201d; (cluster 3), &#x0201c;monosaccharide metabolic process&#x0201d;, &#x0201c;organic substance catabolic process&#x0201d;, &#x0201c;cellular catabolic process&#x0201d; (cluster 4), &#x0201c;response to other organism&#x0201d;, &#x0201c;regulation of lymphocyte proliferation&#x0201d; (cluster 5), &#x0201c;tRNA aminoacylation for protein translation&#x0201d; (cluster 7), &#x0201c;cytokinesis&#x0201d; and &#x0201c;antigen receptor-mediated signaling pathway&#x0201d; (cluster 9, <xref ref-type="supplementary-material" rid="pone.0183572.s004">S3 Table</xref>). No significantly enriched biological terms were identified for cluster 2.</p><fig id="pone.0183572.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183572.g004</object-id><label>Fig 4</label><caption><title>Hierarchical clustering analysis.</title><p>Unsupervised hierarchical clustering analysis of the median centered, log<sub>2</sub>-transformed expression values of 6358 differentially expressed probe sets in canine polarized macrophages as obtained by TM4 MultiExperimentViewer with default settings (Euclidean distance; complete linkage), depicted on a color scale from red (relatively high expression) to green (relatively low expression). <bold>A)</bold> The analysis identified 9 distinct clusters (I-IX) based on similarities as well as differences in the expression intensity of canine polarized macrophages. Two out of these 9 clusters (VIII and VI) visually displayed an expression profile that was clearly associated with either the M1- or M2-phenotype. <bold>B)</bold> Functional annotation of the M1-cluster (magnified from A) using Web-based Gene Set Analysis Toolkit (WebGestalt) identified the enriched biological process category &#x0201c;respiratory burst&#x0201d; (adjusted p-value&#x02264;0.05). <bold>C)</bold> The M2-cluster (magnified from A) is associated with enriched biological GO terms such as &#x0201c;M phase of mitotic cell cycle&#x0201d; and &#x0201c;mitotic spindle organization&#x0201d; (adjusted p-value&#x02264;0.05).</p></caption><graphic xlink:href="pone.0183572.g004"/></fig></sec><sec id="sec017"><title>Literature-based gene signatures and marker genes</title><p>Intersections of genes exclusively up-regulated in M1 <italic>vs</italic>. M0 and down regulated in M2 <italic>vs</italic>. M1 (M1-macrophage genes), as well as genes up-regulated in the comparisons M2 <italic>vs</italic>. M0 and M2 <italic>vs</italic>. M1 (M2-macrophage genes) were selected and compared to literature-based markers that are known to distinguish between human and murine M1- and M2-macrophages (<xref ref-type="fig" rid="pone.0183572.g005">Fig 5A</xref>). Notably, many markers identified in the recent study to be specific for canine M1-polarization (404 unique genes in total corresponding to 565 probesets, <xref ref-type="supplementary-material" rid="pone.0183572.s006">S5 Table</xref>) did not match with the literature-based M1-markers (65 genes). Similarly, predominating numbers of canine M2-markers (700 unique genes in total corresponding to 1029 probesets, <xref ref-type="supplementary-material" rid="pone.0183572.s006">S5 Table</xref>) did not match with the literature-based M2-markers (58 genes; <xref ref-type="fig" rid="pone.0183572.g005">Fig 5A</xref>). However, overlapping expression of genes reflecting M1-polarization state was present for 8 genes, <italic>i</italic>.<italic>e</italic>. <italic>BIRC3</italic>, <italic>CCR7</italic>, <italic>CD80</italic>, <italic>IL15RA</italic>, <italic>IL23A</italic>, <italic>INHBA</italic>, <italic>NAMPT</italic>, and <italic>SLC2A6</italic>. For canine M2-polarization, 11 genes matched reported expression in human and murine M2-macrophages, <italic>i</italic>.<italic>e</italic>. <italic>CCL24</italic>, <italic>CCL13</italic>, <italic>FCER1A</italic>, <italic>FN1</italic>, <italic>EGR2</italic>, <italic>CA2</italic>, <italic>LIPA</italic>, <italic>SLC4A7</italic>, <italic>CD163</italic>, <italic>ADK</italic>, and <italic>FGL2</italic> (<xref ref-type="fig" rid="pone.0183572.g005">Fig 5A</xref>). Conflicting results were present for the genes <italic>P2RY14</italic>, <italic>TGFBR2</italic>, and <italic>TPST2</italic>, which were expected as M2-markers based on the literature but were differentially up-regulated in canine M1-macrophages. Furthermore, <italic>PIK3CB</italic> was up-regulated by both canine M1- and M2-macrophages in the present study. The differentially expressed genes of the intersections, which are not namely mentioned in <xref ref-type="fig" rid="pone.0183572.g005">Fig 5A</xref> are listed in <xref ref-type="supplementary-material" rid="pone.0183572.s005">S4 Table</xref>. The top 50 candidate canine M1- and M2-macrophage genes, as defined above, are given in Tables <xref ref-type="table" rid="pone.0183572.t006">6</xref> and <xref ref-type="table" rid="pone.0183572.t007">7</xref>. The full lists of canine probesets, corresponding to the 404 unique M1 genes and 700 unique M2 genes are shown in <xref ref-type="supplementary-material" rid="pone.0183572.s006">S5 Table</xref>.</p><fig id="pone.0183572.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183572.g005</object-id><label>Fig 5</label><caption><p><bold>Comparative evaluation of canine M1- and M2-associated differentially expressed genes (M1 = 404; M2 = 700) with established literature-based human and murine orthologous genes (A) and detection of polarization-specific biomarkers employing supervised clustering with a K-nearest-neighbors algorithm and correlation-based feature selection using Prophet (B, C). A)</bold> The Venn diagram depicts the numbers and intersections of differential and common canine M1- and M2-genes with literature-based human and murine genes. The majority of literature-based M1- (65 genes = 57+8) and M2-markers (58 genes = 44+11+3) did not comply with the present microarray data upon canine macrophages. However, overlapping expression of 8 genes for the M1-phenotype and 11 genes for the M2-phenotype was identified. The genes of the intersections, not specifically mentioned in the figure, are listed in <xref ref-type="supplementary-material" rid="pone.0183572.s005">S4 Table</xref>
<bold>B)</bold> Biomarker selection detected 4 highly specific probe sets for annotated by the mammalian carboxypeptidase inhibitor <italic>latexin</italic> (<italic>LXN</italic>) to be highly correlated to the M1-phenotype. The boxplots depict the significantly enhanced log<sub>2</sub>-transformed expression values for <italic>LXN</italic> in M1-macrophages as compared to both M0- and M2-macrophages (p = 0.002), as well as between M0- and M2-macrophages (p = 0.002). <bold>C)</bold> For the M2-phenotype, the most significant predicted biomarker was high affinity receptor for IgE, <italic>i</italic>.<italic>e</italic>. membrane-spanning 4-domains, subfamily A, member 2 (<italic>MS4A2</italic>). The expression data of M2-macrophages show significantly higher log<sub>2</sub>-transformed expression values as compared to both M0- and M1-macrophages (p = 0.002) as well as between M0- and M1-macrophages (p = 0.002). Asterisks indicate significance (Kruskal-Wallis-Test with subsequent pairwise Mann-Whitney-U-Tests).</p></caption><graphic xlink:href="pone.0183572.g005"/></fig><table-wrap id="pone.0183572.t006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183572.t006</object-id><label>Table 6</label><caption><title>Top 50 candidate M1-macrophage associated probesets, which were upregulated in M1- vs. M0-macrophages and simultaneously downregulated in M2- vs. M1-macrophages.</title></caption><alternatives><graphic id="pone.0183572.t006g" xlink:href="pone.0183572.t006"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" rowspan="1" colspan="1">Probe Set ID</th><th align="justify" rowspan="1" colspan="1">Gene Symbol</th><th align="justify" rowspan="1" colspan="1">Fold change M1 vs. M0</th><th align="justify" rowspan="1" colspan="1">Fold change M2 vs. M1</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Cfa.12190.1.A1_at</td><td align="left" rowspan="1" colspan="1">PTGES</td><td align="left" rowspan="1" colspan="1">3.34</td><td align="left" rowspan="1" colspan="1">-1274.66</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.30585.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">PTGES</td><td align="left" rowspan="1" colspan="1">4.99</td><td align="left" rowspan="1" colspan="1">-1136.51</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.30585.1.S1_at</td><td align="left" rowspan="1" colspan="1">PTGES</td><td align="left" rowspan="1" colspan="1">4.94</td><td align="left" rowspan="1" colspan="1">-517.22</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.927.1.S1_at</td><td align="left" rowspan="1" colspan="1">P2RY14</td><td align="left" rowspan="1" colspan="1">4.80</td><td align="left" rowspan="1" colspan="1">-344.22</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.20456.1.S1_at</td><td align="left" rowspan="1" colspan="1">IFI6</td><td align="left" rowspan="1" colspan="1">269.13</td><td align="left" rowspan="1" colspan="1">-284.48</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.15155.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">PI3</td><td align="left" rowspan="1" colspan="1">27.22</td><td align="left" rowspan="1" colspan="1">-235.52</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.574.1.A1_at</td><td align="left" rowspan="1" colspan="1">EPHX2</td><td align="left" rowspan="1" colspan="1">119.72</td><td align="left" rowspan="1" colspan="1">-222.01</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.18083.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">SLC39A14</td><td align="left" rowspan="1" colspan="1">15.89</td><td align="left" rowspan="1" colspan="1">-212.19</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.14855.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">SLC39A14</td><td align="left" rowspan="1" colspan="1">13.48</td><td align="left" rowspan="1" colspan="1">-200.01</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.3449.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">PTGS2</td><td align="left" rowspan="1" colspan="1">27.78</td><td align="left" rowspan="1" colspan="1">-183.48</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.15554.1.A1_at</td><td align="left" rowspan="1" colspan="1">TNIP3</td><td align="left" rowspan="1" colspan="1">3.07</td><td align="left" rowspan="1" colspan="1">-178.37</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.9253.1.A1_at</td><td align="left" rowspan="1" colspan="1">RHOU</td><td align="left" rowspan="1" colspan="1">446.23</td><td align="left" rowspan="1" colspan="1">-168.17</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.12477.1.A1_at</td><td align="left" rowspan="1" colspan="1">LOC102152163</td><td align="left" rowspan="1" colspan="1">86.20</td><td align="left" rowspan="1" colspan="1">-156.11</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.16339.1.S1_at</td><td align="left" rowspan="1" colspan="1">CXCR3</td><td align="left" rowspan="1" colspan="1">5.70</td><td align="left" rowspan="1" colspan="1">-140.97</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.10779.1.A1_at</td><td align="left" rowspan="1" colspan="1">IDO2</td><td align="left" rowspan="1" colspan="1">28.65</td><td align="left" rowspan="1" colspan="1">-127.88</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.13394.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">EPHX2</td><td align="left" rowspan="1" colspan="1">110.24</td><td align="left" rowspan="1" colspan="1">-122.12</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.15812.1.S1_at</td><td align="left" rowspan="1" colspan="1">CCL20</td><td align="left" rowspan="1" colspan="1">67.90</td><td align="left" rowspan="1" colspan="1">-119.64</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.1856.1.S1_at</td><td align="left" rowspan="1" colspan="1">TMEM150C</td><td align="left" rowspan="1" colspan="1">40.36</td><td align="left" rowspan="1" colspan="1">-103.02</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.2878.1.A1_s_at</td><td align="left" rowspan="1" colspan="1">CP</td><td align="left" rowspan="1" colspan="1">425.52</td><td align="left" rowspan="1" colspan="1">-96.02</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.3697.1.S1_at</td><td align="left" rowspan="1" colspan="1">STEAP4</td><td align="left" rowspan="1" colspan="1">11.45</td><td align="left" rowspan="1" colspan="1">-92.42</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.13209.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">CP</td><td align="left" rowspan="1" colspan="1">161.88</td><td align="left" rowspan="1" colspan="1">-90.30</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.8846.1.A1_s_at</td><td align="left" rowspan="1" colspan="1">C2 /// CFB</td><td align="left" rowspan="1" colspan="1">4.39</td><td align="left" rowspan="1" colspan="1">-78.67</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.7919.1.S1_at</td><td align="left" rowspan="1" colspan="1">TMEM176A</td><td align="left" rowspan="1" colspan="1">19.58</td><td align="left" rowspan="1" colspan="1">-78.17</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.1718.1.S1_at</td><td align="left" rowspan="1" colspan="1">TNF</td><td align="left" rowspan="1" colspan="1">47.17</td><td align="left" rowspan="1" colspan="1">-71.34</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.3528.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">IL6</td><td align="left" rowspan="1" colspan="1">252.32</td><td align="left" rowspan="1" colspan="1">-69.50</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.20456.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">IFI6</td><td align="left" rowspan="1" colspan="1">68.64</td><td align="left" rowspan="1" colspan="1">-68.46</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.17110.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">MCTP2</td><td align="left" rowspan="1" colspan="1">2.69</td><td align="left" rowspan="1" colspan="1">-66.09</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.15348.1.S1_at</td><td align="left" rowspan="1" colspan="1">SLC22A15</td><td align="left" rowspan="1" colspan="1">15.67</td><td align="left" rowspan="1" colspan="1">-58.69</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.24565.1.S1_at</td><td align="left" rowspan="1" colspan="1">FSCN1</td><td align="left" rowspan="1" colspan="1">35.83</td><td align="left" rowspan="1" colspan="1">-58.64</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.12164.1.A1_at</td><td align="left" rowspan="1" colspan="1">LOC476045</td><td align="left" rowspan="1" colspan="1">5.65</td><td align="left" rowspan="1" colspan="1">-57.39</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.54.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">TNF</td><td align="left" rowspan="1" colspan="1">47.20</td><td align="left" rowspan="1" colspan="1">-55.63</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.11870.1.A1_at</td><td align="left" rowspan="1" colspan="1">PI3</td><td align="left" rowspan="1" colspan="1">17.25</td><td align="left" rowspan="1" colspan="1">-52.33</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.4359.1.S1_at</td><td align="left" rowspan="1" colspan="1">WNK2</td><td align="left" rowspan="1" colspan="1">52.35</td><td align="left" rowspan="1" colspan="1">-52.30</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.1510.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">IRAK3</td><td align="left" rowspan="1" colspan="1">10.70</td><td align="left" rowspan="1" colspan="1">-50.40</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.15202.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">SDC4</td><td align="left" rowspan="1" colspan="1">58.61</td><td align="left" rowspan="1" colspan="1">-49.56</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.1352.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">IL22RA2</td><td align="left" rowspan="1" colspan="1">116.00</td><td align="left" rowspan="1" colspan="1">-48.48</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.26233.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">CXCR3</td><td align="left" rowspan="1" colspan="1">32.55</td><td align="left" rowspan="1" colspan="1">-47.23</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.17136.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">MCTP2</td><td align="left" rowspan="1" colspan="1">6.25</td><td align="left" rowspan="1" colspan="1">-46.94</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.24086.1.S1_at</td><td align="left" rowspan="1" colspan="1">KMO</td><td align="left" rowspan="1" colspan="1">23.66</td><td align="left" rowspan="1" colspan="1">-46.48</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.15086.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">BMP1</td><td align="left" rowspan="1" colspan="1">43.14</td><td align="left" rowspan="1" colspan="1">-43.31</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.261.1.S1_at</td><td align="left" rowspan="1" colspan="1">HCAR3</td><td align="left" rowspan="1" colspan="1">13.88</td><td align="left" rowspan="1" colspan="1">-42.20</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.18962.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">SGK1</td><td align="left" rowspan="1" colspan="1">20.11</td><td align="left" rowspan="1" colspan="1">-39.12</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.3719.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">QPCT</td><td align="left" rowspan="1" colspan="1">22.78</td><td align="left" rowspan="1" colspan="1">-38.99</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.4926.1.A1_s_at</td><td align="left" rowspan="1" colspan="1">LOC476045</td><td align="left" rowspan="1" colspan="1">5.41</td><td align="left" rowspan="1" colspan="1">-37.14</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.6260.1.S1_at</td><td align="left" rowspan="1" colspan="1">C18H7orf10</td><td align="left" rowspan="1" colspan="1">43.19</td><td align="left" rowspan="1" colspan="1">-36.13</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.6458.1.A1_s_at</td><td align="left" rowspan="1" colspan="1">C2 /// CFB</td><td align="left" rowspan="1" colspan="1">5.05</td><td align="left" rowspan="1" colspan="1">-36.01</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.8282.1.A1_s_at</td><td align="left" rowspan="1" colspan="1">KBTBD7</td><td align="left" rowspan="1" colspan="1">3.64</td><td align="left" rowspan="1" colspan="1">-35.38</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.8143.1.S1_at</td><td align="left" rowspan="1" colspan="1">KBTBD7</td><td align="left" rowspan="1" colspan="1">2.59</td><td align="left" rowspan="1" colspan="1">-35.14</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.21252.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">ENPP2</td><td align="left" rowspan="1" colspan="1">188.74</td><td align="left" rowspan="1" colspan="1">-34.85</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.16422.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">CCL20</td><td align="left" rowspan="1" colspan="1">33.43</td><td align="left" rowspan="1" colspan="1">-34.83</td></tr></tbody></table></alternatives></table-wrap><table-wrap id="pone.0183572.t007" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183572.t007</object-id><label>Table 7</label><caption><title>Top 50 candidate M2-macrophage associated probesets, which were upregulated in M2- vs. M0-macrophages and simultaneously upregulated in M2- vs. M1-macrophages.</title></caption><alternatives><graphic id="pone.0183572.t007g" xlink:href="pone.0183572.t007"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Probe Set ID</th><th align="left" rowspan="1" colspan="1">Gene Symbol</th><th align="left" rowspan="1" colspan="1">Fold change M2 vs. M0</th><th align="left" rowspan="1" colspan="1">Fold change M2 vs. M1</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Cfa.11125.1.A1_at</td><td align="left" rowspan="1" colspan="1">SCN2B</td><td align="left" rowspan="1" colspan="1">1061.28</td><td align="left" rowspan="1" colspan="1">1120.45</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.15823.1.S1_at</td><td align="left" rowspan="1" colspan="1">CCL24</td><td align="left" rowspan="1" colspan="1">1060.82</td><td align="left" rowspan="1" colspan="1">1050.11</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.18273.1.S1_at</td><td align="left" rowspan="1" colspan="1">FCER1A</td><td align="left" rowspan="1" colspan="1">35.63</td><td align="left" rowspan="1" colspan="1">922.72</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.20721.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">CCL24</td><td align="left" rowspan="1" colspan="1">819.06</td><td align="left" rowspan="1" colspan="1">819.06</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.17541.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">FBP1</td><td align="left" rowspan="1" colspan="1">160.02</td><td align="left" rowspan="1" colspan="1">748.69</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.2850.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">FBP1</td><td align="left" rowspan="1" colspan="1">57.95</td><td align="left" rowspan="1" colspan="1">422.21</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.3663.1.A1_s_at</td><td align="left" rowspan="1" colspan="1">FCER1A</td><td align="left" rowspan="1" colspan="1">21.07</td><td align="left" rowspan="1" colspan="1">376.89</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.3707.1.A1_at</td><td align="left" rowspan="1" colspan="1">FN1</td><td align="left" rowspan="1" colspan="1">12.68</td><td align="left" rowspan="1" colspan="1">360.42</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.12229.1.S1_at</td><td align="left" rowspan="1" colspan="1">LYVE1</td><td align="left" rowspan="1" colspan="1">322.32</td><td align="left" rowspan="1" colspan="1">321.11</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.10966.1.A1_at</td><td align="left" rowspan="1" colspan="1">DNM1</td><td align="left" rowspan="1" colspan="1">112.78</td><td align="left" rowspan="1" colspan="1">247.10</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.6272.1.S1_at</td><td align="left" rowspan="1" colspan="1">CALD1</td><td align="left" rowspan="1" colspan="1">224.66</td><td align="left" rowspan="1" colspan="1">239.74</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.1504.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">UST</td><td align="left" rowspan="1" colspan="1">7.71</td><td align="left" rowspan="1" colspan="1">226.47</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.2693.1.A1_at</td><td align="left" rowspan="1" colspan="1">LOC102152647</td><td align="left" rowspan="1" colspan="1">194.28</td><td align="left" rowspan="1" colspan="1">194.28</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.3707.1.A1_s_at</td><td align="left" rowspan="1" colspan="1">FN1</td><td align="left" rowspan="1" colspan="1">7.26</td><td align="left" rowspan="1" colspan="1">188.32</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.28024.1.S1_at</td><td align="left" rowspan="1" colspan="1">CLEC4G</td><td align="left" rowspan="1" colspan="1">54.14</td><td align="left" rowspan="1" colspan="1">183.13</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.16206.1.S1_at</td><td align="left" rowspan="1" colspan="1">MS4A2</td><td align="left" rowspan="1" colspan="1">110.05</td><td align="left" rowspan="1" colspan="1">167.77</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.6369.1.A1_at</td><td align="left" rowspan="1" colspan="1">FBP1</td><td align="left" rowspan="1" colspan="1">26.98</td><td align="left" rowspan="1" colspan="1">149.73</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.20346.1.S1_at</td><td align="left" rowspan="1" colspan="1">ARHGAP6</td><td align="left" rowspan="1" colspan="1">37.99</td><td align="left" rowspan="1" colspan="1">147.58</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.1705.1.A1_at</td><td align="left" rowspan="1" colspan="1">JAM3</td><td align="left" rowspan="1" colspan="1">78.46</td><td align="left" rowspan="1" colspan="1">145.24</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.3662.1.S1_at</td><td align="left" rowspan="1" colspan="1">MS4A2</td><td align="left" rowspan="1" colspan="1">54.98</td><td align="left" rowspan="1" colspan="1">137.95</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.19567.1.S1_at</td><td align="left" rowspan="1" colspan="1">UST</td><td align="left" rowspan="1" colspan="1">8.05</td><td align="left" rowspan="1" colspan="1">120.81</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.16206.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">MS4A2</td><td align="left" rowspan="1" colspan="1">76.56</td><td align="left" rowspan="1" colspan="1">108.61</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.3774.1.A1_s_at</td><td align="left" rowspan="1" colspan="1">ANPEP</td><td align="left" rowspan="1" colspan="1">25.55</td><td align="left" rowspan="1" colspan="1">105.73</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.14465.1.S1_at</td><td align="left" rowspan="1" colspan="1">NPNT</td><td align="left" rowspan="1" colspan="1">444.07</td><td align="left" rowspan="1" colspan="1">105.07</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.688.1.S1_at</td><td align="left" rowspan="1" colspan="1">cfa-mir-125b-2</td><td align="left" rowspan="1" colspan="1">58.78</td><td align="left" rowspan="1" colspan="1">103.61</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.7700.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">MRC1</td><td align="left" rowspan="1" colspan="1">136.99</td><td align="left" rowspan="1" colspan="1">89.14</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.2468.1.A1_at</td><td align="left" rowspan="1" colspan="1">UST</td><td align="left" rowspan="1" colspan="1">6.54</td><td align="left" rowspan="1" colspan="1">85.20</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.10794.1.A1_at</td><td align="left" rowspan="1" colspan="1">SCG5</td><td align="left" rowspan="1" colspan="1">6.75</td><td align="left" rowspan="1" colspan="1">82.69</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.20798.1.S1_at</td><td align="left" rowspan="1" colspan="1">ANPEP</td><td align="left" rowspan="1" colspan="1">14.09</td><td align="left" rowspan="1" colspan="1">82.13</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.14701.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">STAB1</td><td align="left" rowspan="1" colspan="1">4.00</td><td align="left" rowspan="1" colspan="1">81.41</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.28463.1.S1_at</td><td align="left" rowspan="1" colspan="1">C3</td><td align="left" rowspan="1" colspan="1">36.53</td><td align="left" rowspan="1" colspan="1">76.45</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.12240.1.A1_at</td><td align="left" rowspan="1" colspan="1">C3</td><td align="left" rowspan="1" colspan="1">44.14</td><td align="left" rowspan="1" colspan="1">67.78</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.16904.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">TGFB2</td><td align="left" rowspan="1" colspan="1">61.84</td><td align="left" rowspan="1" colspan="1">66.97</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.7365.1.S1_at</td><td align="left" rowspan="1" colspan="1">CST9</td><td align="left" rowspan="1" colspan="1">58.21</td><td align="left" rowspan="1" colspan="1">58.53</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.15901.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">LPL</td><td align="left" rowspan="1" colspan="1">52.03</td><td align="left" rowspan="1" colspan="1">57.39</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.7698.1.S1_at</td><td align="left" rowspan="1" colspan="1">MRC1</td><td align="left" rowspan="1" colspan="1">104.41</td><td align="left" rowspan="1" colspan="1">52.68</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.78.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">SLC15A1</td><td align="left" rowspan="1" colspan="1">14.65</td><td align="left" rowspan="1" colspan="1">52.03</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.27914.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">IL13RA2</td><td align="left" rowspan="1" colspan="1">170.59</td><td align="left" rowspan="1" colspan="1">46.70</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.19638.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">TMLHE</td><td align="left" rowspan="1" colspan="1">51.05</td><td align="left" rowspan="1" colspan="1">45.55</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.22229.1.S1_at</td><td align="left" rowspan="1" colspan="1">GPR34</td><td align="left" rowspan="1" colspan="1">6.30</td><td align="left" rowspan="1" colspan="1">42.39</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.21392.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">FKBP7</td><td align="left" rowspan="1" colspan="1">25.81</td><td align="left" rowspan="1" colspan="1">40.60</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.19151.1.S1_s_at</td><td align="left" rowspan="1" colspan="1">ADCY4</td><td align="left" rowspan="1" colspan="1">14.07</td><td align="left" rowspan="1" colspan="1">39.02</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.11222.1.A1_s_at</td><td align="left" rowspan="1" colspan="1">FAM185A</td><td align="left" rowspan="1" colspan="1">23.07</td><td align="left" rowspan="1" colspan="1">38.03</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.10053.1.A1_at</td><td align="left" rowspan="1" colspan="1">RAB40B</td><td align="left" rowspan="1" colspan="1">48.86</td><td align="left" rowspan="1" colspan="1">37.88</td></tr><tr><td align="left" rowspan="1" colspan="1">CfaAffx.24797.1.S1_at</td><td align="left" rowspan="1" colspan="1">EPHX1</td><td align="left" rowspan="1" colspan="1">3.75</td><td align="left" rowspan="1" colspan="1">36.82</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.1930.1.S1_at</td><td align="left" rowspan="1" colspan="1">MRC1</td><td align="left" rowspan="1" colspan="1">25.70</td><td align="left" rowspan="1" colspan="1">36.76</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.3367.1.A1_at</td><td align="left" rowspan="1" colspan="1">TGFB2</td><td align="left" rowspan="1" colspan="1">36.49</td><td align="left" rowspan="1" colspan="1">36.58</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.15824.1.S1_at</td><td align="left" rowspan="1" colspan="1">CCL13</td><td align="left" rowspan="1" colspan="1">172.58</td><td align="left" rowspan="1" colspan="1">34.71</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.14297.1.A1_s_at</td><td align="left" rowspan="1" colspan="1">MAOB</td><td align="left" rowspan="1" colspan="1">33.75</td><td align="left" rowspan="1" colspan="1">33.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Cfa.12621.1.A1_at</td><td align="left" rowspan="1" colspan="1">LRP4</td><td align="left" rowspan="1" colspan="1">7.01</td><td align="left" rowspan="1" colspan="1">33.01</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec018"><title>Biomarker selection</title><p>In a hypothesis-driven approach, polarization specific prediction markers were detected with Prophet using the microarray data of unstimulated macrophages (M0), M1-, and M2-macrophages [<xref rid="pone.0183572.ref041" ref-type="bibr">41</xref>, <xref rid="pone.0183572.ref042" ref-type="bibr">42</xref>]. 369 probe sets were identified by the correlation-based feature selection algorithm of Prophet that discriminated between M0-, M1-, and M2-polarity, using the KNN algorithm with 100% correct predictions. Subsequent &#x0201c;one <italic>versus</italic> all&#x0201d; analyses using SET to create ranked lists of genes, based on their potential to serve as biomarker for M1- or M2-macrophages were performed (<xref ref-type="supplementary-material" rid="pone.0183572.s007">S6 Table</xref>; [<xref rid="pone.0183572.ref043" ref-type="bibr">43</xref>]). The highest scoring probe set differentiating M1- from M0- and M2-macrophages was CfaAffx.14358.1.S1_at, annotated as <italic>latexin</italic> (<italic>LXN</italic>), which was up-regulated in M1-macrophages, exhibiting a prediction-accuracy for the M1-phenotype of 100%. Additionally, the probe set ID&#x02019;s occupying the ranks 2 to 4 (Cfa.5195.1.A1_s_at, Cfa.5195.1.A1_at, Cfa.14007.1.A1_x_at) were similarly annotated to <italic>LXN</italic> (<xref ref-type="supplementary-material" rid="pone.0183572.s007">S6 Table</xref>). Analysis of the expression data of CfaAffx.14358.1.S1_at revealed a relatively high expression in all three polarities with a significantly higher expression in M1-macrophages as compared to M0- and M2-macrophages (pairwise Mann-Whitney-U-Tests; p = 0.02, <xref ref-type="fig" rid="pone.0183572.g005">Fig 5B</xref>). For the comparison of M2 <italic>versus</italic> M0 and M1, the highest scoring probe set was Cfa.3662.1.S1_at, annotated as <italic>membrane-spanning 4-domains</italic>, <italic>subfamily A</italic>, <italic>member 2</italic> (<italic>MS4A2</italic>, <xref ref-type="supplementary-material" rid="pone.0183572.s007">S6 Table</xref>). This probe set was up-regulated in M2-macrophages and displayed a prediction accuracy of 100% for this phenotype. Statistical evaluation with pairwise Mann-Whitney-U-Tests underlined a low expression of <italic>MS4A2</italic> in M0- and M1-macrophages, but a significantly higher expression in M2-macrophages (p = 0.02, <xref ref-type="fig" rid="pone.0183572.g005">Fig 5C</xref>).</p></sec><sec id="sec019"><title>Testing of antibodies for the detection of predicted biomarkers</title><p>In order to test, whether the biomarkers predicted to distinguish between canine M0-, M1-, and M2-macrophages during the transcriptome investigations are also mirrored by altered protein expression, an additional experiment using blood from 3 dogs was performed. The cells were isolated and polarized as described and labeled with antibodies targeting MS4A2 and LXN (<xref ref-type="table" rid="pone.0183572.t001">Table 1</xref>). There was protein expression in canine macrophages in vitro for both molecules (<xref ref-type="fig" rid="pone.0183572.g006">Fig 6</xref>). However, the percentage of cells labeled with an antibody against MS4A2 showed no differences between M0-, M1-, and M2-macrophages (p = 0.117; <xref ref-type="fig" rid="pone.0183572.g006">Fig 6</xref>). The percentage of positive cells for LXN was significantly higher in both M1-and M2-macrophages as compared to M0-macrophages (p = 0.02 and p = 0.01, respectively); however, there was no difference in the percentage of LXN-immunopositive cells between M1- and M2-macrophages (p = 0.06; <xref ref-type="fig" rid="pone.0183572.g006">Fig 6</xref>).</p><fig id="pone.0183572.g006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0183572.g006</object-id><label>Fig 6</label><caption><title>Protein expression of the predicted biomarkers latexin and MS4A2 in canine M0-, M1-, and M2-macrophages.</title><p><bold>A)</bold> Expression of latexin in non-stimulated canine M0-macrophages. <bold>B)</bold> Expression of latexin in canine M1-macrophages. <bold>C)</bold> Expression of latexin in canine M2-macrophages. <bold>D)</bold> Expression of MS4A2 in canine M0-macrophages. <bold>E)</bold> Expression of MS4A2 in canine M1-macrophages. <bold>F)</bold> Expression of MS4A2 in canine M2-macrophages. A-F) Scale bars = 100 &#x003bc;m. Nuclear counterstaining with bisbenzimide. <bold>G)</bold> Dot plots illustrating a significantly higher percentage of immunopositive cells in canine M1- and M2-macrophages as compared to M0-macrophages (One-factorial ANOVA with group-wise t-tests, astrerisk = p&#x0003c;0.05). <bold>H)</bold> Dot plot showing lack of statistical differences in the percentage of immunopositive cells for MS4A2 in canine M0-, M1-, and M2-macrophages.</p></caption><graphic xlink:href="pone.0183572.g006"/></fig></sec></sec><sec sec-type="conclusions" id="sec020"><title>Discussion</title><p>The current investigation is the first report upon the properties of canine polarized macrophages <italic>in vitro</italic> with a special emphasis on the establishment of unique distinctive gene signatures. Even though <italic>in vitro</italic> data on macrophage polarization doubtlessly cannot be simply extrapolated to <italic>in vivo</italic> situations and the paradigm of M1-/M2-polarization represents a simplified approach, which depicts only two extremes of macrophage heterogeneity [<xref rid="pone.0183572.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0183572.ref048" ref-type="bibr">48</xref>&#x02013;<xref rid="pone.0183572.ref050" ref-type="bibr">50</xref>], this initial reductionistic <italic>in vitro</italic> approach will provide a basis for future investigations on the role of macrophage polarization in both healthy and diseased dogs.</p><p>Striking morphological differences were observed between canine M0-, M1-, and M2-macrophages, which are most probably attributed to direct effects of cytokine stimulation. Similar to observations in other species [<xref rid="pone.0183572.ref051" ref-type="bibr">51</xref>&#x02013;<xref rid="pone.0183572.ref054" ref-type="bibr">54</xref>], M1-macrophage cultures appeared to dominantly adapt an amoeboid morphology, although a significant proportion of M0-macrophages also obtained such an amoeboid morphology. Notably, M2-cultures were rather heterogeneous including spindeloid cells and MNGs, which is in line with previous observations in human and murine bone marrow- and blood-derived M2-macrophages [<xref rid="pone.0183572.ref051" ref-type="bibr">51</xref>&#x02013;<xref rid="pone.0183572.ref054" ref-type="bibr">54</xref>]. Interestingly, stimulation of macrophages with IL-4 and IL-13 together with colony stimulation factors can lead to the formation of MNGs [<xref rid="pone.0183572.ref055" ref-type="bibr">55</xref>&#x02013;<xref rid="pone.0183572.ref058" ref-type="bibr">58</xref>]. The recent observation of MNG formation, exclusively in canine M2-cultures, is consistent with reports from other species [<xref rid="pone.0183572.ref044" ref-type="bibr">44</xref>, <xref rid="pone.0183572.ref057" ref-type="bibr">57</xref>, <xref rid="pone.0183572.ref059" ref-type="bibr">59</xref>].</p><p>A variety of different phenotypic markers has been proposed for the differentiation of human and murine M1- and M2-macrophages [<xref rid="pone.0183572.ref004" ref-type="bibr">4</xref>, <xref rid="pone.0183572.ref031" ref-type="bibr">31</xref>]. Even though a multitude of antibodies targeting immune cells including macrophages is known to cross-react with canine antigens [<xref rid="pone.0183572.ref060" ref-type="bibr">60</xref>&#x02013;<xref rid="pone.0183572.ref063" ref-type="bibr">63</xref>], commercially available antibodies explicitly designed for the use on canine cells and tissues are frequently not available. The prototypical literature-based M1-markers CD16, CD32, and iNOS and the M2-markers CD163 and arginase-1 were demonstrated to be inappropriate for the immunophenotypic discrimination of M0-, M1-, and M2-polarization states in canine macrophages in the present study. This may in part be explained by interspecies differences [<xref rid="pone.0183572.ref064" ref-type="bibr">64</xref>, <xref rid="pone.0183572.ref065" ref-type="bibr">65</xref>]. For instance, following classical stimulation with pro-inflammatory cytokines, murine macrophages produce NO, whereas human macrophages nearly lack synthesis of NO in response to classically activating stimuli [<xref rid="pone.0183572.ref066" ref-type="bibr">66</xref>, <xref rid="pone.0183572.ref067" ref-type="bibr">67</xref>]. Moreover, arginase-1 has been reported as a prototype marker for murine M2-macrophages, which is however inappropriate for the detection of human M2-macrophages [<xref rid="pone.0183572.ref013" ref-type="bibr">13</xref>, <xref rid="pone.0183572.ref044" ref-type="bibr">44</xref>, <xref rid="pone.0183572.ref068" ref-type="bibr">68</xref>, <xref rid="pone.0183572.ref069" ref-type="bibr">69</xref>]. Based on the present observations, canine macrophages may thus share closer similarities with human than murine macrophages, thus underlining the role of dogs in translational research. Similar to the immunofluorescence data, and supporting the results of the immunophenotyping, expression values for all probesets annotated with the canine genes NOS2 (2 probesets) and ARG1 (3 probesets), which encode iNOS and arginase-1, respectively, also lacked differences in their expression values between M0-, M1-, and M2-macrophages (data available under accession number: E-MTAB-5458; <ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/arrayexpress">http://www.ebi.ac.uk/arrayexpress</ext-link>). MHC class II is sometimes regarded as a marker for classically activated M1 macrophages [<xref rid="pone.0183572.ref070" ref-type="bibr">70</xref>]; however, a substantial fundus of literature also indicates MHC class II as a pan-macrophage marker, which is expressed on both M1 and M2 macrophages in mice and humans without discriminating between both phenotypes [<xref rid="pone.0183572.ref004" ref-type="bibr">4</xref>, <xref rid="pone.0183572.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0183572.ref068" ref-type="bibr">68</xref>]. Concordantly, the immunofluorescence data demonstrated that MHC class II was found to distinguish between canine M2- and M0-macrophages with a lower expression in the latter (<xref ref-type="fig" rid="pone.0183572.g003">Fig 3</xref>). In fact, it is well known that IL-4 acts as a potent activator of macrophages and induces an up-regulation of MHC class II [<xref rid="pone.0183572.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0183572.ref071" ref-type="bibr">71</xref>&#x02013;<xref rid="pone.0183572.ref075" ref-type="bibr">75</xref>]. However, it must be critically considered that MHC class II appeared inappropriate for the differentiation of canine M0- and M1-macrophages on the protein level, which contradicts reported up-regulation of MHC class II on M1 macrophages [<xref rid="pone.0183572.ref007" ref-type="bibr">7</xref>]. Whether these differences are attributed to true species effects or whether the low number of investigated animals and the quantification method (immunofluorescence) are responsible for not reaching the level of significance remains to be determined.</p><p>Conclusively, it is unlikely that a single antibody will be sufficient to specifically detect canine M1- and M2-macrophages <italic>in vivo</italic>. Due to the paucity of commercially available antibodies detecting canine antigens this will probably also involve the generation of antibodies targeting canine epitopes.</p><p>The present study thus aimed to set up a transcriptomic basis that should encourage future attempts to establish a broader antibody panel against antigens, which are predicted to potentially represent discriminating markers for canine macrophage phenotypes. Interestingly, in the present study, CD206 was among the top regulated genes of canine M2 macrophages on the transcriptome level, and the results of the immunophenotyping also validated CD206 as a promising marker for canine M2 polarized macrophages. This implies that CD206 might constitute a conserved marker, which is appropriate for labeling M2-macrophages in various species including the dog [<xref rid="pone.0183572.ref004" ref-type="bibr">4</xref>, <xref rid="pone.0183572.ref027" ref-type="bibr">27</xref>, <xref rid="pone.0183572.ref031" ref-type="bibr">31</xref>, <xref rid="pone.0183572.ref072" ref-type="bibr">72</xref>, <xref rid="pone.0183572.ref076" ref-type="bibr">76</xref>]. However, a limitation of the present study is that the suitability of markers identified in the transcriptome analyses either still needs to be verified on the protein level or produced partially conflicting results in the immunofluorescence investigations (<italic>i</italic>.<italic>e</italic>. CD163, LXN, and MS4A2).</p><p>For M1-associated up-regulated genes, multiple metabolic pathways such as &#x0201c;steroid biosynthesis&#x0201d;, and &#x0201c;glycolysis/gluconeogenesis&#x0201d; demonstrated to be enriched in the functional annotation of microarray data. Human and murine monocyte to macrophage differentiation has previously been shown to go along with profound changes in the lipid metabolism as a prerequisite for phagocytosis [<xref rid="pone.0183572.ref077" ref-type="bibr">77</xref>]. Moreover, in the hierarchical clustering analysis, the M1-specific cluster was functionally annotated to biological processes involved in &#x0201c;respiratory burst&#x0201d;. M1 macrophages produce a variety of pro-inflammatory mediators including ROS, whereas in contrast, IL-4 inhibits the respiratory burst [<xref rid="pone.0183572.ref078" ref-type="bibr">78</xref>].</p><p>Enriched terms related to the peroxisome proliferator activated receptor (PPAR) signaling pathway were retrieved for the comparison of M2 <italic>vs</italic>. M1 up-regulated genes. PPAR&#x003b3; is a member of the nuclear receptor superfamily with potent anti-inflammatory properties and regulatory functions in fatty acid metabolism [<xref rid="pone.0183572.ref079" ref-type="bibr">79</xref>&#x02013;<xref rid="pone.0183572.ref082" ref-type="bibr">82</xref>]. Interestingly, PPAR&#x003b3; agonists such as rosiglitazone induce an alternative M2a-activation state in murine macrophages and have been used as neuroprotective agents [<xref rid="pone.0183572.ref083" ref-type="bibr">83</xref>, <xref rid="pone.0183572.ref084" ref-type="bibr">84</xref>]. Pharmacological approaches, designed to enhance M2-dominated immune responses may thus similarly represent a promising tool in canine diseases.</p><p>Interestingly, multiple biological processes related to an enhanced cell cycle were enriched in canine M2-macrophages as compared to both M0- and M1-macrophages. IL-4 has previously been reported to induce local macrophage proliferation in the context of chronic inflammation [<xref rid="pone.0183572.ref059" ref-type="bibr">59</xref>]. Moreover, human monocyte to macrophage differentiation in the presence of M-CSF is associated with a dramatic regulation of multiple cell-cycle genes [<xref rid="pone.0183572.ref044" ref-type="bibr">44</xref>]. The transcriptomic link to enhanced cell cycle and proliferation is probably also reflected by the higher cell number of M2-macrophages in the present study as compared to M0-macrophages (<xref ref-type="supplementary-material" rid="pone.0183572.s001">S1 Fig</xref>).</p><p>Comparison of the canine transcriptome data with published murine and human prototype markers demonstrated a relatively low overlap. This confirms recent reports on marked interspecies differences between polarized macrophages [<xref rid="pone.0183572.ref013" ref-type="bibr">13</xref>] and suggests that some properties of polarized macrophages are unique to the dog, demonstrating that reported literature-based markers cannot simply be transferred to another species.</p><p>Based on this observation we sought to predict novel transcriptomic markers using a hypothesis-driven approach. Using a correlation-based algorithm, the carboxypeptidase inhibitor <italic>latexin</italic> (<italic>LXN</italic>) [<xref rid="pone.0183572.ref085" ref-type="bibr">85</xref>&#x02013;<xref rid="pone.0183572.ref088" ref-type="bibr">88</xref>] was retrieved for canine M1-macrophages. Though <italic>LXN</italic>-expression by murine macrophages upon pro-inflammatory stimulation has been demonstrated [<xref rid="pone.0183572.ref085" ref-type="bibr">85</xref>], <italic>LXN</italic> has so far not been proposed as a marker for M1-macrophages in the literature for any species. For the canine M2-phenotype, the high-affinity receptor for IgE <italic>membrane-spanning 4-domains</italic>, <italic>subfamily A</italic>, <italic>member 2</italic> (<italic>MS4A2</italic>) was predicted to represent the most powerful biomarker. Interestingly, other members of the molecule family, <italic>i</italic>.<italic>e</italic>. <italic>MS4A4A</italic> and <italic>MS4A6A</italic>, have been previously shown to be associated with M2-polarization [<xref rid="pone.0183572.ref004" ref-type="bibr">4</xref>, <xref rid="pone.0183572.ref044" ref-type="bibr">44</xref>, <xref rid="pone.0183572.ref089" ref-type="bibr">89</xref>]. In an attempt to validate <italic>LXN</italic> and <italic>MS4A2</italic> as markers for canine macrophages, we demonstrated that MS4A2 showed no differences in the percentage of immunopositive cells between the three conditions. The percentage of immunopositive cells for LXN was higher in both M1- and M2-macrophages as compared to M0-macrophages. However, similar to MS4A2, LXN failed to distinguish between canine M1- and M2-macrophages. Thus, similar to CD163, the protein data did not accurately mirror the transcriptomic prediction. This could be attributed to conflicting differences between RNA- and protein level for these molecules. However, the low number of dogs tested and the fact that low level differences in protein expression may not be detected by immunofluorescence have certainly influenced the statistical power and sensitivity, and thus future validating experiments both in canine tissues and <italic>in vitro</italic> remain to be performed.</p></sec><sec sec-type="supplementary-material" id="sec021"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0183572.s001"><label>S1 Fig</label><caption><title>Dot plot diagrams depicting differences in the absolute number of cells per field (200x) in canine M0-, M1-, and M2-macrophages derived from 3 dogs on day 7 in culture.</title><p>One-factorial ANOVA with group-wise t tests reveals a significantly higher number of cells in M2-polarized macrophages as compared to non-stimulated (M0)-macrophages (p&#x02264;0.05; asterisk).</p><p>(TIF)</p></caption><media xlink:href="pone.0183572.s001.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0183572.s002"><label>S1 Table</label><caption><title>List of the genes included in the M1-associated cluster of the hierarchical clustering analysis (refer to <xref ref-type="fig" rid="pone.0183572.g003">Fig 3</xref>).</title><p>(DOCX)</p></caption><media xlink:href="pone.0183572.s002.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0183572.s003"><label>S2 Table</label><caption><title>List of the genes included in the M2-associated cluster of the hierarchical clustering analysis (refer to <xref ref-type="fig" rid="pone.0183572.g003">Fig 3</xref>).</title><p>(DOCX)</p></caption><media xlink:href="pone.0183572.s003.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0183572.s004"><label>S3 Table</label><caption><title>Overview on retrieved enriched gene ontology biological processes and KEGG pathways of the clusters, resulting from the hierarchical clustering analysis (refer to <xref ref-type="fig" rid="pone.0183572.g003">Fig 3</xref>).</title><p>(DOCX)</p></caption><media xlink:href="pone.0183572.s004.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0183572.s005"><label>S4 Table</label><caption><title>List for the intersections of differentially expressed genes in the comparison of literature-based human and murine markers with canine M1- and M2-associated genes as retrieved by the present study (refer to <xref ref-type="fig" rid="pone.0183572.g004">Fig 4</xref>).</title><p>Excel table.</p><p>(XLSX)</p></caption><media xlink:href="pone.0183572.s005.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0183572.s006"><label>S5 Table</label><caption><title>Lists of differentially expressed M1- and M2-macrophage associated probesets with fold change.</title><p>Sheet 1 depicts all genes, which were upregulated in M1- vs. M0-macrophages and simultaneously downregulated in M2- vs M1-macrophages (i.e. canine M1-macrophage genes). Sheet 2 shows all genes, which were upregulated in M2- vs. M0-macrophages and simultaneously upregulated in M2- vs M1-macrophages (i.e. canine M2-macrophage genes).</p><p>(XLSX)</p></caption><media xlink:href="pone.0183572.s006.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0183572.s007"><label>S6 Table</label><caption><title>Selected biomarkers predicted to discriminate between canine M1- and M2- macrophages as retrieved and ranked by Prophet.</title><p>(DOCX)</p></caption><media xlink:href="pone.0183572.s007.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>This study was in part supported by the German Research Foundation (FOR 1103; BA 815/10-2 and UL 421/1-2) and in part by the Niedersachsen-Research Network on Neuroinfectiology (N-RENNT) of the Ministry of Science and Culture of Lower Saxony. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Franziska Heinrich was supported by the German National Academic Foundation, Bonn, Germany. AK and UD are employed by the commercial company Boehringer Ingelheim Pharma GmbH &#x00026; Co. KG. The funder provided support in the form of salaries for authors [AK, UD], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the &#x02018;author contributions&#x02019; section. This does not alter our adherence to PLOS ONE policies on sharing data and materials. We acknowledge the contribution of the Institute for Parasitology of the University of Veterinary Medicine Hannover for providing blood samples from dogs. The authors gratefully thank Anuschka Unold, Kerstin Rohn, Regina Carlson, Danuta Waschke, Kerstin Sch&#x000f6;ne, and Caroline Sch&#x000fc;tz for excellent technical support.</p></ack><ref-list><title>References</title><ref id="pone.0183572.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Mosser</surname><given-names>DM</given-names></name>, <name><surname>Edwards</surname><given-names>JP</given-names></name>. <article-title>Exploring the full spectrum of macrophage activation</article-title>. <source>Nat Rev Immunol</source>. <year>2008</year>;<volume>8</volume>: <fpage>958</fpage>&#x02013;<lpage>969</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nri2448">10.1038/nri2448</ext-link></comment>
<pub-id pub-id-type="pmid">19029990</pub-id></mixed-citation></ref><ref id="pone.0183572.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Sica</surname><given-names>A</given-names></name>, <name><surname>Mantovani</surname><given-names>A</given-names></name>. <article-title>Macrophage plasticity and polarization: in vivo veritas</article-title>. <source>J Clin Invest</source>. <year>2012</year>;<volume>122</volume>: <fpage>787</fpage>&#x02013;<lpage>795</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1172/JCI59643">10.1172/JCI59643</ext-link></comment>
<pub-id pub-id-type="pmid">22378047</pub-id></mixed-citation></ref><ref id="pone.0183572.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Stout</surname><given-names>RD</given-names></name>, <name><surname>Suttles</surname><given-names>J</given-names></name>. <article-title>Functional plasticity of macrophages: reversible adaptation to changing microenvironments</article-title>. <source>J Leukoc Biol</source>. <year>2004</year>;<volume>76</volume>: <fpage>509</fpage>&#x02013;<lpage>513</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1189/jlb.0504272">10.1189/jlb.0504272</ext-link></comment>
<pub-id pub-id-type="pmid">15218057</pub-id></mixed-citation></ref><ref id="pone.0183572.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>David</surname><given-names>S</given-names></name>, <name><surname>Kroner</surname><given-names>A</given-names></name>. <article-title>Repertoire of microglial and macrophage responses after spinal cord injury</article-title>. <source>Nat Rev Neurosci</source>. <year>2011</year>;<volume>12</volume>: <fpage>388</fpage>&#x02013;<lpage>399</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nrn3053">10.1038/nrn3053</ext-link></comment>
<pub-id pub-id-type="pmid">21673720</pub-id></mixed-citation></ref><ref id="pone.0183572.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Hume</surname><given-names>DA</given-names></name>, <name><surname>Freeman</surname><given-names>TC</given-names></name>. <article-title>Transcriptomic analysis of mononuclear phagocyte differentiation and activation</article-title>. <source>Immunol Rev</source>. <year>2014</year>;<volume>262</volume>: <fpage>74</fpage>&#x02013;<lpage>84</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/imr.12211">10.1111/imr.12211</ext-link></comment>
<pub-id pub-id-type="pmid">25319328</pub-id></mixed-citation></ref><ref id="pone.0183572.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Gerhauser</surname><given-names>I</given-names></name>, <name><surname>Hansmann</surname><given-names>F</given-names></name>, <name><surname>Puff</surname><given-names>C</given-names></name>, <name><surname>Kumnok</surname><given-names>J</given-names></name>, <name><surname>Schaudien</surname><given-names>D</given-names></name>, <name><surname>Wewetzer</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Theiler's murine encephalomyelitis virus induced phenotype switch of microglia in vitro</article-title>. <source>J Neuroimmunol</source>. <year>2012</year>;<volume>252</volume>: <fpage>49</fpage>&#x02013;<lpage>55</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jneuroim.2012.07.018">10.1016/j.jneuroim.2012.07.018</ext-link></comment>
<pub-id pub-id-type="pmid">22967352</pub-id></mixed-citation></ref><ref id="pone.0183572.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Martinez</surname><given-names>FO</given-names></name>, <name><surname>Gordon</surname><given-names>S</given-names></name>. <article-title>The M1 and M2 paradigm of macrophage activation: time for reassessment</article-title>. <source>F1000Prime Rep</source>. <year>2014</year>;<volume>6</volume>: <fpage>13</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.12703/P6-13">10.12703/P6-13</ext-link></comment>
<pub-id pub-id-type="pmid">24669294</pub-id></mixed-citation></ref><ref id="pone.0183572.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Herder</surname><given-names>V</given-names></name>, <name><surname>Iskandar</surname><given-names>CD</given-names></name>, <name><surname>Kegler</surname><given-names>K</given-names></name>, <name><surname>Hansmann</surname><given-names>F</given-names></name>, <name><surname>Elmarabet</surname><given-names>SA</given-names></name>, <name><surname>Khan</surname><given-names>MA</given-names></name>, <etal>et al</etal>
<article-title>Dynamic Changes of Microglia/Macrophage M1 and M2 Polarization in Theiler's Murine Encephalomyelitis</article-title>. <source>Brain Pathol</source>. <year>2015</year>;<volume>25</volume>: <fpage>712</fpage>&#x02013;<lpage>723</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/bpa.12238">10.1111/bpa.12238</ext-link></comment>
<pub-id pub-id-type="pmid">25495532</pub-id></mixed-citation></ref><ref id="pone.0183572.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>YC</given-names></name>, <name><surname>Zou</surname><given-names>XB</given-names></name>, <name><surname>Chai</surname><given-names>YF</given-names></name>, <name><surname>Yao</surname><given-names>YM</given-names></name>. <article-title>Macrophage polarization in inflammatory diseases</article-title>. <source>Int J Biol Sci</source>. <year>2014</year>;<volume>10</volume>: <fpage>520</fpage>&#x02013;<lpage>529</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.7150/ijbs.8879">10.7150/ijbs.8879</ext-link></comment>
<pub-id pub-id-type="pmid">24910531</pub-id></mixed-citation></ref><ref id="pone.0183572.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Orihuela</surname><given-names>R</given-names></name>, <name><surname>McPherson</surname><given-names>CA</given-names></name>, <name><surname>Harry</surname><given-names>GJ</given-names></name>. <article-title>Microglial M1/M2 polarization and metabolic states</article-title>. <source>Br J Pharmacol</source>. <year>2016</year>;<volume>173</volume>: <fpage>649</fpage>&#x02013;<lpage>665</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/bph.13139">10.1111/bph.13139</ext-link></comment>
<pub-id pub-id-type="pmid">25800044</pub-id></mixed-citation></ref><ref id="pone.0183572.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Beyer</surname><given-names>M</given-names></name>, <name><surname>Mallmann</surname><given-names>MR</given-names></name>, <name><surname>Xue</surname><given-names>J</given-names></name>, <name><surname>Staratschek-Jox</surname><given-names>A</given-names></name>, <name><surname>Vorholt</surname><given-names>D</given-names></name>, <name><surname>Krebs</surname><given-names>W</given-names></name>, <etal>et al</etal>
<article-title>High-resolution transcriptome of human macrophages</article-title>. <source>PLoS One</source>. <year>2012</year>;<volume>7</volume>: <fpage>e45466</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0045466">10.1371/journal.pone.0045466</ext-link></comment>
<pub-id pub-id-type="pmid">23029029</pub-id></mixed-citation></ref><ref id="pone.0183572.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Derlindati</surname><given-names>E</given-names></name>, <name><surname>Dei Cas</surname><given-names>A</given-names></name>, <name><surname>Montanini</surname><given-names>B</given-names></name>, <name><surname>Spigoni</surname><given-names>V</given-names></name>, <name><surname>Curella</surname><given-names>V</given-names></name>, <name><surname>Aldigeri</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Transcriptomic analysis of human polarized macrophages: more than one role of alternative activation?</article-title>
<source>PLoS One</source>. <year>2015</year>;<volume>10</volume>: <fpage>e0119751</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0119751">10.1371/journal.pone.0119751</ext-link></comment>
<pub-id pub-id-type="pmid">25799240</pub-id></mixed-citation></ref><ref id="pone.0183572.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Martinez</surname><given-names>FO</given-names></name>, <name><surname>Helming</surname><given-names>L</given-names></name>, <name><surname>Milde</surname><given-names>R</given-names></name>, <name><surname>Varin</surname><given-names>A</given-names></name>, <name><surname>Melgert</surname><given-names>BN</given-names></name>, <name><surname>Draijer</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences</article-title>. <source>Blood</source>. <year>2013</year>;<volume>121</volume>: <fpage>e57</fpage>&#x02013;<lpage>69</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1182/blood-2012-06-436212">10.1182/blood-2012-06-436212</ext-link></comment>
<pub-id pub-id-type="pmid">23293084</pub-id></mixed-citation></ref><ref id="pone.0183572.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Xue</surname><given-names>J</given-names></name>, <name><surname>Schmidt</surname><given-names>SV</given-names></name>, <name><surname>Sander</surname><given-names>J</given-names></name>, <name><surname>Draffehn</surname><given-names>A</given-names></name>, <name><surname>Krebs</surname><given-names>W</given-names></name>, <name><surname>Quester</surname><given-names>I</given-names></name>, <etal>et al</etal>
<article-title>Transcriptome-based network analysis reveals a spectrum model of human macrophage activation</article-title>. <source>Immunity</source>. <year>2014</year>;<volume>40</volume>: <fpage>274</fpage>&#x02013;<lpage>288</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.immuni.2014.01.006">10.1016/j.immuni.2014.01.006</ext-link></comment>
<pub-id pub-id-type="pmid">24530056</pub-id></mixed-citation></ref><ref id="pone.0183572.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Bock</surname><given-names>P</given-names></name>, <name><surname>Spitzbarth</surname><given-names>I</given-names></name>, <name><surname>Haist</surname><given-names>V</given-names></name>, <name><surname>Stein</surname><given-names>VM</given-names></name>, <name><surname>Tipold</surname><given-names>A</given-names></name>, <name><surname>Puff</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Spatio-temporal development of axonopathy in canine intervertebral disc disease as a translational large animal model for nonexperimental spinal cord injury</article-title>. <source>Brain Pathol</source>. <year>2013</year>;<volume>23</volume>: <fpage>82</fpage>&#x02013;<lpage>99</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1750-3639.2012.00617.x">10.1111/j.1750-3639.2012.00617.x</ext-link></comment>
<pub-id pub-id-type="pmid">22805224</pub-id></mixed-citation></ref><ref id="pone.0183572.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Boekhoff</surname><given-names>TM</given-names></name>, <name><surname>Ensinger</surname><given-names>EM</given-names></name>, <name><surname>Carlson</surname><given-names>R</given-names></name>, <name><surname>Bock</surname><given-names>P</given-names></name>, <name><surname>Baumg&#x000e4;rtner</surname><given-names>W</given-names></name>, <name><surname>Rohn</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Microglial contribution to secondary injury evaluated in a large animal model of human spinal cord trauma</article-title>. <source>J Neurotrauma</source>. <year>2012</year>;<volume>29</volume>: <fpage>1000</fpage>&#x02013;<lpage>1011</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1089/neu.2011.1821">10.1089/neu.2011.1821</ext-link></comment>
<pub-id pub-id-type="pmid">21599492</pub-id></mixed-citation></ref><ref id="pone.0183572.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Lapp</surname><given-names>S</given-names></name>, <name><surname>Pfankuche</surname><given-names>VM</given-names></name>, <name><surname>Baumg&#x000e4;rtner</surname><given-names>W</given-names></name>, <name><surname>Puff</surname><given-names>C</given-names></name>. <article-title>Viral oncolysis&#x02014;can insights from measles be transferred to canine distemper virus?</article-title>
<source>Viruses</source>. <year>2014</year>;<volume>6</volume>: <fpage>2340</fpage>&#x02013;<lpage>2375</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3390/v6062340">10.3390/v6062340</ext-link></comment>
<pub-id pub-id-type="pmid">24921409</pub-id></mixed-citation></ref><ref id="pone.0183572.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Rowell</surname><given-names>JL</given-names></name>, <name><surname>McCarthy</surname><given-names>DO</given-names></name>, <name><surname>Alvarez</surname><given-names>CE</given-names></name>. <article-title>Dog models of naturally occurring cancer</article-title>. <source>Trends Mol Med</source>. <year>2011</year>;<volume>17</volume>: <fpage>380</fpage>&#x02013;<lpage>388</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.molmed.2011.02.004">10.1016/j.molmed.2011.02.004</ext-link></comment>
<pub-id pub-id-type="pmid">21439907</pub-id></mixed-citation></ref><ref id="pone.0183572.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Seehusen</surname><given-names>F</given-names></name>, <name><surname>Baumg&#x000e4;rtner</surname><given-names>W</given-names></name>. <article-title>Axonal pathology and loss precede demyelination and accompany chronic lesions in a spontaneously occurring animal model of multiple sclerosis</article-title>. <source>Brain Pathol</source>. <year>2010</year>;<volume>20</volume>: <fpage>551</fpage>&#x02013;<lpage>559</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1750-3639.2009.00332.x">10.1111/j.1750-3639.2009.00332.x</ext-link></comment>
<pub-id pub-id-type="pmid">19775292</pub-id></mixed-citation></ref><ref id="pone.0183572.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Spitzbarth</surname><given-names>I</given-names></name>, <name><surname>Bock</surname><given-names>P</given-names></name>, <name><surname>Haist</surname><given-names>V</given-names></name>, <name><surname>Stein</surname><given-names>VM</given-names></name>, <name><surname>Tipold</surname><given-names>A</given-names></name>, <name><surname>Wewetzer</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Prominent microglial activation in the early proinflammatory immune response in naturally occurring canine spinal cord injury</article-title>. <source>J Neuropathol Exp Neurol</source>. <year>2011</year>;<volume>70</volume>: <fpage>703</fpage>&#x02013;<lpage>714</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/NEN.0b013e3182270f8e">10.1097/NEN.0b013e3182270f8e</ext-link></comment>
<pub-id pub-id-type="pmid">21760535</pub-id></mixed-citation></ref><ref id="pone.0183572.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Lempp</surname><given-names>C</given-names></name>, <name><surname>Spitzbarth</surname><given-names>I</given-names></name>, <name><surname>Puff</surname><given-names>C</given-names></name>, <name><surname>Cana</surname><given-names>A</given-names></name>, <name><surname>Kegler</surname><given-names>K</given-names></name>, <name><surname>Techangamsuwan</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>New aspects of the pathogenesis of canine distemper leukoencephalitis</article-title>. <source>Viruses</source>. <year>2014</year>;<volume>6</volume>: <fpage>2571</fpage>&#x02013;<lpage>2601</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3390/v6072571">10.3390/v6072571</ext-link></comment>
<pub-id pub-id-type="pmid">24992230</pub-id></mixed-citation></ref><ref id="pone.0183572.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Stein</surname><given-names>VM</given-names></name>, <name><surname>Czub</surname><given-names>M</given-names></name>, <name><surname>Hansen</surname><given-names>R</given-names></name>, <name><surname>Leibold</surname><given-names>W</given-names></name>, <name><surname>Moore</surname><given-names>PF</given-names></name>, <name><surname>Zurbriggen</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Characterization of canine microglial cells isolated ex vivo</article-title>. <source>Vet Immunol Immunopathol</source>. <year>2004</year>;<volume>99</volume>: <fpage>73</fpage>&#x02013;<lpage>85</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.vetimm.2004.01.002">10.1016/j.vetimm.2004.01.002</ext-link></comment>
<pub-id pub-id-type="pmid">15113656</pub-id></mixed-citation></ref><ref id="pone.0183572.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>de Waal Malefyt</surname><given-names>R</given-names></name>, <name><surname>Figdor</surname><given-names>CG</given-names></name>, <name><surname>Huijbens</surname><given-names>R</given-names></name>, <name><surname>Mohan-Peterson</surname><given-names>S</given-names></name>, <name><surname>Bennett</surname><given-names>B</given-names></name>, <name><surname>Culpepper</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10</article-title>. <source>J Immunol</source>. <year>1993</year>;<volume>151</volume>: <fpage>6370</fpage>&#x02013;<lpage>6381</lpage>. <pub-id pub-id-type="pmid">7902377</pub-id></mixed-citation></ref><ref id="pone.0183572.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Delirezh</surname><given-names>N</given-names></name>, <name><surname>Shojaeefar</surname><given-names>E</given-names></name>, <name><surname>Parvin</surname><given-names>P</given-names></name>, <name><surname>Asadi</surname><given-names>B</given-names></name>. <article-title>Comparison the effects of two monocyte isolation methods, plastic adherence and magnetic activated cell sorting methods, on phagocytic activity of generated dendritic cells</article-title>. <source>Cell J</source>. <year>2013</year>;<volume>15</volume>: <fpage>218</fpage>&#x02013;<lpage>223</lpage>. <pub-id pub-id-type="pmid">24027662</pub-id></mixed-citation></ref><ref id="pone.0183572.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Frackowiak</surname><given-names>J</given-names></name>, <name><surname>Mazur-Kolecka</surname><given-names>B</given-names></name>, <name><surname>Carroll</surname><given-names>RT</given-names></name>, <name><surname>Chauhan</surname><given-names>A</given-names></name>, <name><surname>Wisniewski</surname><given-names>HM</given-names></name>. <article-title>Factors secreted by activated microglia and monocytes reduce amyloidogenesis in vascular smooth muscle cells</article-title>. <source>Neuroreport</source>. <year>1997</year>;<volume>8</volume>: <fpage>2259</fpage>&#x02013;<lpage>2263</lpage>. <pub-id pub-id-type="pmid">9243622</pub-id></mixed-citation></ref><ref id="pone.0183572.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Gamble</surname><given-names>JR</given-names></name>, <name><surname>Elliott</surname><given-names>MJ</given-names></name>, <name><surname>Jaipargas</surname><given-names>E</given-names></name>, <name><surname>Lopez</surname><given-names>AF</given-names></name>, <name><surname>Vadas</surname><given-names>MA</given-names></name>. <article-title>Regulation of human monocyte adherence by granulocyte-macrophage colony-stimulating factor</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1989</year>;<volume>86</volume>: <fpage>7169</fpage>&#x02013;<lpage>7173</lpage>. <pub-id pub-id-type="pmid">2674950</pub-id></mixed-citation></ref><ref id="pone.0183572.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Durafourt</surname><given-names>BA</given-names></name>, <name><surname>Moore</surname><given-names>CS</given-names></name>, <name><surname>Zammit</surname><given-names>DA</given-names></name>, <name><surname>Johnson</surname><given-names>TA</given-names></name>, <name><surname>Zaguia</surname><given-names>F</given-names></name>, <name><surname>Guiot</surname><given-names>MC</given-names></name>, <etal>et al</etal>
<article-title>Comparison of polarization properties of human adult microglia and blood-derived macrophages</article-title>. <source>Glia</source>. <year>2012</year>;<volume>60</volume>: <fpage>717</fpage>&#x02013;<lpage>727</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/glia.22298">10.1002/glia.22298</ext-link></comment>
<pub-id pub-id-type="pmid">22290798</pub-id></mixed-citation></ref><ref id="pone.0183572.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Pringproa</surname><given-names>K</given-names></name>, <name><surname>Rohn</surname><given-names>K</given-names></name>, <name><surname>Kummerfeld</surname><given-names>M</given-names></name>, <name><surname>Wewetzer</surname><given-names>K</given-names></name>, <name><surname>Baumg&#x000e4;rtner</surname><given-names>W</given-names></name>. <article-title>Theiler's murine encephalomyelitis virus preferentially infects immature stages of the murine oligodendrocyte precursor cell line BO-1 and blocks oligodendrocytic differentiation in vitro</article-title>. <source>Brain Res</source>. <year>2010</year>;<volume>1327</volume>: <fpage>24</fpage>&#x02013;<lpage>37</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.brainres.2010.02.068">10.1016/j.brainres.2010.02.068</ext-link></comment>
<pub-id pub-id-type="pmid">20206147</pub-id></mixed-citation></ref><ref id="pone.0183572.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Kegler</surname><given-names>K</given-names></name>, <name><surname>Imbschweiler</surname><given-names>I</given-names></name>, <name><surname>Ulrich</surname><given-names>R</given-names></name>, <name><surname>Kovermann</surname><given-names>P</given-names></name>, <name><surname>Fahlke</surname><given-names>C</given-names></name>, <name><surname>Deschl</surname><given-names>U</given-names></name>, <etal>et al</etal>
<article-title>CNS Schwann cells display oligodendrocyte precursor-like potassium channel activation and antigenic expression in vitro</article-title>. <source>J</source>
<article-title>Neural Transm (Vienna)</article-title>. <year>2014</year>;<volume>121</volume>: <fpage>569</fpage>&#x02013;<lpage>581</lpage>.</mixed-citation></ref><ref id="pone.0183572.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Ziege</surname><given-names>S</given-names></name>, <name><surname>Baumg&#x000e4;rtner</surname><given-names>W</given-names></name>, <name><surname>Wewetzer</surname><given-names>K</given-names></name>. <article-title>Toward defining the regenerative potential of olfactory mucosa: establishment of Schwann cell-free adult canine olfactory ensheathing cell preparations suitable for transplantation</article-title>. <source>Cell Transplant</source>. <year>2013</year>;<volume>22</volume>: <fpage>355</fpage>&#x02013;<lpage>367</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3727/096368912X656108">10.3727/096368912X656108</ext-link></comment>
<pub-id pub-id-type="pmid">23006619</pub-id></mixed-citation></ref><ref id="pone.0183572.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Kigerl</surname><given-names>KA</given-names></name>, <name><surname>Gensel</surname><given-names>JC</given-names></name>, <name><surname>Ankeny</surname><given-names>DP</given-names></name>, <name><surname>Alexander</surname><given-names>JK</given-names></name>, <name><surname>Donnelly</surname><given-names>DJ</given-names></name>, <name><surname>Popovich</surname><given-names>PG</given-names></name>. <article-title>Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord</article-title>. <source>J Neurosci</source>. <year>2009</year>;<volume>29</volume>: <fpage>13435</fpage>&#x02013;<lpage>13444</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1523/JNEUROSCI.3257-09.2009">10.1523/JNEUROSCI.3257-09.2009</ext-link></comment>
<pub-id pub-id-type="pmid">19864556</pub-id></mixed-citation></ref><ref id="pone.0183572.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Ulrich</surname><given-names>R</given-names></name>, <name><surname>Puff</surname><given-names>C</given-names></name>, <name><surname>Wewetzer</surname><given-names>K</given-names></name>, <name><surname>Kalkuhl</surname><given-names>A</given-names></name>, <name><surname>Deschl</surname><given-names>U</given-names></name>, <name><surname>Baumg&#x000e4;rtner</surname><given-names>W</given-names></name>. <article-title>Transcriptional changes in canine distemper virus-induced demyelinating leukoencephalitis favor a biphasic mode of demyelination</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>: <fpage>e95917</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0095917">10.1371/journal.pone.0095917</ext-link></comment>
<pub-id pub-id-type="pmid">24755553</pub-id></mixed-citation></ref><ref id="pone.0183572.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Medina</surname><given-names>I</given-names></name>, <name><surname>Carbonell</surname><given-names>J</given-names></name>, <name><surname>Pulido</surname><given-names>L</given-names></name>, <name><surname>Madeira</surname><given-names>SC</given-names></name>, <name><surname>Goetz</surname><given-names>S</given-names></name>, <name><surname>Conesa</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Babelomics: an integrative platform for the analysis of transcriptomics, proteomics and genomic data with advanced functional profiling</article-title>. <source>Nucleic Acids Res</source>. <year>2010</year>;<volume>38</volume>: <fpage>W210</fpage>&#x02013;<lpage>213</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/nar/gkq388">10.1093/nar/gkq388</ext-link></comment>
<pub-id pub-id-type="pmid">20478823</pub-id></mixed-citation></ref><ref id="pone.0183572.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Raddatz</surname><given-names>BB</given-names></name>, <name><surname>Hansmann</surname><given-names>F</given-names></name>, <name><surname>Spitzbarth</surname><given-names>I</given-names></name>, <name><surname>Kalkuhl</surname><given-names>A</given-names></name>, <name><surname>Deschl</surname><given-names>U</given-names></name>, <name><surname>Baumg&#x000e4;rtner</surname><given-names>W</given-names></name>, <etal>et al</etal>
<article-title>Transcriptomic meta-analysis of multiple sclerosis and its experimental models</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>: <fpage>e86643</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0086643">10.1371/journal.pone.0086643</ext-link></comment>
<pub-id pub-id-type="pmid">24475162</pub-id></mixed-citation></ref><ref id="pone.0183572.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Ulrich</surname><given-names>R</given-names></name>, <name><surname>Kalkuhl</surname><given-names>A</given-names></name>, <name><surname>Deschl</surname><given-names>U</given-names></name>, <name><surname>Baumg&#x000e4;rtner</surname><given-names>W</given-names></name>. <article-title>Machine learning approach identifies new pathways associated with demyelination in a viral model of multiple sclerosis</article-title>. <source>J Cell Mol Med</source>. <year>2010</year>;<volume>14</volume>: <fpage>434</fpage>&#x02013;<lpage>448</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1582-4934.2008.00646.x">10.1111/j.1582-4934.2008.00646.x</ext-link></comment>
<pub-id pub-id-type="pmid">19183246</pub-id></mixed-citation></ref><ref id="pone.0183572.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Pfankuche</surname><given-names>VM</given-names></name>, <name><surname>Spitzbarth</surname><given-names>I</given-names></name>, <name><surname>Lapp</surname><given-names>S</given-names></name>, <name><surname>Ulrich</surname><given-names>R</given-names></name>, <name><surname>Deschl</surname><given-names>U</given-names></name>, <name><surname>Kalkuhl</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Reduced angiogenic gene expression in morbillivirus-triggered oncolysis in a translational model for histiocytic sarcoma</article-title>. <source>J Cell Mol Med</source>. <year>2016</year>.</mixed-citation></ref><ref id="pone.0183572.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Kanehisa</surname><given-names>M</given-names></name>, <name><surname>Goto</surname><given-names>S</given-names></name>, <name><surname>Sato</surname><given-names>Y</given-names></name>, <name><surname>Furumichi</surname><given-names>M</given-names></name>, <name><surname>Tanabe</surname><given-names>M</given-names></name>. <article-title>KEGG for integration and interpretation of large-scale molecular data sets</article-title>. <source>Nucleic Acids Res</source>. <year>2012</year>;<volume>40</volume>: <fpage>D109</fpage>&#x02013;<lpage>114</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/nar/gkr988">10.1093/nar/gkr988</ext-link></comment>
<pub-id pub-id-type="pmid">22080510</pub-id></mixed-citation></ref><ref id="pone.0183572.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>J</given-names></name>, <name><surname>Duncan</surname><given-names>D</given-names></name>, <name><surname>Shi</surname><given-names>Z</given-names></name>, <name><surname>Zhang</surname><given-names>B</given-names></name>. <article-title>WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013</article-title>. <source>Nucleic Acids Res</source>. <year>2013</year>;<volume>41</volume>: <fpage>W77</fpage>&#x02013;<lpage>83</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/nar/gkt439">10.1093/nar/gkt439</ext-link></comment>
<pub-id pub-id-type="pmid">23703215</pub-id></mixed-citation></ref><ref id="pone.0183572.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>B</given-names></name>, <name><surname>Kirov</surname><given-names>S</given-names></name>, <name><surname>Snoddy</surname><given-names>J</given-names></name>. <article-title>WebGestalt: an integrated system for exploring gene sets in various biological contexts</article-title>. <source>Nucleic Acids Res</source>. <year>2005</year>;<volume>33</volume>: <fpage>W741</fpage>&#x02013;<lpage>748</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/nar/gki475">10.1093/nar/gki475</ext-link></comment>
<pub-id pub-id-type="pmid">15980575</pub-id></mixed-citation></ref><ref id="pone.0183572.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Saeed</surname><given-names>AI</given-names></name>, <name><surname>Sharov</surname><given-names>V</given-names></name>, <name><surname>White</surname><given-names>J</given-names></name>, <name><surname>Li</surname><given-names>J</given-names></name>, <name><surname>Liang</surname><given-names>W</given-names></name>, <name><surname>Bhagabati</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>TM4: a free, open-source system for microarray data management and analysis</article-title>. <source>Biotechniques</source>. <year>2003</year>;<volume>34</volume>: <fpage>374</fpage>&#x02013;<lpage>378</lpage>. <pub-id pub-id-type="pmid">12613259</pub-id></mixed-citation></ref><ref id="pone.0183572.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Medina</surname><given-names>I</given-names></name>, <name><surname>Montaner</surname><given-names>D</given-names></name>, <name><surname>Tarraga</surname><given-names>J</given-names></name>, <name><surname>Dopazo</surname><given-names>J</given-names></name>. <article-title>Prophet, a web-based tool for class prediction using microarray data</article-title>. <source>Bioinformatics</source>. <year>2007</year>;<volume>23</volume>: <fpage>390</fpage>&#x02013;<lpage>391</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/bioinformatics/btl602">10.1093/bioinformatics/btl602</ext-link></comment>
<pub-id pub-id-type="pmid">17138587</pub-id></mixed-citation></ref><ref id="pone.0183572.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Ulrich</surname><given-names>R</given-names></name>, <name><surname>Imbschweiler</surname><given-names>I</given-names></name>, <name><surname>Kalkuhl</surname><given-names>A</given-names></name>, <name><surname>Lehmbecker</surname><given-names>A</given-names></name>, <name><surname>Ziege</surname><given-names>S</given-names></name>, <name><surname>Kegler</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Transcriptional profiling predicts overwhelming homology of Schwann cells, olfactory ensheathing cells, and Schwann cell-like glia</article-title>. <source>Glia</source>. <year>2014</year>;<volume>62</volume>: <fpage>1559</fpage>&#x02013;<lpage>1581</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/glia.22700">10.1002/glia.22700</ext-link></comment>
<pub-id pub-id-type="pmid">24889922</pub-id></mixed-citation></ref><ref id="pone.0183572.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Jen</surname><given-names>CH</given-names></name>, <name><surname>Yang</surname><given-names>TP</given-names></name>, <name><surname>Tung</surname><given-names>CY</given-names></name>, <name><surname>Su</surname><given-names>SH</given-names></name>, <name><surname>Lin</surname><given-names>CH</given-names></name>, <name><surname>Hsu</surname><given-names>MT</given-names></name>, <etal>et al</etal>
<article-title>Signature Evaluation Tool (SET): a Java-based tool to evaluate and visualize the sample discrimination abilities of gene expression signatures</article-title>. <source>BMC Bioinformatics</source>. <year>2008</year>;<volume>9</volume>: <fpage>58</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1471-2105-9-58">10.1186/1471-2105-9-58</ext-link></comment>
<pub-id pub-id-type="pmid">18221568</pub-id></mixed-citation></ref><ref id="pone.0183572.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Martinez</surname><given-names>FO</given-names></name>, <name><surname>Gordon</surname><given-names>S</given-names></name>, <name><surname>Locati</surname><given-names>M</given-names></name>, <name><surname>Mantovani</surname><given-names>A</given-names></name>. <article-title>Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression</article-title>. <source>J Immunol</source>. <year>2006</year>;<volume>177</volume>: <fpage>7303</fpage>&#x02013;<lpage>7311</lpage>. <pub-id pub-id-type="pmid">17082649</pub-id></mixed-citation></ref><ref id="pone.0183572.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Prajeeth</surname><given-names>CK</given-names></name>, <name><surname>Lohr</surname><given-names>K</given-names></name>, <name><surname>Floess</surname><given-names>S</given-names></name>, <name><surname>Zimmermann</surname><given-names>J</given-names></name>, <name><surname>Ulrich</surname><given-names>R</given-names></name>, <name><surname>Gudi</surname><given-names>V</given-names></name>, <etal>et al</etal>
<article-title>Effector molecules released by Th1 but not Th17 cells drive an M1 response in microglia</article-title>. <source>Brain Behav Immun</source>. <year>2014</year>;<volume>37</volume>: <fpage>248</fpage>&#x02013;<lpage>259</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.bbi.2014.01.001">10.1016/j.bbi.2014.01.001</ext-link></comment>
<pub-id pub-id-type="pmid">24412213</pub-id></mixed-citation></ref><ref id="pone.0183572.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Baron</surname><given-names>D</given-names></name>, <name><surname>Bihouee</surname><given-names>A</given-names></name>, <name><surname>Teusan</surname><given-names>R</given-names></name>, <name><surname>Dubois</surname><given-names>E</given-names></name>, <name><surname>Savagner</surname><given-names>F</given-names></name>, <name><surname>Steenman</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>MADGene: retrieval and processing of gene identifier lists for the analysis of heterogeneous microarray datasets</article-title>. <source>Bioinformatics</source>. <year>2011</year>;<volume>27</volume>: <fpage>725</fpage>&#x02013;<lpage>726</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/bioinformatics/btq710">10.1093/bioinformatics/btq710</ext-link></comment>
<pub-id pub-id-type="pmid">21216776</pub-id></mixed-citation></ref><ref id="pone.0183572.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Hoffmann</surname><given-names>R</given-names></name>, <name><surname>Valencia</surname><given-names>A</given-names></name>. <article-title>A gene network for navigating the literature</article-title>. <source>Nat Genet</source>. <year>2004</year>;<volume>36</volume>: <fpage>664</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ng0704-664">10.1038/ng0704-664</ext-link></comment>
<pub-id pub-id-type="pmid">15226743</pub-id></mixed-citation></ref><ref id="pone.0183572.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Mantovani</surname><given-names>A</given-names></name>, <name><surname>Locati</surname><given-names>M</given-names></name>. <article-title>Tumor-associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization: lessons and open questions</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2013</year>;<volume>33</volume>: <fpage>1478</fpage>&#x02013;<lpage>1483</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/ATVBAHA.113.300168">10.1161/ATVBAHA.113.300168</ext-link></comment>
<pub-id pub-id-type="pmid">23766387</pub-id></mixed-citation></ref><ref id="pone.0183572.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Mantovani</surname><given-names>A</given-names></name>, <name><surname>Sica</surname><given-names>A</given-names></name>, <name><surname>Sozzani</surname><given-names>S</given-names></name>, <name><surname>Allavena</surname><given-names>P</given-names></name>, <name><surname>Vecchi</surname><given-names>A</given-names></name>, <name><surname>Locati</surname><given-names>M</given-names></name>. <article-title>The chemokine system in diverse forms of macrophage activation and polarization</article-title>. <source>Trends Immunol</source>. <year>2004</year>;<volume>25</volume>: <fpage>677</fpage>&#x02013;<lpage>686</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.it.2004.09.015">10.1016/j.it.2004.09.015</ext-link></comment>
<pub-id pub-id-type="pmid">15530839</pub-id></mixed-citation></ref><ref id="pone.0183572.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Miron</surname><given-names>VE</given-names></name>, <name><surname>Franklin</surname><given-names>RJ</given-names></name>. <article-title>Macrophages and CNS remyelination</article-title>. <source>J Neurochem</source>. <year>2014</year>;<volume>130</volume>: <fpage>165</fpage>&#x02013;<lpage>171</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/jnc.12705">10.1111/jnc.12705</ext-link></comment>
<pub-id pub-id-type="pmid">24601941</pub-id></mixed-citation></ref><ref id="pone.0183572.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>McWhorter</surname><given-names>FY</given-names></name>, <name><surname>Wang</surname><given-names>T</given-names></name>, <name><surname>Nguyen</surname><given-names>P</given-names></name>, <name><surname>Chung</surname><given-names>T</given-names></name>, <name><surname>Liu</surname><given-names>WF</given-names></name>. <article-title>Modulation of macrophage phenotype by cell shape</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2013</year>;<volume>110</volume>: <fpage>17253</fpage>&#x02013;<lpage>17258</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1073/pnas.1308887110">10.1073/pnas.1308887110</ext-link></comment>
<pub-id pub-id-type="pmid">24101477</pub-id></mixed-citation></ref><ref id="pone.0183572.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Vereyken</surname><given-names>EJ</given-names></name>, <name><surname>Heijnen</surname><given-names>PD</given-names></name>, <name><surname>Baron</surname><given-names>W</given-names></name>, <name><surname>de Vries</surname><given-names>EH</given-names></name>, <name><surname>Dijkstra</surname><given-names>CD</given-names></name>, <name><surname>Teunissen</surname><given-names>CE</given-names></name>. <article-title>Classically and alternatively activated bone marrow derived macrophages differ in cytoskeletal functions and migration towards specific CNS cell types</article-title>. <source>J Neuroinflammation</source>. <year>2011</year>;<volume>8</volume>: <fpage>58</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1742-2094-8-58">10.1186/1742-2094-8-58</ext-link></comment>
<pub-id pub-id-type="pmid">21615896</pub-id></mixed-citation></ref><ref id="pone.0183572.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Verreck</surname><given-names>FA</given-names></name>, <name><surname>de Boer</surname><given-names>T</given-names></name>, <name><surname>Langenberg</surname><given-names>DM</given-names></name>, <name><surname>van der Zanden</surname><given-names>L</given-names></name>, <name><surname>Ottenhoff</surname><given-names>TH</given-names></name>. <article-title>Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-gamma- and CD40L-mediated costimulation</article-title>. <source>J Leukoc Biol</source>. <year>2006</year>;<volume>79</volume>: <fpage>285</fpage>&#x02013;<lpage>293</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1189/jlb.0105015">10.1189/jlb.0105015</ext-link></comment>
<pub-id pub-id-type="pmid">16330536</pub-id></mixed-citation></ref><ref id="pone.0183572.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Waldo</surname><given-names>SW</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Buono</surname><given-names>C</given-names></name>, <name><surname>Zhao</surname><given-names>B</given-names></name>, <name><surname>Billings</surname><given-names>EM</given-names></name>, <name><surname>Chang</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Heterogeneity of human macrophages in culture and in atherosclerotic plaques</article-title>. <source>Am J Pathol</source>. <year>2008</year>;<volume>172</volume>: <fpage>1112</fpage>&#x02013;<lpage>1126</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2353/ajpath.2008.070513">10.2353/ajpath.2008.070513</ext-link></comment>
<pub-id pub-id-type="pmid">18321997</pub-id></mixed-citation></ref><ref id="pone.0183572.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Hornik</surname><given-names>TC</given-names></name>, <name><surname>Neniskyte</surname><given-names>U</given-names></name>, <name><surname>Brown</surname><given-names>GC</given-names></name>. <article-title>Inflammation induces multinucleation of Microglia via PKC inhibition of cytokinesis, generating highly phagocytic multinucleated giant cells</article-title>. <source>J Neurochem</source>. <year>2014</year>;<volume>128</volume>: <fpage>650</fpage>&#x02013;<lpage>661</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/jnc.12477">10.1111/jnc.12477</ext-link></comment>
<pub-id pub-id-type="pmid">24117490</pub-id></mixed-citation></ref><ref id="pone.0183572.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Jay</surname><given-names>SM</given-names></name>, <name><surname>Skokos</surname><given-names>E</given-names></name>, <name><surname>Laiwalla</surname><given-names>F</given-names></name>, <name><surname>Krady</surname><given-names>MM</given-names></name>, <name><surname>Kyriakides</surname><given-names>TR</given-names></name>. <article-title>Foreign body giant cell formation is preceded by lamellipodia formation and can be attenuated by inhibition of Rac1 activation</article-title>. <source>Am J Pathol</source>. <year>2007</year>;<volume>171</volume>: <fpage>632</fpage>&#x02013;<lpage>640</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2353/ajpath.2007.061213">10.2353/ajpath.2007.061213</ext-link></comment>
<pub-id pub-id-type="pmid">17556592</pub-id></mixed-citation></ref><ref id="pone.0183572.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Moreno</surname><given-names>JL</given-names></name>, <name><surname>Mikhailenko</surname><given-names>I</given-names></name>, <name><surname>Tondravi</surname><given-names>MM</given-names></name>, <name><surname>Keegan</surname><given-names>AD</given-names></name>. <article-title>IL-4 promotes the formation of multinucleated giant cells from macrophage precursors by a STAT6-dependent, homotypic mechanism: contribution of E-cadherin</article-title>. <source>J Leukoc Biol</source>. <year>2007</year>;<volume>82</volume>: <fpage>1542</fpage>&#x02013;<lpage>1553</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1189/jlb.0107058">10.1189/jlb.0107058</ext-link></comment>
<pub-id pub-id-type="pmid">17855502</pub-id></mixed-citation></ref><ref id="pone.0183572.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Suzumura</surname><given-names>A</given-names></name>, <name><surname>Tamaru</surname><given-names>T</given-names></name>, <name><surname>Yoshikawa</surname><given-names>M</given-names></name>, <name><surname>Takayanagi</surname><given-names>T</given-names></name>. <article-title>Multinucleated giant cell formation by microglia: induction by interleukin (IL)-4 and IL-13</article-title>. <source>Brain Res</source>. <year>1999</year>;<volume>849</volume>: <fpage>239</fpage>&#x02013;<lpage>243</lpage>. <pub-id pub-id-type="pmid">10592309</pub-id></mixed-citation></ref><ref id="pone.0183572.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Jenkins</surname><given-names>SJ</given-names></name>, <name><surname>Ruckerl</surname><given-names>D</given-names></name>, <name><surname>Thomas</surname><given-names>GD</given-names></name>, <name><surname>Hewitson</surname><given-names>JP</given-names></name>, <name><surname>Duncan</surname><given-names>S</given-names></name>, <name><surname>Brombacher</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>IL-4 directly signals tissue-resident macrophages to proliferate beyond homeostatic levels controlled by CSF-1</article-title>. <source>J Exp Med</source>. <year>2013</year>;<volume>210</volume>: <fpage>2477</fpage>&#x02013;<lpage>2491</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1084/jem.20121999">10.1084/jem.20121999</ext-link></comment>
<pub-id pub-id-type="pmid">24101381</pub-id></mixed-citation></ref><ref id="pone.0183572.ref060"><label>60</label><mixed-citation publication-type="journal"><name><surname>Wunschmann</surname><given-names>A</given-names></name>, <name><surname>Kremmer</surname><given-names>E</given-names></name>, <name><surname>Baumg&#x000e4;rtner</surname><given-names>W</given-names></name>. <article-title>Phenotypical characterization of T and B cell areas in lymphoid tissues of dogs with spontaneous distemper</article-title>. <source>Vet Immunol Immunopathol</source>. <year>2000</year>;<volume>73</volume>: <fpage>83</fpage>&#x02013;<lpage>98</lpage>. <pub-id pub-id-type="pmid">10678401</pub-id></mixed-citation></ref><ref id="pone.0183572.ref061"><label>61</label><mixed-citation publication-type="journal"><name><surname>Pierezan</surname><given-names>F</given-names></name>, <name><surname>Mansell</surname><given-names>J</given-names></name>, <name><surname>Ambrus</surname><given-names>A</given-names></name>, <name><surname>Rodrigues Hoffmann</surname><given-names>A</given-names></name>. <article-title>Immunohistochemical expression of ionized calcium binding adapter molecule 1 in cutaneous histiocytic proliferative, neoplastic and inflammatory disorders of dogs and cats</article-title>. <source>J Comp Pathol</source>. <year>2014</year>;<volume>151</volume>: <fpage>347</fpage>&#x02013;<lpage>351</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jcpa.2014.07.003">10.1016/j.jcpa.2014.07.003</ext-link></comment>
<pub-id pub-id-type="pmid">25172051</pub-id></mixed-citation></ref><ref id="pone.0183572.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Stein</surname><given-names>VM</given-names></name>, <name><surname>Schreiner</surname><given-names>NM</given-names></name>, <name><surname>Moore</surname><given-names>PF</given-names></name>, <name><surname>Vandevelde</surname><given-names>M</given-names></name>, <name><surname>Zurbriggen</surname><given-names>A</given-names></name>, <name><surname>Tipold</surname><given-names>A</given-names></name>. <article-title>Immunophenotypical characterization of monocytes in canine distemper virus infection</article-title>. <source>Vet Microbiol</source>. <year>2008</year>;<volume>131</volume>: <fpage>237</fpage>&#x02013;<lpage>246</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.vetmic.2008.03.009">10.1016/j.vetmic.2008.03.009</ext-link></comment>
<pub-id pub-id-type="pmid">18472370</pub-id></mixed-citation></ref><ref id="pone.0183572.ref063"><label>63</label><mixed-citation publication-type="journal"><name><surname>Heinrich</surname><given-names>F</given-names></name>, <name><surname>Contioso</surname><given-names>VB</given-names></name>, <name><surname>Stein</surname><given-names>VM</given-names></name>, <name><surname>Carlson</surname><given-names>R</given-names></name>, <name><surname>Tipold</surname><given-names>A</given-names></name>, <name><surname>Ulrich</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Passage-dependent morphological and phenotypical changes of a canine histiocytic sarcoma cell line (DH82 cells)</article-title>. <source>Vet Immunol Immunopathol</source>. <year>2015</year>;<volume>163</volume>: <fpage>86</fpage>&#x02013;<lpage>92</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.vetimm.2014.11.006">10.1016/j.vetimm.2014.11.006</ext-link></comment>
<pub-id pub-id-type="pmid">25534080</pub-id></mixed-citation></ref><ref id="pone.0183572.ref064"><label>64</label><mixed-citation publication-type="journal"><name><surname>Jaguin</surname><given-names>M</given-names></name>, <name><surname>Houlbert</surname><given-names>N</given-names></name>, <name><surname>Fardel</surname><given-names>O</given-names></name>, <name><surname>Lecureur</surname><given-names>V</given-names></name>. <article-title>Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin</article-title>. <source>Cell Immunol</source>. <year>2013</year>;<volume>281</volume>: <fpage>51</fpage>&#x02013;<lpage>61</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cellimm.2013.01.010">10.1016/j.cellimm.2013.01.010</ext-link></comment>
<pub-id pub-id-type="pmid">23454681</pub-id></mixed-citation></ref><ref id="pone.0183572.ref065"><label>65</label><mixed-citation publication-type="journal"><name><surname>Vogel</surname><given-names>DY</given-names></name>, <name><surname>Vereyken</surname><given-names>EJ</given-names></name>, <name><surname>Glim</surname><given-names>JE</given-names></name>, <name><surname>Heijnen</surname><given-names>PD</given-names></name>, <name><surname>Moeton</surname><given-names>M</given-names></name>, <name><surname>van der Valk</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status</article-title>. <source>J Neuroinflammation</source>. <year>2013</year>;<volume>10</volume>: <fpage>35</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1742-2094-10-35">10.1186/1742-2094-10-35</ext-link></comment>
<pub-id pub-id-type="pmid">23452918</pub-id></mixed-citation></ref><ref id="pone.0183572.ref066"><label>66</label><mixed-citation publication-type="journal"><name><surname>Genin</surname><given-names>M</given-names></name>, <name><surname>Clement</surname><given-names>F</given-names></name>, <name><surname>Fattaccioli</surname><given-names>A</given-names></name>, <name><surname>Raes</surname><given-names>M</given-names></name>, <name><surname>Michiels</surname><given-names>C</given-names></name>. <article-title>M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide</article-title>. <source>BMC Cancer</source>. <year>2015</year>;<volume>15</volume>: <fpage>577</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12885-015-1546-9">10.1186/s12885-015-1546-9</ext-link></comment>
<pub-id pub-id-type="pmid">26253167</pub-id></mixed-citation></ref><ref id="pone.0183572.ref067"><label>67</label><mixed-citation publication-type="journal"><name><surname>Schwartz</surname><given-names>Y</given-names></name>, <name><surname>Svistelnik</surname><given-names>AV</given-names></name>. <article-title>Functional phenotypes of macrophages and the M1-M2 polarization concept. Part I. Proinflammatory phenotype</article-title>. <source>Biochemistry (Mosc)</source>. <year>2012</year>;<volume>77</volume>: <fpage>246</fpage>&#x02013;<lpage>260</lpage>.<pub-id pub-id-type="pmid">22803942</pub-id></mixed-citation></ref><ref id="pone.0183572.ref068"><label>68</label><mixed-citation publication-type="journal"><name><surname>Gordon</surname><given-names>S</given-names></name>, <name><surname>Martinez</surname><given-names>FO</given-names></name>. <article-title>Alternative activation of macrophages: mechanism and functions</article-title>. <source>Immunity</source>. <year>2010</year>;<volume>32</volume>: <fpage>593</fpage>&#x02013;<lpage>604</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.immuni.2010.05.007">10.1016/j.immuni.2010.05.007</ext-link></comment>
<pub-id pub-id-type="pmid">20510870</pub-id></mixed-citation></ref><ref id="pone.0183572.ref069"><label>69</label><mixed-citation publication-type="journal"><name><surname>Raes</surname><given-names>G</given-names></name>, <name><surname>Van den Bergh</surname><given-names>R</given-names></name>, <name><surname>De Baetselier</surname><given-names>P</given-names></name>, <name><surname>Ghassabeh</surname><given-names>GH</given-names></name>, <name><surname>Scotton</surname><given-names>C</given-names></name>, <name><surname>Locati</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Arginase-1 and Ym1 are markers for murine, but not human, alternatively activated myeloid cells</article-title>. <source>J Immunol</source>. <year>2005</year>;<volume>174</volume>: <fpage>6561</fpage>; author reply 6561&#x02013;6562. <pub-id pub-id-type="pmid">15905489</pub-id></mixed-citation></ref><ref id="pone.0183572.ref070"><label>70</label><mixed-citation publication-type="journal"><name><surname>Stoger</surname><given-names>JL</given-names></name>, <name><surname>Gijbels</surname><given-names>MJ</given-names></name>, <name><surname>van der Velden</surname><given-names>S</given-names></name>, <name><surname>Manca</surname><given-names>M</given-names></name>, <name><surname>van der Loos</surname><given-names>CM</given-names></name>, <name><surname>Biessen</surname><given-names>EA</given-names></name>, <etal>et al</etal>
<article-title>Distribution of macrophage polarization markers in human atherosclerosis</article-title>. <source>Atherosclerosis</source>. <year>2012</year>;<volume>225</volume>: <fpage>461</fpage>&#x02013;<lpage>468</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.atherosclerosis.2012.09.013">10.1016/j.atherosclerosis.2012.09.013</ext-link></comment>
<pub-id pub-id-type="pmid">23078881</pub-id></mixed-citation></ref><ref id="pone.0183572.ref071"><label>71</label><mixed-citation publication-type="journal"><name><surname>Doyle</surname><given-names>AG</given-names></name>, <name><surname>Herbein</surname><given-names>G</given-names></name>, <name><surname>Montaner</surname><given-names>LJ</given-names></name>, <name><surname>Minty</surname><given-names>AJ</given-names></name>, <name><surname>Caput</surname><given-names>D</given-names></name>, <name><surname>Ferrara</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Interleukin-13 alters the activation state of murine macrophages in vitro: comparison with interleukin-4 and interferon-gamma</article-title>. <source>Eur J Immunol</source>. <year>1994</year>;<volume>24</volume>: <fpage>1441</fpage>&#x02013;<lpage>1445</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/eji.1830240630">10.1002/eji.1830240630</ext-link></comment>
<pub-id pub-id-type="pmid">7911424</pub-id></mixed-citation></ref><ref id="pone.0183572.ref072"><label>72</label><mixed-citation publication-type="journal"><name><surname>Estko</surname><given-names>M</given-names></name>, <name><surname>Baumg&#x000e4;rtner</surname><given-names>S</given-names></name>, <name><surname>Urech</surname><given-names>K</given-names></name>, <name><surname>Kunz</surname><given-names>M</given-names></name>, <name><surname>Regueiro</surname><given-names>U</given-names></name>, <name><surname>Heusser</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Tumour cell derived effects on monocyte/macrophage polarization and function and modulatory potential of Viscum album lipophilic extract in vitro</article-title>. <source>BMC Complement Altern Med</source>. <year>2015</year>;<volume>15</volume>: <fpage>130</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12906-015-0650-3">10.1186/s12906-015-0650-3</ext-link></comment>
<pub-id pub-id-type="pmid">25902944</pub-id></mixed-citation></ref><ref id="pone.0183572.ref073"><label>73</label><mixed-citation publication-type="journal"><name><surname>Stein</surname><given-names>M</given-names></name>, <name><surname>Keshav</surname><given-names>S</given-names></name>, <name><surname>Harris</surname><given-names>N</given-names></name>, <name><surname>Gordon</surname><given-names>S</given-names></name>. <article-title>Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation</article-title>. <source>J Exp Med</source>. <year>1992</year>;<volume>176</volume>: <fpage>287</fpage>&#x02013;<lpage>292</lpage>. <pub-id pub-id-type="pmid">1613462</pub-id></mixed-citation></ref><ref id="pone.0183572.ref074"><label>74</label><mixed-citation publication-type="journal"><name><surname>te Velde</surname><given-names>AA</given-names></name>, <name><surname>Klomp</surname><given-names>JP</given-names></name>, <name><surname>Yard</surname><given-names>BA</given-names></name>, <name><surname>de Vries</surname><given-names>JE</given-names></name>, <name><surname>Figdor</surname><given-names>CG</given-names></name>. <article-title>Modulation of phenotypic and functional properties of human peripheral blood monocytes by IL-4</article-title>. <source>J Immunol</source>. <year>1988</year>;<volume>140</volume>: <fpage>1548</fpage>&#x02013;<lpage>1554</lpage>. <pub-id pub-id-type="pmid">3279117</pub-id></mixed-citation></ref><ref id="pone.0183572.ref075"><label>75</label><mixed-citation publication-type="journal"><name><surname>Littman</surname><given-names>BH</given-names></name>, <name><surname>Dastvan</surname><given-names>FF</given-names></name>, <name><surname>Carlson</surname><given-names>PL</given-names></name>, <name><surname>Sanders</surname><given-names>KM</given-names></name>. <article-title>Regulation of monocyte/macrophage C2 production and HLA-DR expression by IL-4 (BSF-1) and IFN-gamma</article-title>. <source>J Immunol</source>. <year>1989</year>;<volume>142</volume>: <fpage>520</fpage>&#x02013;<lpage>525</lpage>. <pub-id pub-id-type="pmid">2492049</pub-id></mixed-citation></ref><ref id="pone.0183572.ref076"><label>76</label><mixed-citation publication-type="journal"><name><surname>Mia</surname><given-names>S</given-names></name>, <name><surname>Warnecke</surname><given-names>A</given-names></name>, <name><surname>Zhang</surname><given-names>XM</given-names></name>, <name><surname>Malmstrom</surname><given-names>V</given-names></name>, <name><surname>Harris</surname><given-names>RA</given-names></name>. <article-title>An optimized protocol for human M2 macrophages using M-CSF and IL-4/IL-10/TGF-beta yields a dominant immunosuppressive phenotype</article-title>. <source>Scand J Immunol</source>. <year>2014</year>;<volume>79</volume>: <fpage>305</fpage>&#x02013;<lpage>314</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/sji.12162">10.1111/sji.12162</ext-link></comment>
<pub-id pub-id-type="pmid">24521472</pub-id></mixed-citation></ref><ref id="pone.0183572.ref077"><label>77</label><mixed-citation publication-type="journal"><name><surname>Wallner</surname><given-names>S</given-names></name>, <name><surname>Grandl</surname><given-names>M</given-names></name>, <name><surname>Konovalova</surname><given-names>T</given-names></name>, <name><surname>Sigruner</surname><given-names>A</given-names></name>, <name><surname>Kopf</surname><given-names>T</given-names></name>, <name><surname>Peer</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Monocyte to macrophage differentiation goes along with modulation of the plasmalogen pattern through transcriptional regulation</article-title>. <source>PLoS One</source>. <year>2014</year>;<volume>9</volume>: <fpage>e94102</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0094102">10.1371/journal.pone.0094102</ext-link></comment>
<pub-id pub-id-type="pmid">24714687</pub-id></mixed-citation></ref><ref id="pone.0183572.ref078"><label>78</label><mixed-citation publication-type="journal"><name><surname>Tugal</surname><given-names>D</given-names></name>, <name><surname>Liao</surname><given-names>X</given-names></name>, <name><surname>Jain</surname><given-names>MK</given-names></name>. <article-title>Transcriptional control of macrophage polarization</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2013</year>;<volume>33</volume>: <fpage>1135</fpage>&#x02013;<lpage>1144</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/ATVBAHA.113.301453">10.1161/ATVBAHA.113.301453</ext-link></comment>
<pub-id pub-id-type="pmid">23640482</pub-id></mixed-citation></ref><ref id="pone.0183572.ref079"><label>79</label><mixed-citation publication-type="journal"><name><surname>Bouhlel</surname><given-names>MA</given-names></name>, <name><surname>Derudas</surname><given-names>B</given-names></name>, <name><surname>Rigamonti</surname><given-names>E</given-names></name>, <name><surname>Dievart</surname><given-names>R</given-names></name>, <name><surname>Brozek</surname><given-names>J</given-names></name>, <name><surname>Haulon</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties</article-title>. <source>Cell Metab</source>. <year>2007</year>;<volume>6</volume>: <fpage>137</fpage>&#x02013;<lpage>143</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cmet.2007.06.010">10.1016/j.cmet.2007.06.010</ext-link></comment>
<pub-id pub-id-type="pmid">17681149</pub-id></mixed-citation></ref><ref id="pone.0183572.ref080"><label>80</label><mixed-citation publication-type="journal"><name><surname>Chawla</surname><given-names>A</given-names></name>. <article-title>Control of macrophage activation and function by PPARs</article-title>. <source>Circ Res</source>. <year>2010</year>;<volume>106</volume>: <fpage>1559</fpage>&#x02013;<lpage>1569</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCRESAHA.110.216523">10.1161/CIRCRESAHA.110.216523</ext-link></comment>
<pub-id pub-id-type="pmid">20508200</pub-id></mixed-citation></ref><ref id="pone.0183572.ref081"><label>81</label><mixed-citation publication-type="journal"><name><surname>Chinetti</surname><given-names>G</given-names></name>, <name><surname>Fruchart</surname><given-names>JC</given-names></name>, <name><surname>Staels</surname><given-names>B</given-names></name>. <article-title>Peroxisome proliferator-activated receptors: new targets for the pharmacological modulation of macrophage gene expression and function</article-title>. <source>Curr Opin Lipidol</source>. <year>2003</year>;<volume>14</volume>: <fpage>459</fpage>&#x02013;<lpage>468</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/01.mol.0000092630.86399.00">10.1097/01.mol.0000092630.86399.00</ext-link></comment>
<pub-id pub-id-type="pmid">14501584</pub-id></mixed-citation></ref><ref id="pone.0183572.ref082"><label>82</label><mixed-citation publication-type="journal"><name><surname>Zizzo</surname><given-names>G</given-names></name>, <name><surname>Cohen</surname><given-names>PL</given-names></name>. <article-title>The PPAR-gamma antagonist GW9662 elicits differentiation of M2c-like cells and upregulation of the MerTK/Gas6 axis: a key role for PPAR-gamma in human macrophage polarization</article-title>. <source>J Inflamm (Lond)</source>. <year>2015</year>;<volume>12</volume>: <fpage>36</fpage>.<pub-id pub-id-type="pmid">25972766</pub-id></mixed-citation></ref><ref id="pone.0183572.ref083"><label>83</label><mixed-citation publication-type="journal"><name><surname>Hong</surname><given-names>G</given-names></name>, <name><surname>Davis</surname><given-names>B</given-names></name>, <name><surname>Khatoon</surname><given-names>N</given-names></name>, <name><surname>Baker</surname><given-names>SF</given-names></name>, <name><surname>Brown</surname><given-names>J</given-names></name>. <article-title>PPAR gamma-dependent anti-inflammatory action of rosiglitazone in human monocytes: suppression of TNF alpha secretion is not mediated by PTEN regulation</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2003</year>;<volume>303</volume>: <fpage>782</fpage>&#x02013;<lpage>787</lpage>. <pub-id pub-id-type="pmid">12670479</pub-id></mixed-citation></ref><ref id="pone.0183572.ref084"><label>84</label><mixed-citation publication-type="journal"><name><surname>Lefevre</surname><given-names>L</given-names></name>, <name><surname>Gales</surname><given-names>A</given-names></name>, <name><surname>Olagnier</surname><given-names>D</given-names></name>, <name><surname>Bernad</surname><given-names>J</given-names></name>, <name><surname>Perez</surname><given-names>L</given-names></name>, <name><surname>Burcelin</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>PPARgamma ligands switched high fat diet-induced macrophage M2b polarization toward M2a thereby improving intestinal Candida elimination</article-title>. <source>PLoS One</source>. <year>2010</year>;<volume>5</volume>: <fpage>e12828</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0012828">10.1371/journal.pone.0012828</ext-link></comment>
<pub-id pub-id-type="pmid">20877467</pub-id></mixed-citation></ref><ref id="pone.0183572.ref085"><label>85</label><mixed-citation publication-type="journal"><name><surname>Aagaard</surname><given-names>A</given-names></name>, <name><surname>Listwan</surname><given-names>P</given-names></name>, <name><surname>Cowieson</surname><given-names>N</given-names></name>, <name><surname>Huber</surname><given-names>T</given-names></name>, <name><surname>Ravasi</surname><given-names>T</given-names></name>, <name><surname>Wells</surname><given-names>CA</given-names></name>, <etal>et al</etal>
<article-title>An inflammatory role for the mammalian carboxypeptidase inhibitor latexin: relationship to cystatins and the tumor suppressor TIG1</article-title>. <source>Structure</source>. <year>2005</year>;<volume>13</volume>: <fpage>309</fpage>&#x02013;<lpage>317</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.str.2004.12.013">10.1016/j.str.2004.12.013</ext-link></comment>
<pub-id pub-id-type="pmid">15698574</pub-id></mixed-citation></ref><ref id="pone.0183572.ref086"><label>86</label><mixed-citation publication-type="journal"><name><surname>Arimatsu</surname><given-names>Y</given-names></name>, <name><surname>Ishida</surname><given-names>M</given-names></name>, <name><surname>Sato</surname><given-names>M</given-names></name>, <name><surname>Kojima</surname><given-names>M</given-names></name>. <article-title>Corticocortical associative neurons expressing latexin: specific cortical connectivity formed in vivo and in vitro</article-title>. <source>Cereb Cortex</source>. <year>1999</year>;<volume>9</volume>: <fpage>569</fpage>&#x02013;<lpage>576</lpage>. <pub-id pub-id-type="pmid">10498275</pub-id></mixed-citation></ref><ref id="pone.0183572.ref087"><label>87</label><mixed-citation publication-type="journal"><name><surname>Arimatsu</surname><given-names>Y</given-names></name>. <article-title>Latexin: a molecular marker for regional specification in the neocortex</article-title>. <source>Neurosci Res</source>. <year>1994</year>;<volume>20</volume>: <fpage>131</fpage>&#x02013;<lpage>135</lpage>. <pub-id pub-id-type="pmid">7808696</pub-id></mixed-citation></ref><ref id="pone.0183572.ref088"><label>88</label><mixed-citation publication-type="journal"><name><surname>Takiguchi-Hayashi</surname><given-names>K</given-names></name>, <name><surname>Sato</surname><given-names>M</given-names></name>, <name><surname>Sugo</surname><given-names>N</given-names></name>, <name><surname>Ishida</surname><given-names>M</given-names></name>, <name><surname>Sato</surname><given-names>K</given-names></name>, <name><surname>Uratani</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Latexin expression in smaller diameter primary sensory neurons in the rat</article-title>. <source>Brain Res</source>. <year>1998</year>;<volume>801</volume>: <fpage>9</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="pmid">9729242</pub-id></mixed-citation></ref><ref id="pone.0183572.ref089"><label>89</label><mixed-citation publication-type="journal"><name><surname>Cao</surname><given-names>L</given-names></name>, <name><surname>He</surname><given-names>C</given-names></name>. <article-title>Polarization of macrophages and microglia in inflammatory demyelination</article-title>. <source>Neurosci Bull</source>. <year>2013</year>;<volume>29</volume>: <fpage>189</fpage>&#x02013;<lpage>198</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s12264-013-1324-0">10.1007/s12264-013-1324-0</ext-link></comment>
<pub-id pub-id-type="pmid">23558588</pub-id></mixed-citation></ref></ref-list></back></article>